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EVOLUTION OF EQUINE ARTERITIS VIRUS DURING PERSISTENT INFECTION 
IN THE REPRODUCTIVE TRACT OF THE STALLION AND THE MALE DONKEY 
 
 
Equine arteritis virus (EAV) establishes persistent infection in the stallion 
reproductive tract, and the carrier stallion continues to shed virus in semen for weeks to 
years or lifelong. The objective of this study was to elucidate the intra-host evolution of 
EAV during persistent infection in stallions. Seven EAV seronegative stallions were 
experimentally infected with EAV KY84 strain and followed for 726 days post-infection, 
and sequential clinical samples including semen were collected for virus isolation and 
next-generation sequencing (NGS). In addition, archived sequential semen samples from 
two stallions that were naturally infected with EAV KY84 for a long-period (up to 10 
years) were also sequenced by NGS. The data demonstrated genetic bottleneck event and 
selection during acute infection followed by intra-host quasispecies diversification during 
persistent infection in the stallion reproductive tract.  
Also, the full-length genome of a novel EAV donkey strain from Chile and a 
noncytopathic bovine viral diarrhea virus-1 (ncpBVDV-1) strain contaminating rabbit 
kidney-13 cells were also sequenced by NGS. The EAV donkey strain was genetically 
distinct but antigenically cross-reacted with EAV antisera, and it was phylogenetically 
closely related to the South African donkey strain of EAV. Genetic and phylogenetic 
analyses demonstrated that ncpBVDV-1 belongs to BVDV-1b group. 
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 1 
CHAPTER ONE  
Literature Review  
 
1. Introduction  
Equine arteritis virus (EAV) is a small, enveloped, positive-sense, single-stranded 
RNA virus that belongs to the family Arteriviridae (genus: Equartevirus, order: 
Nidovirales)
1
. Viruses in the order Nidovirales (Arteriviridae, Coronaviridae and 
Roniviridae) have a similar genome organization and viral replication strategy, mainly 
characterized by the generation of a nested set of subgenomic viral messenger RNAs (sg 
mRNAs) 
1–6
. Recently, the International Committee on Taxonomy of Viruses (ICTV) 
reorganized the genus designation and proposed expansion of the family Arteriviridae, a 
taxonomic group that includes EAV, porcine reproductive and respiratory syndrome virus 
(PRRSV), lactate dehydrogenase-elevating virus (LDV) of mice, simian hemorrhagic 
fever virus (SHFV), wobbly possum disease virus (WPDV) and African pouched rat 
arterivirus (APRAV-1)
6–8
.  
EAV is the causative agent of equine viral arteritis (EVA), which is a 
reproductive and respiratory disease of the family Equidae that occurs worldwide
9–13
. In 
1953, EAV was first isolated from the lung of an aborted fetus during an extensive 
outbreak of respiratory disease and abortion on a Standardbred breeding farm near 
Bucyrus, OH, United States of America (USA)
9,14
. While there is only one known 
serotype of EAV, field strains of the virus can vary in virulence and neutralization 
capabilities
15–21
. The clinical signs of EVA are variable depending on the age and 
physical condition of the horse, route of exposure, virus strain, challenge dose and 
environmental factors
22,23
. Most importantly, EAV can cause abortion in pregnant mares, 
 
 2 
neonatal death in young foals, and establishment of persistent infection in 10-70% of 
infected stallions (carrier state), with significant economic consequences for the equine 
industry
11
.  
This chapter provides a review of EAV (replication cycle, viral structure and 
neutralization determinants) and of the disease it causes (EVA) including epidemiology, 
modes of transmission, immune response, clinical signs, pathogenesis, persistent 
infection in the stallion, diagnosis, treatment, prevention and control. Lastly, an overview 
will be presented on RNA virus quasispecies structure and evolutionary mechanisms. 
  
 
 3 
1.1. Equine arteritis virus (EAV) 
1.1.1. Classification and genome organization 
Table 1.1. The new classification of the Order Nidovirales Table 1. . Order Nidovirales
Order Family Subfamily Genus Species
Dipartevirus Wobbly possum disease virus
Equartevirus Equine arteritis virus
Nesartevirus African pouched rat arterivirus
Lactate dehydrogenase-elevating virus
Porcine reproductive and respiratory syndrome virus 1
Porcine reproductive and respiratory syndrome virus 2
Rat arterivirus 1
DeBrazza's monkey arterivirus
Free State vervet virus
Kafue kinda chacma baboon virus
Kibale red colobus virus 1
Kibale red colobus virus 2
Kibale red-tailed guenon virus 1
Mikumi yellow baboon virus 1
Pebjah virus 
Simian hemorrhagic encephalitis virus
Simian hemorrhagic fever virus
Alphacoronavirus 1
Bat coronavirus CDPHE15
Bat coronavirus HKU10
Human coronavirus 229E
Human coronavirus NL63
Miniopterus bat coronavirus 1
Miniopterus bat coronavirus HKU8
Mink coronavirus 1
Porcine epidemic diarrhea virus
Rhinolophus bat coronavirus HKU2
Scotophilus bat coronavirus 512
Betacoronavirus 1
Hedgehog coronavirus 1
Human coronavirus HKU1
Middle East respiratory syndrome-related coronavirus
Murine coronavirus
Pipistrellus bat coronavirus HKU5
Rousettus bat coronavirus HKU9
Severe acute respiratory syndrome-related coronavirus 
Tylonycteris bat coronavirus HKU4
Bulbul coronavirus HKU11
Common moorhen coronavirus HKU21
Coronavirus HKU15
Munia coronavirus HKU13
Night heron coronavirus HKU19
Thrush coronavirus HKU12
White-eye coronavirus HKU16
Wigeon coronavirus HKU20
Avian coronavirus
Beluga whale coronavirus SW1
Fathead minnow nidovirus 1
White bream virus
Bovine torovirus
Equine torovirus
Human torovirus
Porcine torovirus
Ball python nidovirus 1
Bovine dinovirus 1
Chinook salmon nidovirus 1
Alphamesonivirus 1
Alphamesonivirus 2
Alphamesonivirus 3
Alphamesonivirus 4
Alphamesonivirus 5
Mesonivirus 1
Mesonivirus 2
Roniviridae Okavirus Gill-associated virus
Gammacoronavirus
Torovirinae
Bafinivirus
Torovirus
Unassigned
Mesoniviridae
Alphamesonivirus
Unassigned
Nidovirales
Arteriviridae
Porartevirus
Simartevirus
Coronaviridae
Coronavirinae
Alphacoronavirus
Batacoronavirus
Deltacoronavirus
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EAV was initially classified as a non-arthropod-borne togavirus along with LDV 
and SHFV because of the similarity of their virion morphology and protein 
compositions
24–26
. In 1984, the genus Arterivirus was established within the family 
Togaviridae
27,28
. However, since neither togaviruses nor flaviviruses synthesize a 5′-3′-
coterminal set of nested sg mRNAs during viral replication, the replication strategy of 
EAV was more closely related to that of coronaviruses, LDV, SHFV and PRRSV
3,29–33
. 
Thus, the 6
th
 ICTV report (1995) assigned all four viruses (EAV, LDV, SHFV and 
PRRSV) to the genus Arterivirus, following which the 7
th
 ICTV report (2000) announced 
that the genus Arterivirus belongs to a new family (Arteriviridae) under a new order 
Nidovirales
34,35
. Recently, the ICTV proposed a reorganization and expansion of the 
family Arteriviridae. Under the new proposed classification, the genus designation 
“Arterivirus” is now specifically divided into Dipartevirus, Equartevirus, Nesartevirus, 
Porartevirus and Simartevirus
27
. Currently, there are four families (Arteriviridae, 
Coronaviridae, Mesoniviridae and Roniviridae) within the order Nidovirales, and the 
family Arteriviridae is formalized by five genuses: Dipartevirus, Equartevirus, 
Nesartevirus, Porartevirus and Simartevirus (Table 1.1.).  
The EAV virion is an enveloped, spherical, 50 to 65 nm particle with an isometric 
core that contains a single-stranded, positive-sense ribonucleic acid (RNA) molecule 
(Figure 1.1.B.).  The EAV genome length varies between 12,704 to 12,731 bp among 
different virus strains and includes a 5 leader sequence (224 nucleotides) and at least ten 
open reading frames (ORFs; Figure 1.1.A.). The two large ORFs 1a and 1b occupy the 5′-
proximal three-quarters of the EAV genome and encode two replicase polyproteins (pp1a 
and pp1ab) directly translated from the genomic RNA
3
. These two large replicase 
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polyproteins are processed into at least 13 nonstructural proteins (nsp1-12, including 
nsp7α/β) by three viral proteases (nsp1, nsp2 and nsp4)
36,37
. The 3′-distal quarter of the 
genome consists of eight ORFs (ORF 2a, 2b, 3-4, 5a, 5b, 6 and 7), which encode for the 
structural proteins E, GP2, GP3, GP4, GP5a protein, GP4, M and N proteins, 
respectively
5,38–41
. The seven envelope structural proteins (E, GP2, GP3, GP4, GP5a 
protein, GP5 and M) are classified into two major envelope proteins (GP5 and M) and 
five minor envelope proteins (E, GP2, GP3, GP4 and ORF5a protein)
1
. The structural 
proteins are expressed from a 3′-coterminal nested set of six sg mRNAs (2-7) that have a 
common 5′ leader sequence and transcription regulating sequence (TRS) at the 5′-end of 
each sg mRNA (Figure 1.1.A.)
29,42,43
. The sg mRNAs function monocistronically, except 
for the bicistronic sg mRNAs 2 and 5. The protein translation of sg mRNAs 2 (E and GP2 
proteins) and 5 (ORF5a protein and GP5) is expressed by leaky scanning of the 5′-
proximal end of the same sg mRNAs
39,40
. 
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Figure 1.1. Schematic representations of EAV genome organization and gene 
expression and of the EAV virion particle. (A) The ORFs 1a/b are located at the 5′-end 
of the genome and are translated into two replicase polyproteins (pp1a and pp1ab) and 
further processed into at least 13 nsps by three viral proteases (PCPβ, CP and 
3CLSP)
3,36,37
 (B) The EAV virion particle contains seven envelope structural proteins: E, 
GP2, GP3, GP4, ORF5a protein, GP5 and M. The N protein encapsulates the linear, 
positive-sense, single-stranded RNA genome. This schematic representation was 
modified from Balasuriya et al. (2013) from Elsevier with permission
1
. 
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1.1.2. Nonstructural proteins of EAV  
 The replicases pp1a and pp1ab encoded by ORF1a/1b undergo proteolytic 
processing at 11 cleavage sites by viral proteases (two papain-like cysteine protease 
domains: “accessory protease” nsp1, nsp2 and a chymotrypsin-like serine: “main protease” 
nsp4 which is encoded by ORF1a) and results in 13 nsps (nsp1-12, including 
nsp7α/β)
1,36,37
. The ORF1a protein is comprised of eight cleaved end products, nsp1-8 
including a number of processing intermediates
44–46
.  
The nsp1 is an “accessory protease” that functions in virion biogenesis and 
processes the replicase polyprotein to produce sg RNA
47,48
. The nsp2 is another 
“accessory protease” responsible for the cleavage of the nsp2/3 site through auto-protease 
activity and the cofactor for processing of the nsp4/5 site
44,48,49
. The nsp3 is a 
transmembrane protein involved in double-membrane vesicle formation
48,50
. The nsp4 is 
the “main protease” that plays a significant role during the cleavage of nsp3-8 and nsp3-
12
44,48
. The nsp5 participates in the formation of the EAV replication complex
44,48
. The 
nsp7 is further processed into nsp7α/β; the functions of nsp6-8 are undetermined
44,48,51
.  
 The ORF1b translation (expression of pp1ab) occurs through a -1 ribosomal 
frameshift mechanism by a “slippery” sequence localized in the overlapping region of 
ORF1a/1b
3,36,37,44,45,49,52–62
. The ORF1b generates four major protein products after 
processing mediated by nsp4 that include the RNA-dependent RNA polymerase (RdRp, 
nsp9) and the NTPase/RNA helicase domains (nsp10), which are necessary for viral 
RNA replication and mRNA transcription
3,44,48,63,64
. The nsp11 has endoribonuclease 
activity important for viral RNA synthesis 
48,65
. Lastly, the function of nsp12 has not yet 
been determined
1
. The mature nsps are also involved in the constitution of the membrane-
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anchored replication/transcription complex (RTC) that promotes viral genome replication 
and synthesis of the nested set of sg mRNAs for the expression of the viral structural 
proteins
66,67
. Previous immunofluorescence studies have demonstrated that the ORF1b-
encoded replicase subunits are observed in the perinuclear region of EAV infected cells; 
this suggested that the ORF1b-encoded replicase subunits might be associated with 
intracellular membranous compartments in the endoplasmic reticulum (ER)
61
. 
 
1.1.3. Structural proteins of EAV 
1.1.3.1. Minor envelope proteins 
The EAV virion contains five minor envelope proteins: E, GP2, GP3, GP4 and 
ORF5a protein encoded by ORF2a, ORF2b, ORF3, ORF4 and ORF5a, respectively 
(Figure 1.2.)
1
. The unglycosylated envelope protein E is highly hydrophobic and 
predicted to be a type III integral membrane protein and is intermediately abundant in the 
virion
40
. The E protein is essential for the production of infectious progeny 
40,41
. The GP2 
is a type I transmembrane minor envelope protein that is highly conserved on sequence 
comparison analysis
68
. Although GP2 is not essential for viral RNA replication and 
transcription
40,69
, it is essential for the production of infectious progeny
40,48
. According to 
Wieringa et al. (2002), suppression of ORF3 expression restrains the production of 
infectious virus particles, which implies that GP3 membrane-associated envelope 
glycoprotein is essential for viral replication
48,70
. The GP3 is predicted to be either a type 
II protein or a class IV protein
70,71
. Although the function of GP4 is not fully understood, 
it is predicted to be as essential for viral replication as GP3
48,70
. The ORF5a protein is a 
novel structural protein encoded by an overlapping region in the 5′-end of ORF5
39,72
. The 
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ORF5a protein is a type III membrane protein that is expressed from the same sg mRNA 
as GP5 and is possibly involved in the leaky ribosomal scanning
1
. The function of ORF5a 
protein is not fully understood, but it is predicted to be essential for viral replication and 
infectivity 
1,39
. 
 
Figure 1.2. Predicted membrane topology of the minor envelope proteins (E, GP2, 
GP3, GP4 and ORF5a protein). Two alternative topology predictions for E and GP3 
enveloped membrane proteins are demonstrated above. Predicted N-glycosylation sites in 
these proteins are shown in yellow circles with corresponding amino acid positions. 
Modified from Balasuriya et al. (2013) from Elsevier with permission
1
. 
 
 The minor envelope proteins GP2, GP3 and GP4 are abundantly expressed in 
EAV infected cells and covalently form a GP2/GP3/GP4 heterotrimeric 
complex
38,41,70,73,74
. The GP2 and GP4 proteins are both type I integral membrane 
proteins that contain one and four functional N-glycosylation sites, respectively (Figure 
1.3.)
1,70,75
. The intermolecular cysteine bridges with intra-chain disulfide bonds play a 
significant role in the conformation and stabilization of the GP2/GP3/GP4 heterotrimeric 
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complex (Figure 1.3.)
74
. The E protein may act as an intermediate receptor and is 
associated with the GP2/GP3/GP4 heterotrimeric complex during the process of viral 
attachment/entry and production of infectious viral progeny
1,76
. 
 
 
Figure 1.3. Predicted alternative topology models of the GP2/GP3/GP4 heterodimer 
complex. The GP3 envelope membrane protein is predicted to be either a class II 
membrane protein (A) or a class IV membrane protein (B). The intermolecular cysteine 
bridges are predicted with the covalently-linked disulfide bonds (S-S) at the Cys positions. 
Putative N-glycosylation sites are shown in yellow circles with corresponding amino acid 
positions. Modified from Wieringa et al. (2003) with permission
74
.  
 
1.1.3.2. Major envelope proteins 
The membrane glycoprotein GP5 and nonglycosylated membrane (M) protein are type IV 
integral membrane proteins encoded by ORF5b and ORF6, respectively
38,77
. The GP5 
and M large envelope proteins form disulfide-linked heterodimers in the virus particles 
(Figure 1.4.B.). There are four major neutralization determinants of EAV that have been 
identified in GP5, located at aa 49 (site A), 61 (site B), 67-90 (site C) and 98-106 (site D) 
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(Figure 1.4.A.)
15,16,20,78–81
. Site D expresses overlapping linear epitopes that may enable it 
to interact with three other neutralization sites (A-C) to establish conformational 
epitopes
15,16,81,82
. The nonglycosylated M protein acts as an important scaffold for the 
correct folding of GP5 in order to generate the neutralizing epitopes
1
.  
 
 
Figure 1.4. Schematic membrane topology of GP5 and M heterodimer structure. (A) 
Four major neutralization determinants of EAV are shown at aa 49 (site A), 61 (site B), 
67-90 (site C) and 98-106 (site D) in the GP5 protein. (B) The covalently-linked 
heterodimer complex is formed by a disulfide bond (S-S) between Cys-34 in the GP5 
protein and Cys-8 in the M protein. Putative N-glycosylation sites are shown in yellow 
circles with corresponding amino acid positions: Asn-56 and Asn-81. Another N-
glycosylation site (Asn-73) that was recently found in isolates from an EVA outbreak in 
North America
21
 is shown in a blue circle. Modified from Balasuriya et al. (2013) from 
Elsevier with permission
1
.  
 
 12 
 
 
In EAV infected cells, the newly synthesized GP5 proteins recruit existing M 
proteins from the ER to form a disulfide-linked heterodimeric complex
1,75
. The disulfide-
linked heterodimeric complex of the two major envelope proteins are formed by the 
disulfide bridge between two cysteine (Cys) residues at amino acid position Cys-8 of M 
and Cys-34 of GP5
73
. The heterodimerization of the GP5 and M is indispensable for viral 
infectivity and production of infectious virus particles
41,69,83
. The GP5/M disulfide-linked 
heterodimer complex acts as a bridge between the nucleocapsid and the viral envelope 
during viral assembly
83,84
. Lastly, the GP5/M heterodimerization complex plays an 
essential role in post-translational modification (i.e. glycosylation) and conformational 
maturation of the neutralization determinants in the GP5 ectodomain
82,85
.  
 
1.2. The replication cycle of EAV  
The EAV life cycle begins with the infection of susceptible cells with EAV 
(Figure 1.5.).  EAV can be replicated in various primary cell cultures including equine 
endothelial cells, equine kidney cells, monocytes, macrophages and a small 
subpopulation of CD3
+
 T cells
1,86–88
. EAV has tropism for a broad range of host cell types, 
and it can be propagated in several continuous cell lines such as baby hamster kidney 
(BHK-21), African green monkey kidney (Vero, MA-104), rabbit kidney (RK-13) and 
human kidney cells
1,89–91
. EAV infection is highly cytocidal in both primary and 
continuous cell lines, and it replicates to produce high titered virus causing cytopathic 
effect (CPE)
89,90
. 
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Figure 1.5. Schematic diagram of EAV replication cycle. ER: endoplasmic reticulum; 
ERGIC: ER-Golgi intermediate compartment; NC: nucleocapsid. Modified from 
Balasuriya et al. (2013) from Elsevier with permission
1
. 
 
1.2.1. Virus attachment and entry 
 The replication cycle of EAV involves virus attachment and entry, biosynthesis 
(viral genome replication, mRNA transcription and viral protein synthesis [translation]), 
virus assembly, budding and release
92
. Asagoe et al., (1997) have shown that heparin, 
which is a glycosaminoglycan (GAG), can inhibit EAV infection of RK-13 cells but the 
mechanism of the inhibitory activity by heparin was not elucidated
93
. The first step in the 
virus replication cycle is viral attachment and entry that is mediated by a specific receptor 
on EAV-susceptible cells
92
. Heparin sulphate (HS) is commonly used as an attachment or 
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binding molecule for numerous viruses and other pathogens as it is ubiquitously present 
on the surface of animal cells and in the extracellular matrix, where the initial interactions 
of viruses and target cells occur.  Thus, EAV may also be using HS on cell surfaces as the 
initial attachment molecule
94
. 
Recently, Sarkar et al. (2016) identified EqCXCL16S as an EAV entry receptor 
on EAV-susceptible cells
95,96
. CXCL16S protein has scavenger receptor properties and is 
expressed on equine endothelial cells, a subpopulation of CD3
+
 T cells and a 
subpopulation of CD14
+
 monocytes; its distribution in cells of the reproductive tract has 
not however been determined. The EqCXCL16 gene is located on equine chromosome 11 
(ECA11; positions 49572804 to 49643932), and encodes a type I glycosylated 
transmembrane protein
95,97
. Two isoforms of EqCXCL16 have been identified 
(EqCXCL16S and EqCSCL16R). Interestingly, the protein isoform EqCXCL16S but not 
EqCXCL16R can function as an EAV cellular receptor. Although both molecules have 
equal chemoattractant potential, EqCXCL16S has significantly higher scavenger receptor 
and adhesion properties compared to EqCXCL16R. However, EqCXCL16S is certainly 
not the only receptor because EAV can infect not only equine cells, but also a wide range 
of commonly used laboratory continuous cell lines from other species of animals
1,86–91
. 
Similar to other enveloped viruses, EAV tends to bind to a cell surface receptor followed 
by membrane fusion
95,98
; it is assumed to enter the cell via clathrin-dependent 
endocytosis
99,100
. However, EAV attachment and entry mechanisms still need to be 
further investigated. This should include investigation of the possible role of other virus 
attachment molecules on the cell surfaces, unknown receptors and co-receptors in 
different cells and the mechanism of fusion between EAV and the target host cell. 
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Specific viral proteins involved in EAV attachment and entry are not well 
characterized. However, there have been several studies that investigated the role of 
major (GP5 and M) and minor envelope (E, GP2, GP3 and GP4) proteins of the virus in 
EAV attachment and entry. Firstly, GP5 protein was assumed to be a virus attachment 
protein and acts as the receptor recognition. However, an in vitro reverse genetics 
experiment using a chimeric EAV construct in which the ectodomain of the EAV GP5 
protein was replaced by that of other arteriviruses (e.g. PRRSV or LDV) resulted in no 
alteration in the viral cell tropism
101
. This chimeric virus was still able to propagate in 
BHK-21 and RK-13 cells. Thus, the ectodomain of the GP5 protein was not the major 
determinant of EAV tropism in cell culture
101
. A similar study was performed with the 
ectodomain of the M protein of a PRRS mutant virus, where its exchange for that of EAV 
or LDV did not alter the tropism for porcine alveolar macrophages. It was concluded that 
the M protein of arteriviruses is not responsible for receptor binding
84
. Secondly, the E 
protein is noncovalently associated with the minor structural proteins that integrate the 
GP2/GP3/GP4 heterotrimeric complex
41
. Although the association of this complex is 
essential for viral infectivity, it is not required for the formation of EAV particles; studies 
have suggested that the GP2/GP3/GP4/E complex might be involved in the EAV 
attachment and entry process and that the virus uses more than one attachment molecule 
for binding to the host cell
41,69
. Thirdly, EAV was presumed to attach and enter the host 
cells via a mechanism of receptor-mediated clathrin-dependent endocytosis similar to 
PRRSV
99,100,102
. There are no definitive studies however that have identified the EAV 
viral proteins involved in virus attachment and entry or, for that matter, the detailed 
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mechanisms of viral entry and release of the EAV genome into the cytoplasm to initiate 
viral replication.   
 
1.2.2. Post-translation in processing of replicase polyproteins 
 Translation of the EAV replicase polyproteins (pp1a and pp1ab) generates at least 
13 nsps after cleavage mediated by three ORF1a-encoded proteases (nsp1, nsp2 and nsp4) 
(Figure 1.6.)
36,37,103
. The pp1a is translated directly from ORF1a and processed at seven 
cleavage sites into eight end products, nsp1 to nsp8, with several processing 
intermediates
44–46
. Expression of ppa1ab requires a -1 ribosomal frameshift mechanism 
and is processed into four major end products including viral RdRp and RNA helicase by 
nsp4 proteases
3,63
. 
 
Figure 1.6. Schematic representation of post-translational processing of EAV 
replicase polyproteins. The order of nsps of the EAV replicase polyproteins is numbered; 
their distinct characteristics are abbreviated as follows: leader sequence Mpro: 3C-like 
serine proteases (3CLSP); ZF and Z, zinc-finger and zinc-binding domain, respectively; 
C/H: cysteine/histidine-rich clusters; TM: predicted transmembrane domains; N and HEL: 
N-terminus and the nucleoside triphosphate-binding/helicase (HEL), respectively; and U: 
nidoviral-endonuclease specific for U (NendoU) domain. The PCP1β and CP cleavage 
sites are shown by black arrows. Multiple 3CLSP cleavage sites are located under the 
black triangle points. The structural proteins are highlighted in black. Modified from Van 
Hemert and Snijder. (2008) with permission
104
. 
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The nsp1 is characterized by a zinc finger (ZF) domain and papain-like cysteine 
protease (PCP) with inactive PCP1α and active PCP1β
37,105
. Although EAV PCP1α 
becomes inactive by the loss of an active Cys-site during virus evolution
53
, the PCP1β 
acts as a platform for the ZF domain during transcription
57
. The nsp1 is released from the 
replicase polyprotein by the autocatalytic activity of PCP1β resulting in the cleavage of 
the nsp1/2 site at its C-terminal domain for the purpose of viral sg mRNA 
synthesis
44,47,105
. Secondly, the N-terminal domain of nsp2 acts to activate the cysteine 
protease (CP) that releases the nsp2 from the replicase polyprotein after the cleavage of 
the nsp2/3 site by the internal cysteine autoprotease
44,49
. Furthermore, the mature nsp2 is 
responsible for the processing of the nsp4/5 site through either the major or minor 
processing pathway (Figure 1.7.). Thirdly, the N-terminal domain of nsp4 has 
chymotrypsin-like serine protease (SP) activity
52
. The nsp4 is the “main protease”, also 
known as a 3C-like serine protease (3CLSP), responsible for the production of the viral 
RdRp and NTPase/RNA helicase (nsp9 and nsp10, respectively)
37,46,106
. After nsp1 and 
nsp2 have been autocatalytically released from pp1a, nsp4 initiates further processing, 
cleavage of the polypeptides: five cleavage sites in nsp3-8 of pp1a and three cleavage 
sites in nsp3-12 of pp1ab via two alternative pathways (Figure 1.7.)
44–46,49,62,105
.  
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Figure 1.7. Two alternative proteolytic processing pathways of EAV replicase 
polyprotein pp1a. The important characteristics of EAV replicase polyproteins are 
abbreviated by P and P*: papain-like cysteine protease (PCPα/β) and cysteine protease 
(CP), respectively; Mpro: 3C-like serine protease (3CLSP); C/H: cysteine/histidine-rich 
clusters; and TM: predicted transmembrane domains. The PCP1β and CP cleavage sites 
are shown by black arrows. Multiple 3CLSP cleavage sites are located under black 
triangle points. Modified from the Nidoviruses book chapter: Van Hemert and Snijder. 
(2008) with permission
104
.  
 
As mentioned above, EAV PCP and EAV CP are responsible for processing the 
cleavage sites nsp1/2 and nsp2/3, respectively, to release nsp1 and nsp2 from the 
replicase polyproteins. The 3CLSP processes the rest of the polypeptides in the EAV 
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pp1a and pp1ab at the EAV 3CLSP-specific known cleavage sites: four at Glu|Gly site 
(nsp3/4, nsp5/6, nsp7/8/9 and nsp11/12), three at Glu|Ser sites (nsp4/5, nsp6/7 and 
nsp9/10), and one at Gln|Ser site (nsp10/11) (Figure 1.6.)
37,45,46,62
. There are two 
alternative (major and minor) pathways that have been identified in the processing of the 
carboxyl-terminal part of pp1a (nsp3-8) (Figure 1.7.)
45
. In the major processing pathway, 
the mature nsp2 acts as a cofactor that strongly associates with the processing of nsp3 or 
nsp3-carrying precursors including nsp3-8 required for further processing the nsp4/5 site 
by the nsp4 3CLSP
45
. The EAV 3CLSP first cleaves the nsp4/5 site, then processes the 
nsp3/4 and nsp7/8 sites which results in the rest of the remaining nsp5-7 intermediates 
remaining uncleaved (Figure 1.7.)
44,46
. However, in the case of the nsp2, this is absent 
and the 4/5 site cannot be cleaved; in which case the alternative minor processing 
pathway takes responsibility for further processing
45
. In the minor processing pathway, 
the nsp4/5 site remains uncleaved; instead, the cleavage processing occurs at the nsp5/6 
and nsp6/7 sites
45
. Then, further processing may occur at the nsp3/4 and 7/8 sites (Figure 
1.7.)
45
. 
 
1.2.3. Genome replication 
The typical feature of EAV and other arteriviruses is the formation of paired 
membranes and double-membrane vesicles (DMVs) after 3 to 6 hour post-infection 
(hpi)
107–111
. Expression of EAV nsp2-3 is essential for formation of DMVs
56,112
. Pedersen 
et al., (1999) demonstrated that EAV replicase subunit nsp9, which contains RdRp 
function, assembles the viral replication complex through membrane-associated DMVs 
where the RNA synthesis takes place. The outer membranes of EAV-induced DMVs 
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closely interact with the ER membranes of the target host cells and result in the formation 
of a reticulovesicular network (RVN)
113
. Electron spectroscopic imaging of DMVs has 
revealed the presence of EAV RNA genomes and has identified a network connection 
between EAV-induced RVN and nucleocapsid assembly
114
. Similarly, the presence of 
newly synthesized viral RNA genomes and many replicase subunits with numerous 
amounts of DMVs were observed near the perinuclear region in nidovirus-infected 
cells
112,115,116
. 
 The viral replicase polyproteins are visualized by immunoelectron microscopy to 
be part of the RTC, and DMVs are closely associated with newly synthesized viral RNA 
genomes
112,116–118
. Thus, DMVs are predicted to comprise the enzyme complex that plays 
an important role in viral replication and sg mRNA synthesis
56,112
. The EAV replicase 
subunits including nsp2-3 and nsp5 that have hydrophobic regions are predicted to impact 
the structural function of the anchored-RTC by inducing DMV formation
44,45,56,119
. 
Moreover, a recent study has shown that the isolated RTC-comprised replicase subunits 
are involved in DMV formation (nsp2-3) or viral replication (nsp9-10) with the 
accumulation of newly synthesized viral RNA genomes
120
, indicating the association 
with DMV and its essential role in RTC function
1
. As described above, the assembly of 
the EAV replication complex is based on the expression of replicase polyproteins and the 
membrane of viral induced- and host cell-derived DMVs that lead to viral RNA 
synthesis
92
.  
The EAV genome is a polycistronic RNA molecule that consists of a 5′ cap and 3′ 
poly (A) tail structures
33
. While the EAV RdRp replicates (+) the viral genomic strand 
into full-length (-) viral strands (or anti-sense genome) as full-length (-) strand templates 
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synthesize more (+) viral genomic strands
92
, the subgenomic-sized (-) strands are 
produced to synthesize sg mRNAs during a process of discontinuous RNA synthesis as 
with other nidoviruses
39,66,102,121
. The recognition of signals at the 3′-end of the full-length 
(-) strand viral templates is required for the production of new genomic RNA
122,123
. 
During viral RNA synthesis, more (+) strands are generated than (-) strand RNA 
genomes
124
.   
 
1.2.4. Viral sg mRNA transcription  
 The EAV genome has a 5′ UTR of approximately 225 nucleotides (nts) that 
prevents exonuclease-mediated degradation
125
. Furthermore, the 5′ UTR contains a 
common 5′ leader sequence (211 nt in length)
33
. As in the case of other nidoviruses, EAV 
sg mRNAs synthesis involves a discontinuous transcription mechanism
121
. This 
discontinuous extension of (-) stranded RNA is controlled by the transcription regulatory 
sequence (TRS; Figure 1.8.), a short and conserved sequence element (5′-UCAACU-3′), 
which is essential for leader-to-body joining via a base-pairing interaction between (+) 
and nascent (-) stranded RNAs
126–128
. The leader TRS is located in a hairpin loop 
structure at the 3′-end of the leader sequence
129
 and several body TRSs are found 
upstream of structural protein genes, except for ORFs 2b and 5a
29,39,40,43
. The primary 
sequence of the body TRS located at an active site in each of the six sg mRNAs will be 
transcribed; it plays a significant role in discontinuous RNA synthesis
66,126,127,130,131
. The 
existence of TRSs was also found in the replicase genes
43
.   
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Figure 1.8. Illustration of the replication and transcription model in nidoviruses. (A) 
After viral replication, the “discontinuous extension of (-) strand RNA model” occurs by 
using the sg (+) strand as a template for sg mRNA synthesis
121
. The process by which 
translocation of the nascent (-) strand to the leader TRS region occurs is called RNA 
strand transfer
127,128
. The (-) strand RNA synthesis reinitiates by base pairing interaction 
between the antisense body TRS and sense leader TRS added to the anti-leader sequence. 
The sg-length nascent (-) strand RNA is used as a template strand for sg mRNA synthesis. 
The (+) and (-) strand RNAs are shown in white and black, respectively. The sense leader 
and body TRSs are indicated in red and yellow boxes on the (+) strand RNA and 
antisense leader and body TRSs are shown as black boxes on the (-) strand RNA. (B) 
Like viral genomic replication, the viral sg mRNA transcription is regulated directly by 
the RdRp complex. LTH: leader TRS hairpin; The figure (A) modified from Pasternak et 
al. (2006) with permission from the Journal of General Virology and figure (B) is 
reprinted from van den Born et al. (2005) with permission
66,129
.  
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 The sg (-) strand RNA genomes are used as templates for further sg mRNA 
synthesis
124
. During discontinuous transcription, the viral RdRp controls termination and 
reinitiation of transcription, indicating that the nidovirus transcription model assembles 
by a similar-assisted, copy-choice RNA recombination (Figure 1.8.B.)
128,132,133
. The 
RdRp complex and 3′-end of nascent (-) strand transcript are released and translocated 
from the body TRS at the leader sequence region in the 5′-end of the (+) strand genomic 
template where transcription is reinitiated. During (-) strand synthesis reinitiation, a 
nested set of sg-length nascent (-) strand templates are extended with the complement of 
the genomic leader sequence for the subsequent synthesis of the various sg mRNAs
1
. 
This leader-to-body joining via base-pairing interaction between antisense body TRS at 
the 3′-end of the nascent (-) strand and the sense leader TRS in the (+) genomic template 
generates the additional anti-leader sequence and has an impact on RNA strand transfer 
(Figure 1.8.B.)
127,128
. Additionally, the predicted secondary structure of the leader 
sequence located at nucleotide position nt 1-211 is also important for the sg RNAs 
synthesis
129,134
. The leader sequence forms a hairpin structure called leader TRS hairpin 
(LTH) (Figure 1.8.B.)
128,134
. The synthesis of (-) strand RNA started from the 3′-end of 
the EAV genome becomes attenuated at one of the body TRS regions
66,67
. If attenuation 
does not happen, (-) strand RNA synthesis continues to generate a full-length 
complement of the genome as the intermediate step in EAV replication
121
. Like viral 
genomic replication, the viral sg mRNA transcription is regulated directly by the RdRp 
complex and occurs on the membrane of virus-induced and host cell-derived DMVs
92
.  
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1.2.5. Virus assembly, budding and release  
 The newly synthesized viral RNA genome is encapsulated by nucleocapsid 
formation
1
. EAV obtains its envelope containing viral envelope proteins through the 
internal membranes of infected cell, and assembly takes place in the cytoplasmic region 
near the ER
135
. The budding and maturation processes happen at the ERGIC
1
. The 
completely formed EAV virions mature in the Golgi complex and are released via an 
exocytic pathway from the infected host cells (Figure 1.5.)
1
. 
 As previously described, the seven envelope structural proteins (E, GP2, GP3, 
GP4, ORF5a protein, GP5 and M) are essential for the production of infectious progeny 
virus
40,73,136
. Moreover, the major envelope proteins (GP5, M and N) form virus-like 
particles (VLPs)
41
. However, producing VLPs by the cotransfection of infected cells with 
plasmids encoding EAV GP5, M and N proteins was unsuccessful, indicating that 
additional factors are involved in virus assembly
40,41
. EAV assembly occurs in 
association with nucleocapsid formation, and thus EAV assembly will not take place 
without it
40,41
. However, the interaction between EAV N protein and viral genomic RNA, 
the formation of icosahedral nucleocapsid, and the copy numbers of EAV N proteins 
required to form the nucleocapsid remain unknown
92
. 
The EAV nucleocapsid becomes enveloped though the GP5/M disulfide-linked 
heterodimer complex which acts as a mediator between the nucleocapsid and the viral 
envelope during viral assembly
83,84
. This also suggested that the GP5/M 
heterodimerization complex forms the basic protein matrix of the envelope
77
. From the 
individual expression of these major enveloped proteins, EAV GP5 and M proteins were 
observed only in the ER; however, co-expression of the M and GP5 proteins resulted in 
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the M protein presenting both in ER and ERGIC and the GP5 protein co-localized with 
the M protein only in the ERGIC
85
. This result suggested that transport of EAV GP5 and 
M proteins from ER to the ERGIC depends on the formation of a GP5/M 
heterodimerization complex
85
. Snijder et al. (2003) further confirmed this by genetic 
engineering introducing mutations of Cys residues at amino acid position Cys-8 of M 
protein and Cys-34 of GP5 protein. As a result, mutations caused the blocking of the 
GP5/M heterodimerization complex and virus assembly, interrupting the transport of both 
GP5 and M from Golgi to the ERGIC and production of infectious viral progeny
83
. The 
authors concluded that the GP5/M heterodimerization complex is a prerequisite for virus 
assembly and occurs in the ER. Additionally, the interaction between cytoplasmically 
exposed domains of the GP5/M heterodimerization complex and the synthesized 
nucleocapsid suggested that EAV nucleocapsids bud in the ERGIC by acquiring lipid 
membrane-carrying viral envelope proteins
92
. 
After EAV nucleocapsid formation, the minor envelope proteins (E, GP2, GP3 
and GP4) also gather at the lipid membrane of the ERGIC and bud into the lumen
92
. The 
minor enveloped proteins form a GP2/GP3/GP4 heterotrimeric complex and along with 
the E protein, they participate in the process of viral attachment/entry and production of 
infectious viral progeny
1,76
. GP2 and GP4 form a heterodimer, which subsequently 
covalently associates with GP3
137
. The intermolecular cysteine bridges with an intra-
chain disulfide bond at the amino acid position Cys-48, 102 and 137 play a significant 
role in the conformation and stabilization of the GP2/GP3/GP4 heterotrimeric complex 
(Figure 1.3.)
74,75,137
. When a protein subunit of the GP2/GP3/GP4 heterotrimeric complex 
is missing, the formation of the heterotrimeric complex fails and the amount of E protein 
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in the viral envelope decreases
41
. Furthermore, the absence of E protein will entirely 
block the formation of the GP2/GP3/GP4 heterotrimeric complex in the EAV particle
41
. 
With the formation of the EAV nucleocapsid bud into the ERGIC, the virus 
obtains a lipid membrane consisting of viral major and minor envelope proteins to form 
the virus particles. The newly produced EAV particles are transported from the 
intracellular compartments to the plasma membrane of the EAV-infected cell, and then 
finally, the virus particles exit the cell through exocytosis
92
. 
 
1.3. Equine viral arteritis  
1.3.1. Epidemiology 
EVA is a reproductive and respiratory disease of equids caused by 
EAV
16,9,13,18,138–141
. EAV was first isolated from the lung of an aborted fetus during an 
extensive outbreak of the respiratory disease and abortion at a Standardbred breeding 
farm near Bucyrus, Ohio, in 1953
9,14
. EAV causes a significant economic impact on the 
equine industry due to the occurrence of abortion, neonatal death and establishment of 
persistent infection in stallions
9,14,139,142,143
. According to serological surveys, EAV has a 
worldwide distribution that includes North and South America, Europe, Australia, Africa 
and various countries in Asia
11
. Iceland, Japan and New Zealand are known as free from 
the disease
144
. EAV seroprevalence varies according to age and breed. For instance, in the 
United States a very high percentage of adult Standardbred and Saddlebred horses are 
seropositive (70-90% and 8-25%, respectively) while a low serprevalence is observed in 
the Thoroughbred population (<5.4%)
11,145–148
. The 1998 National Animal Health 
Monitoring System (NAHMS) equine study reported only 0.6% EAV seropositivity in 
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the Quarter horse population in the United States
149
, but an extensive EVA occurrence 
involving multiple states during 2006 to 2007 probably increased the seroprevalence in 
the Quarter horse population
150
. In Europe, a high seroprevalence is observed among 
Warmblood stallions and Spanish purebred horses (55-93% and 17.3%, respectively)
151–
153
. Variability in EAV seroprevalence is correlated with age and sex
154
. Recent studies 
have suggested the linkage of a specific dominant haplotype of the EqCXCL16 gene 
located in ECA11 at positions: 49572804 to 49643932 with the susceptibility of CD3
+
 T 
lymphocytes to in vitro EAV infection and the establishment of persistent infection
86,87,155
. 
It has been shown that those stallions with CD3
+
 T lymphocyte susceptiblity phenotype 
have a higher risk of becoming long-term EAV carriers than those that lack this 
phenotype
155
. 
 
1.3.1.1. Transmission 
Transmission of EAV between horses occurs by the horizontal, venereal and 
vertical routes
11,14,138,139,156,157
. Horizontal transmission happens by the aerosolization of 
respiratory secretions or fetal fluids at time of abortion.  During the acute phase of 
infection, the virus spreads via the respiratory route by the aerosolization of respiratory 
secretions
13,138,141,152,158–160
. Nasal shedding continues for 7 to 14 days with viral titers 
ranging from 10 to >2 x 10
3
 plaque-forming units per mL (PFU/mL)
138,161,162
. Venereal 
transmission occurs through infective semen during natural breeding, artificial 
insemination (AI) and embryo transfer. The venereal transmission happens via the semen 
of both acutely and persistently EAV-infected stallions by natural or artificial breeding
157
. 
Most EVA outbreaks are caused by venereal transmission after a naïve mare is bred to an 
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EAV carrier stallion
163,164
. Approximately, 10 to 70% of EAV infected stallions can 
become persistently infected and continuously shed EAV in their semen for several 
weeks to years or lifelong with the presence of high levels of neutralizing antibodies in 
serum
11,156,157
. The establishment and maintenance of the EAV carrier state in the stallion 
is testosterone-dependent and the virus mainly persists in the ampulla of the vas 
deferens
165
. Carrier stallions constitute the natural reservoir of EAV and are responsible 
for the maintenance, perpetuation and evolution of EAV in equine 
populations
11,17,19,21,142,146,164,166
. Previous studies have demonstrated that EAV evolves in 
the stallion reproductive tract resulting in the emergence of novel viral genetic variants 
with neutralizing phenotypes that allow for viral immune escape
17,142,164,166
. EAV can also 
be spread from donor mares inseminated with EAV-contaminated semen to naïve 
recipient mares through embryo transfer
167
. Vertical (transplacental) transmission occurs 
from pregnant mares to the fetus during the latter stage of pregnancy
168
. Congenital 
infection of foals results in development of rapid progressive, fulminating interstitial 
pneumonia and fibrinonecrotic enteritis
169–173
. Lastly, the lateral transmission of EAV can 
also take place through contact with EAV-contaminated fomites that include personnel, 
clothing, vehicles and equipment such as artificial vaginas and phantoms
11,146,160
.  
 
1.3.1.2. Immune response to EAV infection 
EAV infection induces a strong and protective immune response in the host
154
. 
Even though the innate immune response has not yet been fully understood, recent 
studies have demonstrated that EAV regulates the innate immune response by blocking 
type I interferon (IFN) production
174
. Specifically, the three EAV nonstructural proteins 
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(nsp 1,2 and 11; mainly nsp1) have the ability to inhibit IFN synthesis. After EAV 
infection, the horse develops EAV-specific complement-fixing (CF) and viral 
neutralizing (VN) antibodies
154,175,176
. These CF and VN antibodies are initially detected 
within 7 to 14 days post-infection (dpi) and reach their peak by 2 to 3 weeks or 2 to 4 
months post-infection, respectively
162,176–179
. Although CF antibodies decrease by 8 
months post-infection, VN antibodies last for 3 years or longer
180
. Foals receive VN 
antibodies through the colostrum of immunized mares, which provide them with 
protection against EAV infection. Although high neutralizing antibody titers remain in 
serum, EAV still persists in the stallion reproductive tract
97,98
. Recently, it has also been 
shown that EAV also induces a mucosal antibody response in the reproductive tract with 
shedding of virus-specific immunoglobulins (IgA, IgM, IgG1, IgG3/5 and IgG4/7) into 
the seminal plasma as well as the homing of plasma cells in the accessory sex glands
165
. 
However, despite the systemic neutralizing antibody, local inflammatory and mucosal 
antibody responses, EAV evades local host immunity mechanisms and persistence is 
maintained.  
 
1.3.2. Clinical signs 
 Most primary EAV infections are subclinical or inapparent. However, when 
clinical signs of EVA develop, they present as an influenza-like illness in adult horses, 
abortion in pregnant mares and interstitial pneumonia or pneumoenteritis in young 
foals
11,13,171,181182
. The range and severity of the clinical signs depends on various factors 
including an individual’s genetic background, age, physical and environmental conditions, 
route of exposure, challenge dose and viral strain
11,140
. Field strains of EAV can vary in 
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virulence and in the clinical severity of the disease they cause. For instance, some field 
strains cause moderate to severe disease (e.g. EAV KY84, AZ87, IL93 and PA96 strains), 
moderate disease (e.g. EAV PA76 and KY77 strains), mild disease (e.g. EAV SWZ64, 
AUT68, IL94 and CA97 strains) or asymptomatic infection (e.g. EAV KY63 and CA95 
strains)
15,16,21,23,96,183–190
. While the highly virulent experimentally-derived horse-adapted 
Bucyrus strain of EAV (EAV VBS) can cause high morbidity and mortality in healthy 
mature horses following infection, in natural outbreaks of EVA caused by field strains of 
EAV, mortality is very uncommon
11,183
. 
 Acutely infected animals may develop a wide range of clinical signs
154
. The 
average incubation period is 3 to 14 days (6 to 8 days after venereal transmission 
exposure). Infected horses may develop respiratory disease and reproductive 
consequences including the development of pyrexia of up to 41°C (39-41°C) which may 
last for 2 to 9 days. Infected animals may also develop all or any combination of the 
following clinical signs: depression, anorexia, nasal and/or ocular discharge, 
conjunctivitis, rhinitis, leukopenia, periobital or supraorbital edema, edema of the limbs, 
edema involving the scrotum and prepuce of the stallion and mammary glands of the 
mare, urticarial around the head, sides of neck and/or body and abortion of pregnant 
mares
9,11,140,191–193
. Other less frequent clinical signs include icterus, photophobia, corneal 
opacity, coughing, dyspnoea, colic, diarrhea, ataxia, petechiation of the nasal mucosa, 
conjunctiva and oral mucous membranes, submaxillary and submandibular 
lymphadenopathy and adventitious edema in the intermandibular space, beneath the 
sternum or in the shoulder region
9,139,180,191,193–195
. The most frequent clinical signs of 
EVA include pyrexia and leukopenia. Most naturally infected horses recover 
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spontaneously. Abortion in pregnant mares may occur from early to late gestation (3 to 
over 10 months of gestation) and abortion rates have varied from less than 10% to >70%. 
Congenitally infected foals develop a rapidly progressive pneumoenteric syndrome and 
severe fulminating interstitial pneumonia
169–171
. 
 
1.3.3. Pathogenesis 
The pathogenesis of EVA has been studied by following natural outbreaks or by 
experimentally inoculating horses with different EAV 
strains
9,14,138,138,139,159,161,177,183,184,193,196–199
. Following initial infection, viral replication 
occurs within alveolar macrophages and bronchiolar epithelial cells, with subsequent 
spread to regional (respiratory tract-associated) lymph nodes within 42 hpi
138,146,200
. 
Within 72 hpi, a cell-associated viremia develops and frequently lasts for 3 to 19 dpi. 
During the viremic phase, the virus spreads throughout the body replicating in pulmonary 
macrophages, vascular smooth muscle cells and endothelial cells and causing a systemic 
panvasculitis
1,138,183,194,198,201–203
. The severe systemic panvasculitis of small vessels with 
endothelial cell injury increases vascular permeability and leukocyte infiltration. This can 
cause foci of intimal, subintimal and medial necrosis with hemorrhage, edema and 
permeation with lymphocytes and neutrophils in the muscular arteries
183,189,197,198,201,202
. 
The endothelial cells and macrophages are recognized as the principal target cells as well 
as all the epithelial, mesothelium and smooth muscle cells of the tunica media of smaller 
arteries, venules and the myometrium
179,202
. However, the relative roles and importance 
of direct virus-mediated endothelial cell injury and increased vascular permeability in the 
pathogenesis of EAV infection have not yet been clearly defined
179
. 
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Recent studies of the pathogenesis of EAV infection have demonstrated that the 
virus localizes in CD3
+
 T lymphocytes, CD172a
+
 myeloid cells and a small population of 
IgM
+
 B lymphocytes in the connective tissue
204
. Interestingly, the virus was not detected 
in epithelial cells in the upper respiratory tract during the acute infection period
204
. The 
nasopharynx and tubal-nasopharyngeal tonsils are suggested to be important primary sites 
of EAV replication
189
. Previous in vitro and in vivo studies with EAV have suggested that 
increased transcription of genes encoding the proinflammatory interleukin (IL) mediators 
IL-1β, IL-6, IL-8 and tumor necrosis factor (TNF-α) play a significant role in determining 
the severity of the disease
186
. Recently, Go et al. (2012) demonstrated experimental 
inoculation of horses with in vitro CD3
+
 T cell susceptible and resistant phenotype with 
EAV generate different levels of proinflammatory and immunomodulatory cytokine 
mRNAs. Additionally, horses with in vitro CD3
+
 T lymphocyte resistant phenotype 
developed more severe clinical signs than the horses with the susceptible CD3
+
 T 
lymphocyte phenotype
205
. 
EAV infection can result in abortion in pregnant mares. Fetuses and placentas 
may be partially autolyzed at the time of expulsion
9,14,193
. Johnson et al. (1991) suggested 
that abortion in mares is caused by systemic vascular necrosis that weakens uterine and 
placental blood supply. It has also been suggested that the abortions are caused by the 
vasculitis of myometrial blood vessels with placental dysfunction
202
. MacLachlan et al. 
(1996) have suggested that abortion happens due to EAV infection directly affecting the 
fetus causing stress and interfering with the fetal hypothalamic-pituitary axis. There are 
no pathognomic gross or histopathological lesions associated with abortion. Interlobular 
pulmonary edema, pleural and pericardial effusion, and petechial and ecchymotic 
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hemorrhages on the serosal and mucosal surfaces of the small intestine were observed on 
necropsy of an aborted fetus
202
.  
With the exception of persistently infected stallions, viral clearance from serum 
and body tissues usually occurs at ~28 dpi and coincides with an increase in serum 
neutralizing antibodies
206,207
. However, an in vivo study by Vairo et al. (2012) recently 
reported that the virus could still be demonstrated in the tonsil at 28 dpi. In the carrier 
stallion, EAV primarily persists in the ampullae of the vas deferens
165,189,208,209
. Recently, 
Carossino et al. (2017) has determined the specific tropism of EAV for stromal cells and 
identified that the virus primarily persists in fibrocytes and T (CD2
+
, CD3
+
, CD5
+
 and 
CD8
+
) and B  (CD21
+
) lymphocytes in the ampullae
165
. The study indicated that EAV 
expresses different host-cell tropism depending on the tissue compartment and duration 
of infection (i.e. acute vs. chronic)
165
. For instance, EAV infects CD3
+
 T lymphocytes 
and CD14+ monocytes, but does not infect CD21
+
 B lymphocytes in the accessory sex 
glands of the stallion reproductive tract
87
. The authors concluded that EAV persistence 
may drive immunosuppression and/or T cell exhaustion to suppress the host immune 
response
165
. The viral strategy of host immune evasion has to be further determined.  
Recently, Carossino et al. (2017) investigated the EAV tissue and cellular tropism 
in the reproductive tract and the inflammatory response induced during persistent 
infection. They used reproductive tract tissues from normal, short-term and long-term 
EAV carrier stallions in their studies. EAV tissue and cellular tropism was determined by 
virus isolation, nucleocapsid-specific single and dual immunostaining (IFA/IHC) and 
transmission electron microscopy (TEM). The inflammatory response was characterized 
by histopathology and IHC using a panel of differentiation (CD) markers. The ampulla 
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was demonstrated to be the tissue with the highest viral titer (1.0 x 10
3
 – 1.7 x 10
5
 PFU/g) 
among the accessory sex glands of carrier stallions. Dual IFA/IHC demonstrated the 
presence of viral antigen in fibrocytes and lymphocytes (mainly CD3
+
 [CD8
+
] and CD21
+
) 
within the lamina propria and inflammatory infiltrates in the ampullae. The virus was not 
detected in the epithelium of the ampullae or any other accessory gland. The 
inflammatory response was characterized by multifocal lymphoplasmacytic ampullitis 
which included moderate and high infiltration of CD4
+
/CD25
+ 
and CD8
+ 
T lymphocytes, 
respectively; clusters of CD21
+
 B lymphocytes and moderate Iba-1
+
 and CD83
+
 
macrophage and dendritic cell infiltration. Evidence of CD25
+
 and FOXP3
+
 T regulatory 
lymphocytes with lack of expression of IFN-gamma and limited expression of granzyme 
B in CD8
+
 T lymphocytes indicate that immunoregulatory mechanisms in conjunction 
with CD8
+
 T cell exhaustion are likely involved in maintenance of persistent infection. In 
summary, EAV was demonstrated to be primarily lymphotropic (including T and B 
lymphocytes with a restricted homing pattern to the ampulla) and fibrocyte-tropic 
(vimentin
+
). Despite the strong local inflammatory and serum neutralizing antibody 
response, EAV evades host immunity in a tissue under immune surveillance and is 
capable of establishing long-term persistence in the male reproductive tract. Furthermore, 
EAV was not detectable in lymphoid tissues including those associated with lymph 
drainage from the reproductive tract, suggesting that infected T and B lymphocytes 
exhibit a specific homing pattern to the reproductive tract and restricted migration from 
reproductive tract tissues to secondary lymphoid organs.  
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1.3.4. Persistent EAV infection 
As previously mentioned, EAV persists exclusively in the reproductive tract of 
infected stallions. During the acute phase of the disease (average range of first 21 days), 
the stallions show decreased libido and reduced sperm motility, concentration and 
percentage of morphologically normal sperm cells
156,190,191
. Subsequently, 10 to 70% of 
infected stallions and sexually mature colts remain persistently infected and continuously 
shed EAV in their semen for weeks, months, years or lifelong without alteration in the 
semen quality
143,156,157
. Viral shedding appears in semen at 5 dpi and is associated with 
the sperm-rich fraction of the ejaculate
157,210,211
. Viral titers in seminal plasma show a 
broad range (10
1
 to >10
7
 PFU/mL)
209,211
. Although the duration of the carrier state can 
vary, it has been arbitrarily divided into three categories: short-term carrier state (several 
weeks), intermediate carrier state (3 to 7 months) and the long-term persistent or chronic 
carrier state (years and even lifelong) 
11,156
.  
The mechanism(s) involved in EAV persistence and the factors that lead to viral 
clearance in stallions is not yet defined. However, the establishment and maintenance of 
the EAV carrier state in the stallion is testosterone-dependent
11,209,212
. Thus, surgical 
castration of carrier stallions is the only certain method to cause cessation of viral 
shedding
212
. Previous studies have suggested that testosterone is strongly associated with 
an interaction between the host immune response and EAV in the reproductive tract such 
as immunosuppressive activities or maintenance of a susceptible host cell population that 
results in maintenance of EAV persistence
208,213–216
. It is proposed that high levels of 
testosterone in the stallion reproductive tract are important during long-term EAV 
persistence, but not for viral replication or persistence of intermediate duration
217
. An in 
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vivo study of attempted establishment of persistent EAV infection in prepubertal and 
peripubertal colts has demonstrated that the carrier state could not be established without 
the presence of testosterone during intermediate duration
217
. Thus, the carrier state of 
EAV infection is androgen-dependent, and so persistent infection cannot occur in 
prepubertal colts, mares, geldings and fetuses
11,140,156,209,212
.  
As indicated above, carrier stallions provide the means by which EAV 
evolves
11,17,19,21,142,146,164,166
. EAV continuously evolves via genetic divergence called 
EAV quasispecies during persistent infection in the stallion reproductive tract
142,163,164
. 
EAV quasispecies generate novel genetic variants with phenotypic diversity that 
contributes to the occurrence of EAV
142,163,164,218
. Significant nonsynonymous 
substitutions at high rates were observed in GP3 and GP5 proteins suggesting that ORF3 
and ORF5 are under strong selective pressure in persistently infected stallions
16,17,142
. A 
limited number of critical amino acid substitutions were especially observed in the V1 
variable region of the GP5 protein (aa 61 to 84)
16,218
. The emergence of viral variants 
from EAV quasispecies present in the long-term carrier may be endowed with novel 
genetic and phenotypic properties (i.e. neutralization) and could be susceptible for new 
outbreaks of EVA
17,142,156
.  
 
1.4. Diagnosis of EAV infection 
1.4.1. Appropriate specimen collection for examination 
Equine viral arteritis clinically mimics a number of other infectious and non-
infectious diseases and therefore, it is not possible to establish a diagnosis of EVA based 
solely on the nature of clinical signs
89
.
  
Thus, the clinical diagnosis of EVA should be 
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confirmed by laboratory diagnosis.  During the acute phase of the disease, the most 
appropriate specimens include nasopharyngeal swabs or washings, conjunctival swabs 
and blood samples for separation of buffy coat cells (citrated or in 
ethylenediaminetetraacetic acid [EDTA]) for virus isolation (VI) or PCR
219
. From 
infected stallions, semen samples containing the sperm-rich fraction are essential for VI 
or PCR
11
. During the necropsy of aborted fetuses, clinical specimens including placenta, 
fetal fluids, lung, spleen and lymphoid tissues should be collected for VI, PCR or 
immunostaining to confirm cases of EAV-induced abortion
219
. All clinical samples listed 
should be stored and submitted under conditions of refrigeration via overnight delivery 
for laboratory testing. After a necropsy, tissue samples should be fixed and placed in 10% 
neutral buffered formalin for virus detection, histopathologic examination and 
immunohistochemical staining
220
. In suspicious cases of EVA in young foals, various 
organs and lymph nodes associated with the gastrointestinal and respiratory tracts should 
be collected
219
. Serum samples are collected for serologic diagnosis, and paired samples 
obtained at least 14 days apart or preferably a 21-to 28-day interval are recommended
219
. 
 
1.4.2. Virus isolation in cell culture 
 VI is the World Animal Health Organisation (OIE)-approved “gold standard” test 
for EAV detection, especially in semen samples from stallions and is the prescribed test 
for international trade
221
. VI should be attempted from specimens collected from clinical 
or fatal cases using rabbit, equine or monkey kidney cell cultures in accordance with 
established procedures
222
. The cell system of choice for VI is the rabbit kidney cell line 
(RK-13), and generally EAV can be isolated on first or second passage.  However, some 
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strains may require additional blind passages in cell cultures
169
.
 
Virus isolates should be 
further confirmed by cross neutralization assay using EAV-specific equine antiserum or 
specific standard or real-time RT-PCR
223
.   
 
1.4.3. Molecular diagnosis (nucleic acid detection by RT-PCR) 
 Molecular testing (i.e. detection of viral nucleic acids) has several advantages 
including high sensitivity, rapid turnaround, convenience and cost
224
. Several molecular 
diagnostic assays (reverse transcription polymerase chain reaction [RT-PCR]) have been 
developed including RT-PCR and RT-nested PCR (RT-nPCR), real-time RT-PCR (rRT-
PCR) and insulated isothermal RT-PCR (iiRT-PCR) assays for EAV nucleic acid 
detection from clinical specimens
225–231
. The primers/probes have been designed to target 
conserved regions of the viral genome, and especially target the 3′-end of ORF1b of the 
viral polymerase gene and ORF7 (encoding N protein)
225,226,228,229
.  
The RT-nPCR assay is more sensitive than the standard RT-PCR but it tends to 
give false positive results due to cross contamination of a sample
219
. In light of this, the 
rRT-PCR which avoids handling of PCR amplicons has replaced gel-based assays
219
. 
Previous studies evaluated the rRT-PCR assay and proved an equal or higher sensitivity 
than VI for EAV detection
232
. Recently, a TaqMan
®
 probe-based iiRT-PCR assay has 
been developed for qualitative detection of EAV nucleic acid from clinical 
specimens
233,234
. This system is based on the use of the field-deployable POCKIT
TM 
Nucleic Acid Analyzer (GeneReach USA, Lexington, MA, USA) which allows point-of 
need use
234,235
  including veterinary clinics, racetracks, breeding facilities and diagnostic 
laboratories
233
.  
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Recently, two RNA in situ hybridization (ISH) assays (conventional and 
RNAscope
®
 ISH) for the detection of EAV RNA in formalin-fixed paraffin-embedded 
(FFPE) tissues have been described
236
. The conventional RNA ISH assay had a 
significantly lower sensitivity as compared to the RNAscope
®
. The use of oligonucleotide 
probes along with a signal amplification system (RNAscope
®
) can enhance detection of 
EAV RNA in FFPE tissues. 
 
1.4.4. Antigen visualization by immunohistochemistry 
EAV antigen can also be demonstrated in FFPE tissues from aborted fetuses using 
nucleocapsid-specific monoclonal antibody (immunohistochemistry [IHC])
236
. Evaluation 
of 80 FFPE tissues collected from 16 aborted fetuses showed that IHC had a similar 
sensitivity to RNAscope
®
. The conventional RNA ISH assay had a significantly lower 
sensitivity as compared to the RNAscope
®
 and IHC assays.  
 
1.4.5. Serological diagnosis 
The virus neutralization test (VNT) is the current OIE-approved “gold standard” 
test for EAV antibody determination required for international trade
221
. Although the 
VNT is highly sensitive and accurate, it has a few disadvantages including cost, labor, 
turnaround time and variability among different laboratories. It requires standardized 
reagents and protocol
224
. Furthermore, serum cytotoxicity due to anti-cellular antibodies 
directed against RK-13 cells can interfere with test interpretation at lower serum 
dilutions
224
. Also, the VNT cannot distinguish antibody responses between vaccinated 
and naturally infected horses
224
. To get over the disadvantages of VNT, several enzyme-
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linked immunosorbent assays (ELISA) have been developed and evaluated to detect 
EAV-specific antibodies using whole virus, synthetic peptides or recombinant viral 
proteins (e.g. GP5, M and N) as antigens
215,219,237–243
.  
The GP5 is the major target as an antigenic protein of virus neutralization that has 
the potential for development of serological diagnostic assays
224
. Since the M and N 
proteins consist of conserved sequences among different EAV strains and isolates, these 
proteins also have the potential to be used as antigens for diagnostic purposes
244
. Firstly, 
an ELISA using a recombinant fusion protein expressing GP5 (aa 55-98) had a sensitivity 
and specificity of 99.6% and 91.1%, respectively
239
. Another ELISA based on the 
ovalbumin-conjugated synthetic peptide containing amino acids 81-106 of GP5 had a 
sensitivity and specificity of 96.7% and 95.6%, respectively
237
. Secondly, an ELISA 
using sera from naturally or experimentally infected horses against a cocktail of 
recombinant GP5, M and N proteins expressed in baculoviruses resulted in a sensitivity 
and specificity of 100% and 92.3% respectively; it was not able to detect antibodies in the 
sera from the vaccinated horses
215
. Thirdly, a blocking ELISA using partially purified 
EAV and MAb against the GP5 protein was developed, and it provided a sensitivity and 
specificity of 99.4% and 97.7%
238
. Fourthly, an ELISA using the carboxyl terminus of 
the M protein (aa 88-162) is frequently recognized by EAV-specific equine sera
245
. 
Lastly, a microsphere immunoassay (MIA) has been developed using a combination of 
microspheres and three well-developed technologies: bioassays, solution-phase 
microspheres and flow cytometry
224
. However, all of the above mentioned ELISA assays 
were neither sensitive nor specific enough to replace the VNT. Recently, a commercial 
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cELISA assay (VMRD, Pullman, WA) was developed that showed high sensitivity and 
specificity compared to the VNT, but this needs further evaluation
219
.  
 
1.4.6. Differential diagnosis 
 A range of viral (e.g. equine herpesvirus 1 and 4 infections and equine influenza), 
and bacterial (e.g. Streptococcus) respiratory diseases that commonly affect horses cannot 
be distinguished clinically from EVA. Other infectious diseases that can cause systemic 
signs of illness resembling EVA are equine infectious anemia, dourine, African horse 
sickness fever and Getah virus infection. EVA also bears many many clinical similarities to 
the syndrome caused by hoary alyssum (Berteroa incona) toxicosis. Abortions or deaths in 
foals due to EAV need to be differentiated in particular from those caused by equine 
herpesvirus 1 as well as other infectious causes of abortion in the mare
97,98
. 
 
1.5. Treatment of EVA 
1.5.1. Antiviral therapy  
Even though several antiviral medications have been investigated, there is still no 
effective antiviral treatment for EAV infection
150,219,246
 A potential antiviral compound 
(phosphorodiamidate morpholino oligomers [PMOs]) has been evaluated
150,246
. PMOs are 
20-25 bases in length of single-stranded DNA analogues that tend to be water-soluble and 
nuclease-resistant
247,248
. PMOs form base pairs with complementary viral RNA target 
sequences to interfere with viral gene expression and its translation
248,249
. Additionally, 
peptide-conjugation to the PMO (P-PMO) is involved in transporting more PMO into 
infected cells
250
. The 5′ UTR of the EAV genome is the most sensitive target site of P-
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PMOs
246
. According to in vitro studies, 5-10 uM of antisense P-PMO was able to target 
the EAV 5′ terminus from persistently infected HeLa cells
150
. However, the in vivo 
efficacy of P-PMO therapy needs to be evaluated. 
 
1.5.2. Anti-GnRH vaccination and GnRH antagonists 
Previous studies have demonstrated that the application of gonadotropin-releasing 
hormone [GnRH] antagonists, anti-GnRH vaccination and single-layer centrifugation
251–
259
 can facilitate viral clearance in some stallions or eliminate semen infectivity in some 
cases. However, none of them has 100% efficacy in inducing complete viral clearance 
from the reproductive tract
154
. For instance, Burger et al. (2006) have demonstrated in a 
vaccination study in EAV carrier stallions injecting twice 4 weeks apart with anti-GnRH 
vaccination resulted in cessation of virus shedding in semen 4 to 6 months after the first 
immunization and from all subsequent semen collections
154,255
. However, all the 
vaccinated stallions developed reduced libido, scrotal size, total sperm number and 
percentage of normal sperm indicating that this protocol would not be a suitable 
treatment for EAV-infected breeding stallions
154
. 
 
1.6. Disease prevention and control  
The purpose of EVA control and prevention strategies is to prevent the risk of 
spread of EAV in horse populations
149,260,261
. In the USA, the standards of EVA control 
and prevention are described in the Equine Viral Arteritis: Uniform Methods and Rules 
developed by the USDA-APHIS
260
. Several European countries: United Kingdom (UK), 
Ireland, Germany, France and Italy established a Code of Practice which provides 
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guidelines for the control and prevention of several equine diseases including EVA
262
. 
Globally, the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals and 
the Terrestrial Animal Health Code
261,263
 provides standards for EVA laboratory testing 
procedures for international trade of horses and semen. Detailed information on the 
application of this testing process is also available at the American Association for 
Equine Practitioners (AAEP) (www.aaep.org).  
It is important to correctly identify carrier stallions by determining their 
serological status and whether they have a prior history against EVA
154
. All stallions 
should be tested for the presence of serum neutralizing antibodies at least 60 days before 
the breeding season
154
. If the stallion is seropositive (neutralizing antibody titer ≥ 1:4) 
without a vaccination history or confirmation of seronegative status prior to vaccination, 
virological assessment of semen is required to determine its status
154
. The collection of 
two semen samples containing the sperm-rich fraction of the ejaculate is required
154
. The 
test can be performed on samples obtained on the same collection day, consecutive days, 
or after an interval of several days or weeks
154
. Another way of identifying EAV carrier 
stallions is to perform test breeding by which two seronegative mares are bred or 
inseminated twice, each on two consecutive days, for a total of four covers
154
. These 
tested mares will be isolated for 28 days until checked for the presence of neutralizing 
antibodies
154
. If one or both mares show seroconversion after being bred, this is 
indicative that the stallion is persistently infected or the semen used is infective
154
. 
Carrier stallions can still be used for breeding purposes under strict conditions: physical 
isolation and breeding to seropositive mares only as indicated previously
11,157,264–266
. With 
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exception of the USA, other countries do not accept the introduction of EAV carrier 
stallions or EAV-infective semen
154
. 
It is highly recommended to vaccinate horses against EVA if they frequently 
travel and interact with other horses at competitions
154
. The OIE Terrestrial Animal 
Health Code provides the general recommendations for the international movement of 
horses and importation of equine semen
154
. Horses should be subjected to a quarantine 
period of 28 days without clinical signs of EVA, a stable or declining EAV antibody titer 
or a seronegative status between two serum samples collected at least 14 days apart
154
. 
When the state veterinarian receives the notification of EVA outbreak, it is important to 
suspend the routine activities (training or breeding) and animal movement and isolate all 
of the clinically affected or in-contact animals by following AAEP guidelines. The 
immediate quarantine will allow vaccination and laboratory confirmation to prevent 
wider spread of EVA, associated abortions, neonatal death and persistent infection in 
stallions from the horizontal mode of transmission of EAV
21,154,267
. Appropriate clinical 
sample collection should be immediately performed with the cooperation of farm 
managers and veterinarians for laboratory testing
154
. Disinfection of stalls and equipment 
is recommended using a disinfectant including phenolic, chlorine, iodine and quaternary 
ammonium compounds to inactive EAV
154
. The quarantine will be continued for 3 to 4 
consecutive weeks after the last confirmed case is reported
154
.  
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1.6.1. Vaccine 
There are two commercially available vaccines for the prevention of EVA, a 
modified live attenuated (MLV; ARVAC
®
) and an inactivated product (Artervac
®
). The 
MLV vaccine
 
was developed by serial passage (P266) of the VBS strain in horse kidney 
(HK-131), rabbit kidney (RK-111) and equine dermal (ED-24) cells. It has been used 
since 1985 in the USA and Canada
146,154,159,161,206,268,269
 The MLV vaccine has been 
proven to be safe and effective in providing protective immunity in vaccinated 
horses
161,175,206,268
. However, MLV vaccination does not necessarily prevent reinfection 
of first-time vaccinated horses so that revaccination is encouraged
146,161,188
. The MLV 
vaccine induces neutralizing antibodies within 5 to 8 days post-vaccination, with a peak 
in antibody titers occurring between 7 to 14 days post-vaccination
146,161,175,188,206,268–270
. 
Neutralizing antibodies may last for at least 2 years. It has been determined that a titer of 
at least 1:64 is required for protection
271
.  Few vaccinated horses may develop fever with 
transient lymphopenia, and the attenuated virus can be detected from nasal secretions and 
buffy coat cells up to 7 days post-vaccination in the vast majority of the horse 
population
146,146,159,268,270,272,273
. Additional to the MLV product, an inactivated EAV 
vaccine (Artervac
®
) has been developed and is licensed in several European countries 
including the UK, Ireland, France, Hungary and Denmark
154
. As Artervac
® 
has a lower 
immunogenicity compared to the MLV vaccine, a booster vaccination 3 to 4 weeks after 
the primary vaccination is recommended with semiannual revaccinations. Although this 
vaccine stimulates neutralizing antibodies, its efficacy against EAV infection and 
prevention of the establishment of persistent infection in stallions is substantially less 
characterized than the MLV vaccine
154
.  
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In the USA, it is highly recommended to immunize seronegative stallions with the 
MLV vaccine (ARVAC
®
) at least 28 days prior to the breeding season, followed by an 
isolation period of 21 days after the primary vaccination to allow maximal development 
of the VN antibody response and to avoid exposure of other animals during the transient 
shedding period of the vaccine virus
260
.  An in vivo study reported that a low level of 
vaccine virus (<1 PFU/mL) was detected in the semen of one stallion at 4 to 6 days post-
vaccination
270
. Annual revaccination prior to the breeding season is highly 
recommended
154
. Unfortunately, vaccinating persistently infected stallions will not 
induce clearance of the carrier state
154
. Most importantly, the current VN test is not able 
to distinguish between vaccinated and naturally infected horses, thus it is critical to 
confirm the stallions’ seronegative status before primary vaccination. The MLV vaccine 
is effective in the prevention of EVA outbreaks and establishment of carrier state in 
stallions
154
. 
Carrier stallions should only be bred to EAV seropositive mares which were 
naturally infected or vaccinated against EVA
146
. The mares should be vaccinated at least 
3 weeks before breeding followed by a 21 day period of isolation after breeding as 
previously indicated
154
. Neutralizing antibody titers should be determined (≥ 1:64) in 
EAV seropositive mares at least 30 days before breeding to a persistently infected stallion 
or using infective semen for artificial insemination or embryo transfer
274,275
. Following 
breeding, the mares should be kept in isolation for at least 21 days away from EAV 
seronegative horses
154
. The use of the MLV vaccine is not recommended in pregnant 
mares especially in the last 2 months of gestation to avoid abortion
276
. Vaccination is also 
not recommended in foals less than 6 weeks old; they should be vaccinated at ~6 months 
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of age when maternal acquired antibodies are no longer detectable
154
. So far, the efficacy 
of the MLV vaccine has been proven in the prevention of EVA outbreaks and persistent 
infection in stallions
154
.   
As previously mentioned, the currently available VN test is not able to 
differentiate vaccinated from infected animals (DIVA). The development of a DIVA 
vaccine would contribute to the equine industry by facilitating the serological 
identification of infected from vaccinated animals and supporting surveillance programs 
for national and international movement of horses
154
. Even though several studies have 
been undertaken to develop new vaccines, none of them have thus far reached the market. 
The development of an infectious cDNA clone of the MLV strain (pEAVrMLVB) 
showed itself to be safe and capable of stimulating protective immune response 
comparable to the MLV vaccine (ARVAC
®
)
188
. This infectious clone has the advantage 
that it could be further manipulated by genetic engineering to generate a second-
generation DIVA vaccine
154
. The development of subunit vaccines would also be another 
suitable alternative as a second-generation DIVA
224
.  DNA vaccination has been tested in 
mice
277
. The vaccine with plasmid DNA encoding ORF5 generated the highest VN 
antibodies in vaccinated animals
277
. A DNA vaccine expressing a combination of viral 
genes (ORFs 2, 5 and 7) and equine IL-2 was also tested in horses resulting in high VN 
antibodies titers, which lasted for at least a year
278
. Lastly, Balasuriya et al. (2002) used 
alphavirus replicon particles (VRP) to co-express the major viral envelope proteins (GP5 
and M) as a recombinant vaccine candidate. The in vivo study using mice established 
VRP co-expressing GP5/M heterodimer that was able to induce neutralizing antibodies 
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against EAV
177
. However, all of the above vaccine candidates require further testing to 
determine their safety and efficacy.  
 
2. Evolution of RNA viruses  
Where did viruses come from and how did they survive? Unfortunately, very few 
records of viruses are available unlike the situation for other cellular organisms about 
which we are able to infer from fossils
279
. However, the application of modern 
technologies such as next-generation sequencing (NGS) and reverse genetic engineering 
has helped to provide some answers concerning the origins and evolution of viruses
279,280
. 
By comparing the sequences of viral genomes, it is now possible to estimate the degree of 
evolutionary relationship between ancestral viruses using bioinformatics, mathematical 
and phylogenetic techniques
279,280
.  
Viruses evolve as a result of reassortment or recombination between virus strains 
in addition to nucleotide substitutions introduced during the replication cycle
279
. RNA 
viruses in particular rapidly produce large populations in a short period of replication
281
. 
Most RNA viruses encode for a low fidelity RNA-dependent RNA polymerase (RdRp) 
enzyme that can result in a mutation rate of 10
3
 to 10
5
 errors per nucleotide per 
replication cycle. This rate is 10,000-fold lower than that which occurs during DNA virus 
replication
282–284
. As a result, DNA viruses evolve more slowly than RNA viruses
279
.  
A continuous process of genetic variation in RNA viruses is responsible for 
heterogeneous mutant distributions also termed “mutant swarms or mutant clouds or 
quasispecies”
280,281
. Viral quasispecies allow RNA viruses to adapt to a given 
environment with the advantages of dynamics of infection, virus spread, attenuation and 
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virulence, complexity and self-organization
285,286
. The main features of viral quasispecies, 
biological implications of quasispecies dynamics and the specific viral system related to 
viral quasispecies will be further discussed. RNA viruses evolve by four mechanisms in 
nature and each of these are described in detail below.   
The accumulation of nonsynonymous mutations in the genome will lead to 
antigenic drift which is one of the main mechanisms involved in the evolution of 
influenza viruses
287
. Antigenic drift is the result of point mutations in influenza virus 
gene, encoding HA and NA that cause alternations in the structure of the main viral 
surface antigens. This is a slow process that is on-going and which causes antigenic 
differences in strains of influenza virus
288
. The evolutionary process sometimes is under 
certain limitation; for example, the viral attachment proteins must maintain the eligible 
configurations and catalytic abilities for the virus to be able to bind to the target host’s 
cell receptor and enzymes (e.g. reverse transcriptase)
279
. The RNA viral genome 
undergoes virus evolution via the quasispeices effect (the establishment of mutant 
spectra)
280
. Once the RNA virus enters the susceptible host cell, the virus replicates itself 
rapidly and generates numerous numbers of virus population. Due to lack of proofreading 
capability of RdRp, the RNA viruses generate numbers of mutations in the virus 
population that is called mutant spectra (mutant swarm or mutant clouds). The mutant 
spectrum is the ensemble of genomes that forms a viral quasispecies, and its complexity 
and formation are closely related to its biological environment. The complexity of a 
mutant spectrum can be demonstrated in the nucleotide sequences obtained either by 
classic molecular cloning and Sanger sequencing or by next-generation sequencing 
(NGS)
285
. 
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2.1. Mechanisms of virus evolution 
2.1.1. Accumulation of mutations  
RNA viruses mainly evolve through mutation errors that are generated during 
viral replication. Although all polymerases cause errors by inserting incorrect nucleotides 
into the template during viral replication, the DNA-dependent DNA polymerases have 
proofreading ability in their exonuclease activities that enable them to modify or correct 
any such mistakes. In contrast, RdRp does not have proofreading ability as previously 
mentioned
284
. If the errors are located in the protein-coding sequences, then it introduces 
random substitutions in the encoded amino acid sequence
279
. The theory of Darwinian 
natural selection applies to the mutations that ensure the continuous survival of the 
viruses
279
.  
 
2.1.1.1. Concept of viral quasispecies  
Manfred Eigen and Peter Schuster developed the quasispecies theory by looking 
at the quasispecies (dynamic mutant distributions) which are displayed as a dominant 
master sequence of the virus population
289
. Then, Wiessmann and his colleagues 
provided the first evidence of quasispecies distribution in RNA viruses by the 
bacteriophage Qβ virus using T1 oligonucleotide fingerprinting through reverse genetics. 
Serial passages of bacteriophage Qβ virus clones in E. coli demonstrated competition 
between wild-type virus and mutant clones
290,291
. Interestingly, the rate of mutation of 
bacteriophage Qβ virus was 10
4
-fold constantly higher than the values of DNA 
bacteriophage
292
.  This was the first calculation of the rate of mutation for an RNA virus 
that demonstrates the quasispecies dynamics using bacteriophage Qβ virus. The 
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quasispecies theory formulates an error-threshold relationship at the maximum error rate 
compatible with maintaining genetic complexity in a replicative system
289
. The value of 
the error-threshold is determined by the replication accuracy and the virus fitness of the 
dominant or master sequence corresponding to the mean fitness value of the error 
copies
289
. Eigen and other authors proposed that the quasispecies contains the finite 
replicon populations expanded under nonequilibrium conditions of variable fitness 
landscapes
293–304
. The quasispecies theory can be mathematically determined based on 
the dynamics of error copy production and the error threshold relationship and that 
describes the evolutionary dynamics model
305
. The quasispecies theory introduces a 
molecular view of evolutionary biology as well as viral quasispecies evolution
285
. The 
alternative terms for quasispecies include “Mutant swarm, intrahost variation, intrahost 
diversity, mixture of mutants, nucleotide degeneracy, hyperploidy, heterospecies and 
heteropopulations”
306
.  
 
2.1.1.2. Major characteristics of viral quasispecies  
Viral quasispecies is defined as the continuous process of genomic distributions 
of genetic variation, competition and selection
307,308
. There are two types of selection: 
positive and negative that influence the generation of viral quasispecies in the virus 
population. Positive selection is the process of a dominant genotype resulting in the 
positive evolution of phenotypic traits expressed by the individuals of the evolving 
population
285
. For instance, the viral quasispecies of a reconstructed foot-and-mouth 
disease virus (FMDV) generate a dominant mutant distribution by antibody selection
309
. 
Negative selection is the process of removing a genotype in an evolving population that 
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causes the negative evolution of phenotypic traits expressed by individuals
285
. However, 
the outcome of negative selection is sometimes the same as positive selection or vice 
versa during a competition process
285
. During replication of a viral subpopulation, 
positive selection increases frequency of subsets of genomes with a net fitness gain
310–312
. 
This increased fitness of the resulting subpopulations is maintained as memory 
genomes
313
. The quasispecies memory is present in the mutant spectrum at higher 
frequencies than mutation rates
313,314
. There are two parameters related to 
characterization of the viral quasispecies: mutation rate and mutation frequency
285
. 
Mutation rate is the frequency of occurrence of a mutation during genome replication that 
can be calculated by mutations per site per replication. It is a value that is independent of 
the fitness of the parental and mutated genomes
285
. Mutation frequency is the proportion 
of mutant viruses in a population and is affected by many biochemical and environmental 
selective factors
285
.  
Additional to variation and continuity of core information of a biological adaptive 
system, the viral quasispecies tends to maintain its memory of past events
313
. Evolving 
viral quasispecies maintains the molecular memory as a form of minority components in 
their mutant spectra and it is called viral quacispecies memory
313
. The viral quasispecies 
memory plays an important adaptive role in the host environment such as the immune 
system and results in the quasispecies dynamics
285
. During viral replication, memory 
genomes with fitness gain in the most frequent genomes of the same quasispecies is 
subjected to the Red Queen hypothesis
315,316
. This hypothesis defines that the continuous 
selection of the most fit genomes in competing viral populations
317–321
. However, the 
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quasispecies memory level can be gradually lost in the parallel lineages of replicating 
populations and that is called memory decay
321
.  
The viral fitness and the effect of population size, known as bottleneck events, are 
another important characteristic of viral quasispecies
285
. Viral fitness is a major parameter 
which results in a viral population adapting to a specific environment and producing 
infectious progeny under the formulation of quasispecies theory and the error threshold 
relationship
282,285
. Cristina Escarmís and her colleagues have demonstrated the molecular 
basis of fitness loss associated with successive bottleneck events in biological clones of 
FMDV. Some numerous, unusual mutations were observed in the large viral population 
following in vitro passage of FMDV; these were not found in any field isolates or 
clones
322–324
 Hundreds of bottleneck passages have driven an evolution of noncytopathic 
variants of FMDV to be capable of establishing persistent infections in BHK-21 cells
325–
327
. The constant steady replication of large viral populations result in a consequence of 
high fitness called adaptation to new environment; in contrast, the repeated bottleneck 
events with accumulation of mutations result in low fitness, is called de-adaptation in the 
environment
280
 As the result of a reduction in fitness and the biological changes in 
viruses, repeated bottleneck event transfers mediate distributions of neutral mutants in 
mutant spectra
285,328,329
. There are two types of population bottleneck events called 
plaque-to-plaque transfers and intrahost bottleneck intensity. In the case of plaque-to-
plaque transfers, a single infectious genome undergoes replication and diversification
285
. 
Depending on a different intensity, the number of genomes from a larger ensemble starts 
replication. Following which, a small number of genomes from the larger ensemble will 
have limited variants by selective constraint
285
. During the replication cycle of a virus, 
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viruses infect through host-to-host interaction as well as intrahost bottleneck intensity 
that influences the intrahost evolutionary events
330–340
. The bottleneck events happen to 
modify viral population sizes resulting in the heterogeneous and dynamic nature of viral 
populations that are suitable in the environment by fitness gain
341–343
. Bottleneck events 
occur in both short-term and long-term periods of virus evolution
285
. 
Virus evolution does not always occur by modifications in consensus sequence, it 
also happens through non-equilibrium of a mutant spectrum in variable fitness landscapes, 
a theoretical construction of the evolutionary process
285,344
. In contrast, population 
equilibrium plays an important role in maintaining a constant consensus sequence in viral 
populations
345,346
. The positive selection influences the subpopulation of viral genomes in 
the mutant spectrum increasing in frequency or replacing the previous distribution and 
this results in a new consensus adapted to the biological environment
285
. The virus 
undergoes the evolutionary process in a dynamic mutant spectrum either by evolutionary 
stasis (rates of evolution of around 10
-4
 substitutions per site per year or lower) or rapid 
evolution of its consensus sequence (rates of evolution of about 10
-1
 to 10
-2
 substitutions 
per site per year) depending on its given environment
286
. In the case of avian influenza 
virus, the evolutionary stasis in the natural target host will not give rise to a disease 
outbreak, but the rapid evolution of the same virus will cause a disease outbreak in 
different mammalian hosts when the virus starts to replicate
347
. Another viral 
quasispecies parameter is the rate of evolution, which is the number of accumulated 
mutations in viral genomes through a time point
285
. The major difference from the 
previously mentioned mutation rate and frequency is counting the time factor
285
. The unit 
of rate of evolution is expressed as the number of substitutions per site per year. This may 
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affect replication of a viral population during short-term (intrahost) or long-term 
(interhost) virus evolution
285
. 
 
2.1.1.3. Biological outcomes of quasispecies dynamics 
As previously mentioned, the major characteristics of viral quasispecies produce 
several outcomes in the virus-host relationship including host range mutant and viral 
emergence, escape mutant, mutagen-resistant mutants, virus extinction and long-term 
virus evolution
285
. Firstly, the viral quasispecies dynamics influence modifications in the 
cell tropism and host range during virus evolution
285
. Viruses use cellular receptors which 
are composed of different macromolecules such as proteins, lipoproteins, glycoproteins, 
glycolipids and glycosoaminoglycans to attach and enter the host cells
348–353
. For instance, 
canine parvovirus-2 (CPV-2), which causes highly contagious after fatal disease in dogs, 
is closely related to feline parvovirus (FPV) and therefore assumed to be a host variant of 
FPV
354–356
. As the result of continuous genetic variation, two or three genetic mutations 
in FPV caused the emergence of a novel strain of CPV and allowed it to expand its host 
range to infect dogs
357
. Either amino acid substitutions on external surface proteins or 
exchange of modules such as encoding relevant protein motifs by recombination affects 
the modification of the host cell tropism
285
. Presence of a single or few amino acid 
substitutions in a mutant spectrum may influence the host cell tropism and define the 
phenotypic characteristics of a virus
285
. After serial passage of FMDV in cell culture, 
amino acid substitutions were observed in the capsid surface that allows FMDV binding 
to heparan sulfate (HS) on the cellular surface
348,349,358–360
. These HS-binding variants of 
FMDV are also present in infected cattle tissues
361
. Modification of antigenic sites also 
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impact the antibody dependent enhancement (ADE) of viral infection, a mechanism used 
by several viruses
362
. Depending on the cross-linking of complexes of virus-antibody or 
virus-activated complement components through infection with cellular molecules such 
as Fc receptor on certain immune cells, the virus uses ADE mechanism to enhance its 
infectivity to the susceptible host cells
362
. Analysis of the mutant spectrum composition 
may enable one to predict the potential evolutionary outcomes related to receptor 
recognition
285
. Interestingly, host cell tropism and viral pathogenicity are closely 
associated with substitutions in the level of the structural or nonstructural viral proteins
285
. 
For instance, amino acid substitutions in the polymerase subunit PB2 of influenza virus 
promotes adaptation to alternative hosts and enhances the viral replication cycle
363–367
.  
Secondly, viral quasispecies facilitate the emergence of escape mutants which are 
the subset of mutants observed in the viral population that are associated with continuous 
viral replication despite the presence of selective constraint in the host environment
285
. A 
virus may generate mutations for the purpose of defending itself against the host immune 
responses or selective constraints. Selective constraints include antiviral drugs, immune 
components of the innate or the adaptive immune response including those induced by 
vaccination and interfering RNAs
285
. By considering frequency factors of inhibitor-
resistant amino acid mutants, genetic barriers and the fitness cost represented in mutant 
spectra, the frequency of inhibitor-resistant mutants of viruses is about in the range of 10
-
3
 to 10
-5
 
368–371
. Similar to the positive selection events, one or a few point mutations or 
multiple mutations by recombination events can initiate resistance to an antiviral drug
285
. 
According to Domingo et al. (2012), the drug resistance for human immunodeficiency 
virus 1 (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV) is systematically 
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reviewed as follows
285
: (i) Drug resistance is a general phenomenon and the selection of a 
drug-resistant mutant against a specific antiviral drug is evidence of the 
phenomenon
368,371–373
. (ii) Multiple different mutations or combinations of mutations 
called mutational pathways can lead to drug resistance
374,375
. For instance, multiple amino 
acid replacements at different sites in the protein may decrease affinity for a drug or a 
target protein complex
285
. (iii) High-level resistance to a drug may require mutations that 
are different from mutations associated with low-level resistance. Different frequencies 
of these mutations have been identified to the same drug
376–379
. (iv) Substitutions that are 
influenced by drug resistance increase viral fitness and absence of the drug decreases 
fitness
285
. (v) When multiple drug-resistant mutations occur, only some mutations are 
selected for a fitness-enhancing effect, but not all of the mutations will be directly 
involved in reducing affinity to the drug
285
. Vaccination is another selective constraint 
that exerts evolutionary forces on viruses
380
. For instance, Hepatitis A virus (HAV) has a 
single serotype, and its vaccine escape mutants have been identified in the complex 
mutant spectra of the viral population
381–384
. HAV requires rare codons in the capsid-
coding region to regulate ribosomal traffic for proper capsid folding proteins and to 
prevent antigenic variants producing a new serotype
317,385
. However, the HAV escape 
mutants continuously evade adaptive immune responses of vaccinated 
immunocompromised individuals
348,386,387
. Multiple selective constraints establish the 
adaptive immune response in the host to block virus replication and remove infected cells 
through neutralizing antibodies derived from virus specific T cells
285
. Also, investment in 
immunotherapeutic approaches has the potential of eliminating viruses by targeting 
highly conserved epitopes or neutralizing antibodies in the conserved regions of the viral 
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proteins
388,389
. The development of effective antiviral drugs, vaccinations and 
immunotherapeutic approaches is a challenge when it comes to inhibiting mutant viruses.  
Thirdly, evidence of virus extinction observed in mutant spectrum complexity 
occurs by an increase in the mutation rate above an extinction threshold. This suppresses 
the replication of high fitness variants through a process called lethal mutagenesis
390
.  
The hallmarks of lethal mutagenesis are increased frequency of defective genomes and a 
constant consensus sequence
391–393
. The types of defective mutants are called defectors 
and are associated with virus extinction caused by lethal mutagenesis
280
. This could be a 
potential approach for antiviral protocols by targeting mutagenic agents
285
. During lethal 
mutagenesis of viruses, there is evidence of a precarious mutant spectra suppressing the 
virus replication of high fitness variants
390
. For example, populations of FMDV that are 
resistant to polyclonal antibodies tend to have reduced fitness compared with wild types 
of the virus
394
. The mutant spectrum interactions are affected by the interaction between 
mutagenic agents and also by potential inhibitors of sequential treatments which can be 
focused on lethal mutagenesis
280
. Combination therapies with two or more inhibitors are 
generally used to prevent or reduce the production of inhibitor-resistant mutants
280
. 
Additionally, combination of therapeutics of mutagenic agents and inhibitors will have 
the advantage of reducing viral load and further result in virus extinction
280
. 
Lastly and most importantly, the viral quasispecies dynamics will drive long-term 
virus evolution in vivo
285
. While reviewing published information about the evolution of 
RNA viruses and quasispecies evolution, two questions arise
285
. Firstly, does the outcome 
of experimentally designed evolution studies reflect the viral population dynamics in the 
natural environment? Fortunately, the findings suggest there is no discrepancy in virus 
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behavior between experimental and natural infections in terms of genetic variation, 
selection competition within the mutant spectrum or selection of genome subsets
285
. 
Secondly, why should the consequences of quasispecies dynamics be considered for 
understanding long-term virus evolution? This is because the mutant spectra determine 
which type of genomes will be spread into susceptible target hosts
285
. Frequent complex 
cycles of the quasispecies swarm and transmission influence long-term evolutionary 
patterns by alternating the constitution of mutant spectra
285
. Viral lineages can undergo 
slow or rapid evolution; these are related to pathogenicity
395
. For example, the genetic 
diversity generated by a high polymerase error rate impacts the pandemic occurrence of 
norovirus
396
. Also, viral fitness level determines the severity of dengue disease
397
. The 
quasispecies dynamics proposes that RNA viruses evolve as a consequence of 
disequilibria in mutant distributions instead of linear accumulation of mutations
285
. 
However, there are contradictions concerning dating of viral ancestors and rates of co-
divergence between viruses and hosts
398,399
. A study involving phylogenetic analyses of 
divergence has been conducted on HIV-1 and HIV-2 based on the common ancestor of 
retroviruses and using strict or relaxed clock models that sometimes give conflicting 
results
400
. The steady accumulation of mutations has randomly selected from the 
quasispecies that was amplified in the susceptible hosts
401
. From the average rates of 
virus evolution in the range of 1x10
-1
 to 3x10
-5
 substitution per site per year
402
, 
phylogenetic analyses interestingly showed that the virus isolated in a short time span 
presented a higher rate of evolution than isolates after a long time
402,403
. The operation of 
a molecular clock follows the neutral theory of molecular evolution that means the rates 
of evolution reflect mutation rates
285
. However, this does not support the quasispecies 
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dynamics concept with reference to dating of viral ancestors, rates of co-divergence of 
viruses and their hosts
398,399
. These discrepancies might arise because of insufficient data 
concerning the population disequilibria to support the short-term and long-term evolution 
under the assumption of a linear accumulation of mutations
285
. Overall, the quasispecies 
dynamics through disequilibria of mutant swarms plays an important role during short-
term intrahost and long-term evolution
285
. In conclusion, the virus evolution and viral 
population biology require continuous investment with regard to a rapidly replicating, 
error-prone, viral quasispecies in integrated biological systems
285
. 
 
2.1.2. Reassortment 
RNA viruses with segmented genomes such as reoviruses, bunyaviruses and 
influenza viruses evolve through a process called reassortment
279
. When a susceptible 
host cell is coinfected by two strains of a virus, the progeny virus may have mixture of 
genome segments from the two parental strains of a virus that are called reassortants
279
. 
For instance, a susceptible cell is infected by two strains of influenza A virus that have 
unique envelope glycoproteins: hemagglutinin (H) and neuraminidase (N). After 
replication, the combination of parental RNA segments encoding H and N proteins now 
produce new progeny viruses
279
. This continuous reassortment process results in new 
reassortants of influenza A viruses that were responsible for three pandemics of influenza 
during the 20
th
 century
279
. The largest scaled pandemic known as “Spanish Flu” occurred 
in 1918-19 resulting in the number of people killed by this influenza virus “H1N1” was 
greater than the number of deaths during the First World War
279
.   
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2.1.3. Recombination 
Many RNA viruses exchange nucleotide sequences among RNA molecules of 
different genomes producing new genomes
284
. This process is called RNA recombination; 
RNA viruses evolve by rearranging their genomes or functional parts among different 
viruses
284
. Recombination also occurs in DNA viruses
279
. There are two mechanisms of 
recombination, namely base-pairing dependent and base-pairing independent. Base-
pairing dependent occurs between identical nucleotide sequences and base-pairing 
independent happens between variable nucleotide sequences
284
. Recombination plays a 
role in viral pathogenesis; for example, the noncytopathic bovine viral diarrhea virus 
(BVDV) can become cytopathic BVDV causing severe fatal gastrointestinal disease in 
cattle. The nonstructural protein 3 (NS3) synthesis of BVDV is critically associated with 
pathogenicity, and the base-pairing independent RNA recombination generates extra 
protease cleavage sites at the N terminus of the NS3 proteins
284
. Both DNA and RNA 
viruses use recombination mechanism for their evolution
279
. Many DNA viruses usually 
do not enter the nucleus during viral replication, except for herpesviruses that enter into 
the nucleus closely interacting with target host cells to mimicking cellular proteins. For 
instance, human herpesviruses can similarly modulate the host immune system including 
major histocompatibility complex proteins and cytokines (e.g. IL-10)
279
.  
 
3. Research objectives  
Viruses have coexisted with human and animal populations on the earth for 
millions of years. They are considered a parasite, because the virus cannot replicate itself 
without the host organism. The virus is a causative agent of infectious disease in allliving 
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organisms. Most virus infections in mammals are cleared following development of the 
host immune response. However, some viruses have evolved to establish long-term 
persistent infection in their natural hosts in the presence of strong host immune response.  
Such viruses could either establish latent infection (dormant infection) or produce 
smoldering infection in a specific tissue or organ and continue to produce infectious 
progeny virus (persistent infection), which can be transmitted to susceptible naïve 
animals.  These viruses have evolved mechanisms to evade the host immune response.  In 
addition, these viruses tend to evolve during persistent infection generating novel genetic 
and antigenic variants that can precipitate new disease outbreaks.  EAV is one of the 
classic examples of persistent viral infections in the natural host. Following natural and 
experimental infection, the virus establishes persistent infection in the stallion 
reproductive tract. Interestingly, 10% to 70% of the stallions that are infected with EAV 
become persistently infected carriers and continue to shed the virus in semen for several 
weeks to years to lifelong
11
. The primary objectives of the this research is to study EAV 
evolution during persistent infection by determining the full-length genome sequences of 
sequential EAV isolates present in the semen of long-term EAV carrier stallions by next-
generation sequencing (NGS). We have included virus strains from both experimentally 
(49 sequential isolates over a two-year period from seven experimentally infected carrier 
stallions) and naturally infected (4 sequential isolates over a period of 10 years) stallions. 
Both experimentally and naturally infected stallions were exposed to the KY84 strain of 
EAV (EAV KY84). We used next-generation sequencing (NGS) to determine the 
complete genome sequence of each strain. Subsequently, the annotated full-length 
genome sequences were obtained, processed and subjected to complex bioinformatics 
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analyses. In this study, we investigated the intra-host evolutionary dynamics during acute 
and persistent infection periods. Furthermore, we characterized the virus quasispecies 
diversity, rate of evolution and selective pressure during the different time periods (e.g. 
acute and chronic) of EAV infection. Chapter two focuses on the evolution of EAV 
KY84 strain during acute and persistent infection in the stallion.   
EAV infection is highly species-specific and only infects members of the family 
Equidae such as horses, donkeys, mules and zebras
10,11
. Recently, we have isolated a 
strain of EAV from a feral donkey in Chile. The second objective of this research was to 
obtain the full-length genome of this EAV donkey isolate using NGS. Thus, the second 
objective of this study is to analyze genomic, phylogenetic and antigenic characterization 
of this field strain of EAV from a donkey, which is a different member of the family 
Equidae. Comparative nucleotide and amino acid sequence analysis and phylogenetic 
analysis demonstrated that there is a unique relationship between EAV strains from 
horses, as well as other donkey isolates from Italy and South Africa. Subsequently, EAV 
strain-specific antisera and neutralizing monoclonal antibodies against the prototype 
EAV Bucyrus strain were used to determine the antigenic variation of the Chilean donkey 
isolate.  Chapter three is focused on the molecular characterization and evolution of the 
Chilean donkey strain. 
As previously mentioned, virus isolation is the OIE-approved “gold standard” test 
for EAV detection
221
. It is known that the high passage rabbit kidney (RK-13) cell line 
that is used for EAV isolation is contaminated with noncytopathic bovine viral diarrhea 
virus 1 (BVDV). During NGS sequencing of the EAV isolates from RK-13 cells, we 
were able to obtain the full-length genome of the contaminating BVDV.  The third 
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objective of this research was to assemble the complete genome sequence of BVDV-1 
strain contaminating the RK-13 cells. Chapter four is dedicated to the comparative 
nucleotide amino acid sequence analysis of the BVDV-1 strain.   
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CHAPTER TWO 
Genetic Bottleneck and Selection of Equine Arteritis Virus During Acute Infection 
and Intra-host Quasispecies Diversification During Long-term Persistent Infection 
in the Reproductive Tract of the Stallion 
 
2.1. Summary  
Equine arteritis virus (EAV) is a small enveloped, positive-sense, single-stranded 
RNA virus in the Arteriviridae family. It infects the upper respiratory tract of equids 
(horses, donkey and zebra) with initial replication in nasopharyngeal epithelium and 
alveolar macrophages. Systemic spread is through infection of cells of the monocyte 
lineages and CD3
+ 
T lymphocytes. It establishes persistent infection in the reproductive 
tract of 10 to 70 % of infected stallions. Such stallions continually shed EAV in the 
semen ensuring successful transmission of EAV to susceptible naïve horses. In this study, 
seven EAV seronegative stallions were experimentally inoculated with EAV KY84 
strain and followed for 726 dpi. Nasal secretions (swabs), unclotted blood and semen 
were sequentially collected, and a total of 53 sequential viruses were deep sequenced to 
elucidate the intra-host micro evolutionary process of EAV after a single transmission 
event. In addition, the viruses from two long-term EAV carrier stallions (seven to ten 
years duration) were deep sequenced; these carrier stallions were naturally infected with 
the same KY84 strain of EAV. The intra-host viral population dynamics of the 
experimentally infected stallions were compared and contrasted with the two naturally 
infected stallions. In this study, the analysis of viral sequences in nasal secretions and 
buffy coat cells showed a lack of extensive positive selection; however, characteristics of 
the mutant spectra were different in the two sample types. By contrast, semen virus 
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populations during acute infection had undergone a strong selective bottleneck as 
reflected by a reduction in population size and multiple sites of the viral genome that was 
under diversifying selection. During the period of persistent infection, virus solely 
evolved inside the reproductive tract of the stallions in the presence of strong 
neutralizing antibody response, resulting in a non-stochastic evolutionary process with a 
number of atypical high frequency minor variants being identified. This indicates that an 
active selection pressure continually morphs EAV quasispecies population structures and 
dynamics during persistent infection. Comparative analysis of the experimental 
evolution with that of naturally infected stallions showed a higher degree of correlation 
in the rate of sequence divergence through time with mirroring patterns of selection 
between experimental and naturally infected stallions. 
 
2.2. Introduction 
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis 
(EVA), a reproductive and respiratory disease of horses, donkeys, mules and 
zebras
10,11,97,154,404–406,406
. EAV was first isolated from the lung of an aborted fetus 
during an extensive outbreak of respiratory disease and abortion storm on a 
Standardbred breeding farm near Bucyrus, OH, USA, in 1953
9–11,14,194
. Depending on 
the host’s age, physical condition, immune status and the strains of virus, EAV infection 
causes mild to moderate clinical signs including leukopenia, pyrexia, depression, 
anorexia, dependent edema (scrotum, ventral trunk, and limbs), stiffness of gait, 
conjunctivitis, lacrimation and swelling around the eyes (periorbital and supraorbital 
edema and urticaria)
11,97,154,168
. EAV infection can also cause abortion in broodmares 
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and congenital infection can lead to interstitial pneumonia in young foals and death in 
newborn foals
171
. Most importantly 10-70% of acutely infected stallions become 
persistently infected carriers and can continue to shed virus in semen for a long 
time
11,157,158,208
. The carrier state is testosterone-dependent and can last from several 
weeks (short-term carrier state), 3 to 7 months (intermediate carrier state) and years or 
even lifelong (long-term persistent or chronic carrier state) despite the development of a 
strong serum neutralizing antibody response
1,11,97,98,143,154,156,157,407
.  EAV primarily 
persists in the ampulla of the vas deferens in the reproductive tract of carrier stallions
165
. 
Persistently infected stallions play a central role in the maintenance, perpetuation and 
evolution of the virus in the horse population
142
. An increase in the incidence of the 
disease has been observed in the past twenty years, associated inter alia with increased 
national and international movement of horses and shipment of frozen or chilled semen 
19,21,142,160,164,167,184,265–267,408
. 
EAV is a small, enveloped, positive-sense, single-stranded RNA virus that 
belongs to the family Arteriviridae (genus: Equartevirus, order: Nidovirales), which 
includes lactate dehydrogenase-elevating virus (LDV), simian hemorrhagic fever virus 
(SHFV), porcine reproductive and respiratory syndrome virus (PRRSV), wobbly 
possum disease virus (WPDV) and African pouched rat arterivirus (APRAV-1)
1,409
. The 
EAV genome contains approximately 12.7 kb with at least 10 known open reading 
frames (ORFs). The ORFs 1a and 1b are located in the 5′-three quarter of the genome 
and encode for two polyproteins (1a and 1ab), which are subsequently processed into 13 
nonstructural proteins (nsp1-13; including nsp 7α and 7β) by viral proteases
1
. The ORFs 
2a, 2b, 3, 4, 5a, 5b, 6 and 7 are located at the 3′-distal quarter of the genome 
38,40
 and 
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encode seven envelope proteins (E, GP2, GP3, GP4, ORF5a protein, GP5 and M) and 
the nucleocapsid (N) protein, respectively. The GP2, GP3 and GP4 are minor envelope 
glycoproteins and form a heterotrimer; whereas GP5 and M are the major envelope 
proteins of the virus and are assembled into a heterodimer in the virus particle. The 
major neutralization determinants of EAV are located in the N-terminal ectodomain of 
the GP5 major envelope glycoprotein of EAV. Studies using neutralization-resistant 
variants to monoclonal antibodies (MAbs) and polyclonal equine antisera in 
combination with reverse genetics have identified four major neutralization sites in the 
N-terminal ectodomain of the GP5 major envelope glycoprotein of EAV GP5 (site A 
[aa 49], site B [aa 61], site c [aa 67 to 90], and site D [aa 98-106])
1,82
. The changes in 
conformational neutralization epitopes is influenced by the GP5 interaction with the M 
protein
16,82
. Although there is only one known EAV serotype, field strains differ in their 
virulence and neutralization phenotypes 
21,23,155,162,177,179,183,184,188,189,199
. Phylogenetic 
analysis based on partial ORF5 sequences segregated EAV isolates from around the 
world into North American (NA) and the European (EU) lineages, and each lineage is 
further subdivided into two North American (NA-1, NA-2) and European (EU-1 and 
EU-2) clades
21,408,410–412
.  
The lack of proofreading capability of the viral RNA-dependent RNA 
polymerase (RdRp) enzyme leads to a high mutation rate in the EAV genome resulting 
in the occurrence of viral quasispecies
282
. Often times, a novel virus variant arises from 
the quasispecies pool under conditions that regulate the frequency of minor variants. A 
number of studies have demonstrated intra-host quasispecies variation and the resultant 
genomic diversity in a number of important human and animal viruses
361,413–417
. 
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Establishment of EAV-persistent infection in the reproductive tract of stallions has been 
known for decades but very little work has been performed to better understand the 
molecular basis of natural evolution of this virus during long-term persistent infection in 
infected stallions. Earlier findings from T1 oligonucleotide fingerprinting analysis 
demonstrated the presence of a population level diversity in naturally infected stallion
418
. 
Furthermore, partial sequence analysis (ORFs 2-7) of sequential viruses from two 
persistently infected stallions following the 1984 outbreak in Kentucky have shown 
marked genetic divergence over time with emergence of new phenotypic variants
142
. 
However, these initial studies on EAV evolution during persistent infection were 
hampered due to the limitations in sequencing technology and data analysis capabilities 
17,19,21,142,164,410
. In recent years, next-generation sequencing (NGS) technologies have 
improved the processing capacity and allowed for high throughput analysis of viral 
genomic data
361,419
. This allowed identification of low frequency variant populations in 
unprecedented detail and opened the door for more precise characterization of viral 
qausispecies population and its evolution during acute and persistent viral infections.     
In this study, the comprehensive analysis of the dynamic events associated with 
EAV evolution was reported by following intranasal inoculation of seven 
experimentally inoculated stallions and two naturally infected stallions. The data 
showed successful transmission of EAV founder populations with distinct evolution 
during acute and persistent infections and also demonstrated the temporal regulation of 
variant populations following a single transmission event driven by genetic bottlenecks 
and episodic selections. 
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2.3. Materials and methods 
Cells and viruses 
The high passage (HP) rabbit kidney cell line RK-13 (KY), passage level 399-
409, was maintained in Eagle’s minimum essential medium (EMEM; Mediatech, 
Manassas, VA, USA) supplemented with 10% ferritin-supplemented bovine calf serum 
(Hyclone Laboratories, Logan, UT, USA), 100 U/mL penicillin/streptomycin 
(Mediatech, Manassas, VA, USA) and 1 μg/mL amphotericin B (Sigma-Aldrich, St. 
Louis, MO, USA). Equine pulmonary artery endothelial cells (EECs) were maintained 
in Dulbecco’s modified essential medium (Mediatech, Herndon, VA, USA) with 
sodium pyruvate, 10% fetal bovine serum (Hyclone Laboratories, Inc., Logan, UT, 
USA), 100 U/μg per mL of penicillin/streptomycin and 200mM L-glutamine
68
.   
The KY84 strain of EAV was originally isolated from pooled blood collected 
during the 1984 EVA outbreak (5/1984) from three stallions acutely infected with EAV 
(stallion E and two other stallions) and was serially passaged three times in horses and 
subsequently once in EECs to make the working virus stock
419
. This moderately 
virulent EAV KY84 strain was used as the challenge virus in this study
22,420
. The KY84 
strain of EAV has been shown to establish persistent infection in the reproductive tract 
of stallions and to cause moderate to severe clinical signs of EVA in infected 
horses
156,208,420
. Tissue culture fluid (TCF) containing the commercial live attenuated 
vaccine strain of EAV (ARVAC
®
; Zoetis, Kalamazoo, MI, USA) was used as reference 
virus to determine the serum neutralizing antibody responses during acute and persistent 
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infection of the stallions in accordance with the World Organisation for Animal Health 
(OIE) standardized virus neutralization test (VNT) protocol
421
. 
 
Ethics statement  
This study was performed in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
The Institutional Animal Care and Use Committee (IACUC) at the University of 
Kentucky, Lexington, KY, USA approved this protocol (number 2011-0888). Stallions 
were humanely euthanized by pentobarbital overdose following the American 
Veterinary Medical Association (AVMA) guidelines for the euthanasia of animals, and 
all efforts were made to minimize suffering. 
 
Stallions used for experimental infection 
Seven sexually mature (4 to 16 years of age) stallions of mixed breed were 
included in the study (stallion IDs: L136 to L142). Horses were obtained from a local 
commercial vendor and acclimated to their new environment for approximately two 
months before the study commenced.  During this period, animals were accommodated 
in individual paddocks and trained to mount a mare or a phantom for collection of 
semen into an artificial vagina.  All stallions exhibited good libido and normal sexual 
behavior and were seronegative (titer <1:4) for EAV neutralizing antibodies several 
times prior to intranasal inoculation with the EAV KY84 strain using a previously 
described protocol
405
. The animals were housed in individual stalls in an isolation 
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facility for the duration of the study at the University of Kentucky Maine Chance Farm, 
Lexington, KY, USA.   
 
Experimental infection of stallions with EAV KY84 strain and clinical examination 
Stallions were inoculated intranasally with 3.75 × 10
5
 plaque-forming units 
(PFU) of the EAV KY84 strain in 5.0 mL of EMEM (inoculum) using a fenestrated 
catheter passed via the posterior nares into the nasopharynx as previously described
199
. 
All stallions were examined and clinical parameters were recorded by the same 
veterinarian. Pre-inoculation (7, 5 and 2 days before experimental challenge) clinical 
examinations were performed once daily to determine baseline values for body 
temperature and also to certify that the parameters were within normal limits before 
experimental challenge of the stallions. Specifically, fever and scrotal edema were 
monitored twice daily (every 12 hours) for the first 15 days after infection, and the 
highest value of the day was recorded.  Clinical signs continued to be monitored once 
per week during the following four weeks of the experiment (at 21, 28, 35 and 42 dpi).  
Blood samples were collected at 0, 2, 4, 6, 8, 10, 12, 14, 21, 28, 35 and 42 dpi to 
determine individual serum neutralizing antibody responses to EAV.  The neutralizing 
antibody titers were determined as per the OIE-prescribed test
263
.  
 
Semen collection from experimentally infected stallions 
Two ovariectomized mares previously vaccinated with the commercial MLV 
vaccine against EVA (ARVAC

, Zoetis Animal Health, Inc., Kalamazoo, MI, USA) 
(serum neutralizing antibody titers ≥1:256) were used to “tease” the stallions.  Each 
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stallion was allowed to mount either one of the mares or a breeding phantom to enable 
semen collection in an artificial vagina (Botucatu model, Botupharma, Botucatu, SP, 
Brazil).  The artificial vagina was disinfected with a disinfectant (Roccal
®
-D Plus, 
Pfizer Inc., New York, NY, USA) between collections. A disposable liner lubricated 
with sterile lubricant (Priority Care, First Priority Inc., Elgin, IL, USA) was used to 
collect semen from each stallion to avoid cross-contamination between ejaculate 
samples.  A pre-semen sample was collected and evaluated 2 days before challenge, and 
then the samples were collected on days 1, 3, 5, 7, 9, 11, 13, 15 and 23 during acute 
period of infection. Once the stallions became persistently infected, semen samples 
were collected from each stallion once per month up until 726 days and processed to 
evaluate the samples. Specifically, the numbers of sequential EAV isolates from each 
stallion were selected at 5, 9, 107, 170, 345, 380, 548 and 726 dpi (Figure 2.1.).  
 
EVA outbreak in 1984 and semen collection from two naturally infected stallions 
(D and E) 
An extensive outbreak of EVA occurred in Central Kentucky in 1984
158
. This 
outbreak was the first recorded occurrence of EVA in the North American 
Thoroughbred population, and subsequent investigation established that stallions could 
be persistently infected with EAV; furthermore, carrier stallions were critical to the 
epidemiology of EAV infection
146,156,157
. Two stallions from the index premises 
(designated D and E) were infected during this outbreak and subsequently became long-
term EAV shedders. Semen was collected from the two stallions at regular intervals 
(stallion D, 6/84 [month/year], 9/85, 12/86, 9/87, 7/88, 1/89, 1/91, 9/92 and 8/94 [seven 
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sequential samples] and stallion E, 6/84, 9/85, 11/86, 2/88, 1/89 and 1/91 [six sequential 
samples]) following initial infection of the stallions, which occurred in May 1984. 
Semen was collected until the stallions ceased shedding EAV, as determined by virus 
isolation as previously described
157
. 
 
Virus isolation 
Virus isolation from raw gel-free semen samples was attempted in the RK-13 
(KY) cell line according to a standard protocol used by the OIE Reference Laboratory at 
Maxwell H. Gluck Equine Research Center, University of Kentucky, USA
222
. Briefly, 
after sonication, serial decimal dilutions (10
-1
 to 10
-4
) of each sample supernatant were 
prepared in EMEM (Cellgro
®
, Mediatech, Inc, Manassas, VA, USA), and 1 mL of each 
dilution was inoculated into each of two 25-cm
2
 flasks containing a confluent 
monolayer of RK-13 (KY) cells grown in supplemented EMEM and overlaid with the 
supplemented EMEM containing 0.75% carboxymethylcellulose (CMC; Sigma-Aldrich, 
St. Louis, MO, USA).  Flasks not showing cytopathic effect (CPE) after 4 days were 
subinoculated onto new RK-13 (KY) monolayers using 1 mL of culture supernatant as 
the inoculum.  Tissue culture fluid (TCF) was harvested and stored at -80°C for viral 
RNA extraction.  First and second passage flasks were stained with a 0.2% crystal violet 
solution in buffered formalin on day 4 post-inoculation to count plaques and calculate 
virus titers.  The same individual performed all attempted virus isolations. Virus isolates 
were, confirmed later by an EAV-specific TaqMan
®
 real-time RT-PCR assay as 
previously described
223
.  
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Phenotypic characterization of EAV isolates against neutralizing monoclonal 
antibodies and equine sera 
The EAV microneutralization assay was performed as previously described
15,16
.  
Neutralization titers were determined for each virus isolated from the semen of 
individual carrier stallions using a panel of EAV-specific MAbs and polyclonal equine 
antisera
422
.  
 
Real-time RT-PCR 
Briefly, viral RNA was directly isolated from 50 µl of tissue culture fluid (TCF) 
using a commercial RNA isolation kit (MagMAX
TM
 -96 Viral RNA Isolation Kit, 
Applied, Foster City, CA, USA) according to the manufacturer’s instructions.  Viral 
RNA was eluted in 50 l of nuclease-free water and stored at -80°C.  RNA extracted 
from TCF derived from RK-13 (KY) cells inoculated with semen samples that were 
negative for EAV, as well as from nuclease free water were included as negative 
controls.  Viral RNA extracted from TCF containing the KY84 strain of EAV was used 
as a positive control.  A one-tube TaqMan
®
 real-time RT-PCR assay was performed as 
described by Miszczak et al.
223
  
 
Next-generation and Sanger sequencing 
The total viral RNA was extracted from the TCF containing EAV KY84 strain 
(inoculum) or from the cell lysate following freeze-thaw of HP RK-13 (KY) cell 
monolayer (P1) in 25 cm
2
 flasks using a total RNA purification kit (Catalog no. 17200, 
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Norgen Biotek Corp., Ontario, Canada).  The RNA was quantified using a Qubit 2.0 
spectrophotometer (Life Technologies, Carlsbad, CA, USA). The cDNA libraries were 
constructed from 100 ng of total RNA using a TruSeq Stranded total RNA sample 
preparation kit (Illumina, San Diego, CA, USA) according to the manufacturer’s 
instructions. Multiplex libraries were prepared using barcoded primers and a median 
insert size of 340 base pairs (bp). Libraries were analyzed for size distribution using a 
Bioanalyzer and quantified by quantitative RT-PCR using a Kapa library quantification 
kit (Kapa Biosystems, Boston, MA, USA), and relative volumes were pooled 
accordingly. The pooled libraries were sequenced on an Illumina MiSeq platform with 
150 bp end reads following standard Illumina protocols. The Sanger sequencing was 
performed by RT-PCR amplification of the entire EAV genome in multiple overlapping 
segments using high-fidelity DNA polymerase enzyme as previously described. Primer 
sequences used for RT-PCR amplification and sequencing will be available upon 
request from the corresponding authors17,21,150. The nucleotide sequences of the 5' 
untranslated region (UTR) and 3' UTR termini region were further confirmed by 
standard Sanger sequencing of the reverse transcription-PCR products. Overlapping 
sequences were analyzed and assembled into a full-length genome sequence using the 
Geneious 7.0.6 software (Biomatters Ltd., Auckland, New Zealand). 
 
Read mapping and variant calling  
Raw reads in FASTq formats were imported into a CLC Genomics Workbench 
Version 8.5.1 (CLCBio, Aarhus, Denmark) after quality associated trimming; reads were 
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paired using the Illumina short read default parameters. Paired reads were then mapped to 
the reference genome (EAV KY84 in the inoculum) and the frequency of viral 
quasispecies population in individual samples, were called from reads coverage. The 
mapping procedures were normalized by subsampling of the reads across data sets using 
samtools 1.1 to 1000 x coverages to avoid the biases from a high and low read coverage 
across samples sets. Mapped files in (BAM) were imported back to CLC genomic 
workbench and numbers of single nucleotide variants (SNVs) were estimated by applying 
a minimum frequency filter of 1% and ignoring broken reads and nonspecific matches. 
Reference masking was set up for reads coverage >100,000 and < 100 in individual 
samples. A technology-associated filter was used to remove any pyro error variant with a 
minimum length of 3 and a frequency below 0.8.   
 
Nucleotide diversity and evolutionary selection analysis  
The statistical measure of nucleotide diversity (∏), which quantifies the average 
number of pairwise differences within a sample, was calculated using open-source 
software SNPGenie (https://github.com/chasewnelson/snpgenie). SNPGenie is a Perl 
script which analyzes SNV caller results to calculate an evolutionary parameter, such as 
nucleotide diversity (nonsynonymous and synonymous diversity, ∏n and ∏s).  Reference 
sequences in FASTA format, SNV report from CLC Genomics Workbench were used as 
input files. To produce GTF formats, the script snpgenie-gb2gtf.pl. was used and an 
estimation of nucleotide diversity ∏ was performed by running snpgenie.pl. from the 
command line. Values generated for the whole genome were used to show the diversity 
estimate at different time points. Individual ORFs were used to calculate ∏n 
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(nonsynonymous diversity) and ∏s (synonymous diversity). A ratio of ∏n/∏s > 1 was 
considered indicative of positive selection, <1 means purifying selection and 1 indicates 
neutrality.  
For selected ORFs with evidence of positive selection, the codon level was 
estimated to investigate particular areas under selection pressure.  In this analysis for each 
codon, estimates of the numbers of inferred synonymous (s) and nonsynonymous (n) 
substitutions are presented along with the numbers of sites that are estimated to be 
synonymous (S) and nonsynonymous (N). These estimates are produced using the joint 
maximum likelihood reconstructions of ancestral states under a Muse-Gaut model of 
codon substitution and model of nucleotide substitution. For estimating maximum 
likelihood values, a tree topology was automatically computed. The test statistic dN - dS 
is used for detecting codons that have undergone positive selection, where dS is the 
number of synonymous substitutions per site (s/S) and dN is the number of 
nonsynonymous substitutions per site (n/N). A positive value for the test statistic 
indicates an overabundance of nonsynonymous substitutions. Normalized dN - dS for the 
test statistic is obtained using the total number of substitutions in the tree (measured in 
expected substitutions per site) and used for making comparisons across data sets. 
Maximum likelihood computations of dN and dS were conducted using hypothesis 
testing and the phylogenies (HyPhy) software package.  
In addition, the presence of selection pressure at the codon level is further 
assessed using an online server at http://www.datamonkey.org. Fast unconstrained 
Bayesian analysis for inferring selection (FUBAR) algorithms was used to characterize 
selective pressure that are aggregated in all the branches of the constructed phylogenies, 
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and the mixed effect model of evolution (MEME) was used to identify individual sites 
subject to episodic positive selection along a subset of phylogenetic tree branches.    
 
Sequence analysis and SNV detection from consensus sequences  
Reads from individual samples were assembled de novo as indicated above using 
ABySS (vb1.3.7). The highest-ranking base at a position and with highest quality scores 
(highest calculated Q-score) were used to determine the consensus sequence. Once the 
consensus sequence was determined for each sample, the annotation of individual ORFs, 
and other genomic features was conducted using an automated gene transfer algorithm, 
Glimmer 3. The EAV reference genome in the NCBI database (NC_002532) was used to 
benchmark this procedure. The annotated ORFs and nonstructural proteins encoding 
regions were manually inspected and curated for correct enzyme cleavage sites, 
translation frame, start and stop codon coordinates.     
Finally, the full genome nucleotide sequences (derived from the consensus) and 
parts representing a genomic region were aligned using Clustal W plugin in Geneious 
V6.1.7.  For the nucleotide analysis, a default setting was in Clustal W cost matrix, a gap 
opening cost 15 and gap extension cost of 6.6. For translated amino acid sequence 
alignment, the GONNET cost matrix was used with a gap opening cost of 10 and a gap 
extension cost of 0.1. The original EAV KY84 strain used for the inoculum was the 
reference sequence for multiple sequence alignments. Single nucleotide variants (SNVs) 
in positions were identified using Geneious V6.1.7 and the effect of each SNP on 
translation (synonymous and nonsynonymous) was calculated for individual ORFs.   
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Phylogenetic analysis  
A phylogenetic tree was constructed using the same parameters described by 
Guindon et al. (2010)
423
. Evolutionary and genetic divergence analyses were performed 
by estimating the maximum likelihood of phylogenies using the PhyML program as a 
plugin for Geneious V6.1.7. These trees were constructed based on the GTR model, with 
1000 bootstrap replicates.  In addition, trees for molecular evolution were assessed using 
the maximum likelihood method based on the Tamura-Nei model as implemented in 
MEGA 7.0.21. Maximum likelihood trees were also generated using TempEst-v1.5 
(formerly known as Path-O-Gen) to investigate the temporal signals (clock-likeness) of 
the sequential genomes generated in this study. These trees were used to estimate the root 
tip distance by regression analysis. The relationship between root to tip divergence and 
sample collection date supports the use of molecular clock trees in this study. Molecular 
clock trees were generated by Bayesian inference analysis, as implemented in MrBayes 
version 3.2.2
424
. These trees were estimated using the GTR substitution model and 
gamma distribution rate of variation. The posterior probabilities were calculated using 
MCMC chain length generating 1,000,000 trees and sampling every 100th tree. The 
initial 25% of trees were discarded as a burn-in, and the others were used to construct a 
majority rule tree.   
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2.4. Results 
Establishment of EAV persistent infection in experimentally infected stallions  
A major aim of this study was to investigate intra-host evolutionary dynamics of 
EAV during acute and persistent infection in stallions. To achieve this goal, an 
experimental model of persistent infection was established by using the moderately 
virulent EAV KY84 strain. The selection of this strain was based on two important 
phenotypic traits relevant to this study, one is a moderately virulent phenotype which 
can be used to assess clinical and behavioral parameters following infection and the 
second is a demonstrated ability to establish long-term persistent infection in the stallion 
reproductive tract.         
Following infection, all seven stallions developed moderate to severe clinical 
signs. The detailed description of the clinical signs, virus effect on semen quality, as well 
as its tissue and cellular tropism have been previously described
211
. Briefly, clinical signs 
started at 2 dpi, with signs that included fever (38.7°C to 40.8°C [101.7°F to 105.6°F]), 
leukopenia, ocular, scrotal, preputial and limb edema, nasal and ocular discharge, 
congestion and petechial or ecchymotic hemorrhages on the oral mucosal membrane and 
decreased libido. These clinical signs lasted for up to 20 days, and the peak 
manifestations occurred at a median of 7 dpi. Once stallions recovered from these signs 
there were no recurrences of signs up to the conclusion of the experimental study (726 
dpi). Viral shedding in nasal secretions was detected as early as 2 dpi and lasted up to 19 
dpi. Viral titers varied from ≤10 – 5.7 x 10
4
 PFU/mL (mean viral titer of 4.36 x 10
3
 
PFU/mL). Similarly, viremia was detected in buffy coat cells at 2 dpi but was extended to 
between 28 and 42 dpi, and a mean viral infectivity titer varied from ≤10 – 5.1 x 10
3
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PFU/mL (mean viral titers 2.35 x 10
2
 PFU/mL). The peak for both nasal shedding and 
viremia occurred at a median of 6 dpi. The clearance of virus from blood mononuclear 
cells coincided with the appearance of neutralizing antibodies.  
All experimentally infected stallions exhibited decreased libido during the acute 
phase of infection. However, neither clinical signs of EVA nor reproductive dysfunction 
were observed in any of the experimentally infected stallions (n=7) following recovery 
from acute infection. Viral shedding in semen started at 5 dpi, except for one stallion 
(L141) where it was detected at 3 dpi. Viral infectivity titers in semen varied from 1.0 x 
10
1
 to 1.88 x 10
7
 PFU/mL during the acute infection (up to 21 dpi), with a mean titer of 
7.85 x 10
5 
PFU/mL. A peak in viral infectivity titer in semen occurred at a median of 9 
dpi.  Stallions seroconverted from 8 dpi and maintained high serum neutralizing antibody 
titers until the end of the study (1:64 to >1:512 [median titer of 1:256]).  
Two out of seven experimentally infected stallions (L136 and L140) continued to 
shed EAV in their semen for ≥ 726 dpi (i.e. long-term persistently infected stallions). By 
the end of the study, viral titers in semen of these two stallions were 6.5 x 10
3 
and 7.8 x 
10
3
 PFU/mL, respectively
165
, but infectivity titers in these stallions fluctuated from 1.2 x 
10
3
 to 8.8 x 10
5
 PFU/mL during persistent infection in the reproductive tract (Figure 2.1.).  
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Figure 2.1. Schematic presentation of the experimental design for this study. Darker 
horses were used to represent experimentally infected stallions (n=7), arrow showing 
timeline of sampling. Grey shaded horses were used to represent naturally infected 
stallions and arrow showing timeline of semen collection for isolation of the sequential 
viruses. 
 
Persistent EAV infection in naturally infected stallions 
Stallions D and E were naturally infected and became persistently infected during 
the extensive outbreak in 1984
142
.  These stallions have been monitored up to ten years, 
and during this period, EAV was shed in semen with titers ranging from 10 x 10
3
 to 1.0 x 
10
5
 PFU/mL (Figure 2.1.). There were neither apparent clinical signs nor any evidence of 
reproductive dysfunction in these stallions during the follow up to the conclusion of the 
study
142
.  
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Complete genome sequence of EAV KY84 strain used for experimental infection  
The complete genome sequence of EAV KY84 strain used as inoculum was 
determined using two methods. Consensuses derived independently from Sanger and 
NGS were compared and showed a 100% pairwise nucleotide identity. A fully annotated 
and complete sequence of EAV KY84 strain is deposited in GenBank with the accession 
number (MG137429).  
 
Virus population in the inoculum  
In order to understand the transmission dynamics of EAV quasispecies population 
following experimental infection, the quasispecies population was first characterized in 
the inoculum (original EAV KY84) by investigating the SNV present at minimum allelic 
frequency of 1%. The analysis showed that a genetically more homogenous viral 
population with structure constituted by a major variant (consensus virus; with ≥77% in 
frequency) and minority SNV population that was circulating from 13 to 25 %. However, 
this is likely to represent only a subset of the true variation present within the viral 
inoculum and characterizes the variants present at a frequency of >1% (Figure 2.2.).  
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Figure 2.2. SNV population in the inoculum used for experimental infection. Each 
dot in the figure represents a major and minor SNV population (nucleotide numbers 
A407G, A2337G, T4616C, T7414C, A8759C and C12582T). Population frequencies on 
y-axis and genomic position on x-axis are plotted in 2000 bp intervals. Blue dot (a 
synonymous SNV), red dot (nonsynonymous SNV) and light green (major variant). 
 
The minor variant populations in the inoculum were dominated by synonymous 
substitutions that are distributed evenly along the EAV genome. One exception to this 
was a SNV population with nonsynonymous substitution from A->G (T->A) at genomic 
position 2,337 corresponding to nsp2. The allelic frequency for this specific substitution 
in the virus inoculum was 13.5 %; whether this substitution is associated with specific 
adaptive function in cell culture is hard to predict in the absence of experimental data. 
However, a higher degree of conservation in the dominant nucleotide “A” across cell 
culture-passaged EAV field isolates (data not shown) suggest that it is unlikely that this 
substitution is associated with any specific advantage in the cell culture.  
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Founder virus analysis and nucleotide diversity during acute infection period 
Viruses isolated in the first nine days of the experimental infection were uniquely 
positioned to provide information on the mechanism of adaptive evolutionary process of 
EAV in a variety of host cells following initial infection. During this period, the virus 
present in the inoculum had successfully established infection in the respiratory 
epithelium and blood cells of all seven experimentally inoculated stallions. Virus 
shedding in the nasal secretions and viremia in blood (virus in buffy coat cells) were 
detected as early as 2 dpi, and then appeared for the first time in the semen at 5 dpi, 
suggesting an initial infection of the stallion reproductive tract where EAV established 
persistent infection. 
This adaptation to infect and replicate in various tissues along with an active 
challenge from host innate and fledgling adaptive immune responses could constitute 
evolutionary bottlenecks that select specific viral variants to shape an effective 
population size. In order to test this hypothesis and also elucidate the early event of 
quasispecies dynamics, representative viruses from time points of highest nasal shedding 
and viremia (6 dpi) and the initial semen isolates (5 and 9 dpi) were deep sequenced from 
viral RNA derived in the first TCF passage 1 (P1) in RK-13 (KY) cells. Thus in this 
section, results from deep sequencing of 28 sequential viruses are systematically 
presented to highlight the early events in EAV KY84 infection.  
First, the variant population present in the inoculum was compared with the 14 
sequential viruses from nasal swab and buffy coat samples. For this, the SNV populations 
(A407G, A2337G, T4616C, T7414C, A8759C and C12582T) were identified in the 
inoculum and were traced in the nasal swab and buffy coat viruses. Each of these six 
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minor variant populations was detected at least in five of the seven experimental stallions 
without causing a major shift in the population frequency (Figure 2.3.). 
 
Figure 2.3. Mapping of SNV in nasal secretions (NS), buffy coat (BC) cells and 
semen (S) in seven experimentally infected stallions during acute infection (0 to 9 
dpi). (A) Frequencies of the six SNV (represents variants in the inoculum) in an 
individual stallion. (B) Average detection frequencies of the six mapped SNV were 
steady in nasal secretion and buffy coat cells at 6 dpi. However, the SNV populations in 
the S (semen) at 5 and 9 dpi had undergone a shift in frequencies, which resulted in the 
fixation of T7417C at 5 dpi and A407G, T4616C, A8759C and C12582T at 9 dpi. The 
nonsynonymous substitutions from A2337G were below the detection limit at 5 dpi and 
then attained its average detection frequency at 9 dpi.    
T	
T	
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These results have confirmed transmission of all virus populations present in the 
inoculum and successful establishment of infection. Then, the overall similarities were 
identified between the major variants in the inoculum and initial viruses from the 
experimentally inoculated stallions by constructing phylogenetic trees and assessing 
consensus level. The results as demonstrated by the star-like phylogenetic tree structure 
and a 100% consensus agreement between the virus inoculum and the seven viruses from 
nasal secretions indicating that a single major founder virus population was responsible 
for establishment of the experimental infection  (Figure 2.4.). However, there were 
marked differences in quasispecies population composition and structure between the 
virus inoculum and viruses derived from nasal swabs. In this regard, nasal swab viruses 
have shown an expansion of the minor variant population by accumulating mutations that 
were not present in the inoculum. As a result, the quasispecies population frequencies 
were increased by more than 20-fold in the nasal swab viruses (Figure 2.5.A and B.). 
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Figure 2.4. Maximum likelihood phylogenetic trees showing a star-like network, 
which demonstrates the presence a major founder population in the experimental 
stallions similar to the stock virus. (A) Viruses from nasal secretions and buffy coat at 6 
dpi; (B) tree showing divergence of initial semen viruses from the major founder 
population at 5 dpi; and (C) at 9 dpi, the virus from semen was shown to evolve further in 
the stallion reproductive tract. The rates of evolution (nucleotide substitutions / site) in 
each tree are indicated under the bar. 
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Figure 2.5. SNV population and structure during the acute phase of infection (0 to 9 
dpi). Each dot in the figures represents a major and minor variant population. Population 
frequencies on y-axis and genomic position on x-axis are plotted in 2000 bp interval. 
Blue dot (synonymous SNV) and red dot (nonsynonymous SNV). (A) Less 
heterogeneous population in viral inoculum used for experimental infection of stallions, 
(B) nasal swab viruses at 6 dpi, (C) buffy coat viruses at 6 dpi, (D) semen viruses at 5 dpi 
and (E) semen viruses at 9 dpi. 
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To evaluate the level of polymorphism in this expanded quasispecies population, 
the nucleotide diversity was estimated within the nasal swab viruses by computing 
nucleotide diversity (∏) statistics. In this method, SNV are weighted at the population 
level and high frequency polymorphisms will be considered to be more diverse than 
populations with the same number of low frequency variants. The method also allowed us 
to calculate within the sample nonsynonymous nucleotide diversity ∏n and synonymous 
diversity ∏s separately. The ratio of the two estimates was performed to evaluate the 
presence of a selective pressure. A value of 1 suggested neutrality or absence of selection 
pressure, whereas a value of >1 suggested the presence of positive selection and a value < 
1 suggested a purifying type of selection. Based on these analyses, a higher nucleotide 
diversity was detected in nasal swab (1.9 x10
-4
) viruses than in the inoculum virus (1.3 x 
10
-5
). The ∏n/∏s ratio for nasal swab viruses was 3.1 x 10
-1
, suggesting a dominant 
purifying type of selection across the entire viral genome. However, during the SNV 
enumeration, the most nonsynonymous mutations were aggregated in nsp9 and nsp10 
(RNA-dependent RNA polymerase [RdRp] and zinc-binding domain [ZBD]) encoding 
regions in the viruses present in the nasal secretions.  
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Figure 2.6. Sliding window analyses showing evidence for positive evolutionary 
selections in the sequential viruses during acute infection. Selection was estimated by 
calculating the ratio of nonsynonymous and synonymous nucleotide diversity (∏n/∏s). A 
value of >1 was indicative of positive selection, value of 1 = neutrality and value < 1 was 
indicative of purifying selection; results were plotted against genomic position (x-axis) in 
2000 bp intervals. (A) Viruses from nasal swab, a positive selection was identified in 
genomic position corresponding to nsp9 and nsp10; (B) viruses from buffy coat, no 
region was found under positive selection pressure; (C) and (D) semen viruses at 5 and 9 
dpi respectively, semen virus at 5 dpi showed strong positive selection at multiple 
locations, whereas at 9 dpi, the selection pressure decreased except in the nsp9 region.  
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To investigate whether this is due to positive selection, the sliding window 
analysis (∏n/∏s) was performed via spanning the entire genome of nasal swab viruses. 
The results showed that the presence of strong positive selection (∏n/∏s >1) at the 
genomic regions spanning nucleotides (nts) 6729 to 6816 (within nsp9 peptide) and nts 
8469 to 8565 (within nsp10 peptide) (see previous page)  (Figure 2.6.A.). Similar 
analysis was conducted with viruses present in the BC samples at 6 dpi. Interestingly in 
the case of these samples, a decline in quasispecies diversity was observed as measured 
by the decreased nucleotide diversity (1.6 x 10
-4
) and total population size (Figure 2.7.A.). 
In addition, a minor shift in the population structure was identified in two stallions (L140 
and L138) that resulted in fixation of synonymous nucleotide substitutions at genomic 
positions 422 [G->A], 2567 [C->T] and 7417 [T->C]  (Figure 2.5.C.). However, contrary 
to what was observed in the case of nasal swab viruses, the sliding window analysis of 
∏n/∏s in the buffy coat viruses has shown no supporting evidence for localized positive 
selection (Figure 2.6.B.). In summary, despite a high level of consensus agreement and 
same date of isolation (6 dpi), the analyses have identified differences in viral 
quasispecies diversity, population size and evolutionary selection pattern between viruses 
from nasal swab and buffy coat samples.   
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Figure 2.7. Quasispecies diversity and population size of sequential viruses in nasal 
secretions, buffy coat and semen during acute and persistent infections. (A) 
Comparison of synonymous nucleotide diversity in the sequential viruses. The diversity 
in the two long-term carrier stallions (L-136 and L-140) at later dpi (380 and 726) were 
significantly higher (p< 0.0001; one-way ANOVA) than diversity detected in all other 
samples in this study. (B) Nonsynonymous diversity at 5 dpi in the semen viruses had a 
significantly higher substitution rate (p< 0.0001; one-way ANOVA) than any other 
sequential virus isolate in this study. (C) The quasispecies population size in sequential 
viruses has shown a trend of decline in the initial semen samples (at 5 and 9 dpi), where 
at 9 dpi it attains its lowest point in the experimental period. NS (nasal swab), BC (buffy 
coat) and S (semen). 
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Quasispecies diversity and evolutionary selection in the initial semen viruses 
Virus first appeared in semen at 5 dpi; the analysis of the viral quasispecies 
population in these samples revealed marked differences in overall evolutionary 
dynamics compared to viruses in the initial inoculum, nasal secretions and buffy coat 
samples. One major observation is semen viruses at 5 dpi have a high rate of 
nonsynonymous nucleotide diversity occurring at a rate (∏n = 4.2 x10
-3
) (Figure 2.7.B.). 
This was the highest nonsynonymous substitution rate recorded for the entire 
experimental period (p <0.0001). Interestingly, the viral quasispecies population size at 5 
dpi demonstrated a slight decline compared to what it was in buffy coat viruses and a 3-
fold reduction when compared to viruses in the nasal swab (Figure 2.7.C.). This showed 
that virus populations were bottlenecked during the initial infection of the stallion 
reproductive tract. In addition, the presence of a high level of nonsynonymous nucleotide 
diversity within the population (∏n=4.2 x 10
-3
) and the shifts of the minor and majority 
variant population characterizes the type of bottleneck as a selective one (Figure 2.5.C.). 
The sliding window analyses for ∏n/ ∏s also support the finding with additional 
evidence of strong selective sweeps in multiple genomic positions of the semen viruses 
(Figure 2. 6.C.). More interestingly, there were 29 new SNV fixed in the consensus 
genome that contributed 8 nonsynonymous substitutions in the structural protein 
encoding genes and in ORFs 1a and 1b. Given the nonstructural region is three-fourths of 
the entire EAV genome, the rate of nonsynonymous substitutions was higher in the 
structural protein encoding ORFs, which occupy one-fourth of the EAV genome. The 
regions of nsp2 peptide and ORF5 each acquired three amino acid substitutions. The 
changes in the nsp2 peptide region were at nucleotide positions 1,018 [P->L], 1633 [K-
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>R] and 1713 [A->T], whereas they were at genomic position 11,133[R->H], 11,162 [V-
>A] and 11,663[L->P] in ORF5 (Figure 2.5.C.). 
At 9 dpi, in contrast to what was observed in 5 dpi semen viruses, the ∏n values 
dropped significantly (p<0.0001), suggesting the selective sweeps observed in the initial 
semen viruses. Very interestingly, examining the population structure and sliding window 
analysis of ∏n/∏s showed only a very limited positive selection localized to the nsp9 
encoding region of ORF1b (Figure 2.5.E. and Figure 2.6.D.). 
Overall, the analysis of the viral population dynamics during the acute infection 
period (0 to 9 dpi) has identified a selective genetic bottleneck event during establishment 
of infection in the stallion reproductive tract (around 5 to 9 dpi). This is evidenced by the 
initial number of limited variant population in the parental virus that gave rise to a higher 
number of the variant population in nasal and buffy coat viruses with a dominant 
purifying type of selection. That was followed by a decline in the viral quasispecies 
population in the initial semen viruses. The presence of a strong positive selection across 
multiple genomic regions and, at the same time, a shift of the quasispecies population 
structure was clear indication of a selective bottleneck scenario that promotes variants 
with an adaptive fitness to establishing infection in the stallion reproductive tract.  
Additionally, the phylogenetic tree constructed from the nasal swab and buffy 
coat viruses showed star-like features that identify a responsible major founder virus 
population for establishment of the infection process. In contrast, the semen viruses (5 
and 9 dpi) were shown to diverge from the founder virus population indicating the 
emergence of a new dominant variant in the stallion reproductive tract (Figure 2.4.).  
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Intra-host evolution of EAV KY84 strain in the stallion reproductive tract during 
persistent infection 
Of the 34 sequential EAV semen isolates from seven experimentally infected 
stallions, 20 were isolated during the persistent infection period. Sequences from these 
viruses were systematically analyzed to gain a detailed insight into the characteristic feature 
of the EAV KY84 evolution in the stallion reproductive tract during long-term persistent 
infection.  
During the course of this experiment, five stallions had stopped shedding virus by 
different dpi (stallions L137 and L138 at 170 dpi and L139, L141 and L142 at 345 dpi). 
In contrast, stallions L136 and L140 became long-term carriers and continued shedding 
virus throughout the experimental period (726 dpi). The data showed a general increase 
in the viral quasispecies population size and diversity in the reproductive tract of these 
two stallions (Figure 2.8.A.). However, it is interesting to note that quasispecies diversity 
at later time points (380-726 dpi, where only L136 and L140 were shedding) was 
significantly higher compared to any other time point in this study (p<0.007 to 0.0001) 
(Figure 2.7.A.). This indicates the presence of a higher degree of heterogeneity in the 
virus population of the two long-term carrier stallions at later dpi (380-726), compared to 
those stallions that had stopped shedding. Overall, sequential viruses in this study were 
more under strong purifying types of evolutionary pressure (p< 0.0057) than positive 
(diversifying) selection (Figure 2.8.A.).  
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Figure 2.8. Heat map showing the evolution of 49 sequential viruses from seven 
experimentally infected stallions. At the full genome level, a strong purifying pressure 
played a significant role in long-term evolution of the sequential viruses (**p< 0.0057).  
(A) Nucleotide diversity (∏), nonsynonymous nucleotide diversity (∏n) and synonymous 
nucleotide diversity (∏s) in the 49 sequential viruses. (B) Illustrates the temporal changes 
in the SNV population detected in the inoculum over the two years of the experimental 
period. This founder virus population was detected consistently in the nasal swab (NS) 
and buffy coat (BC) samples, and detection and frequency shown to be variable in the 
subsequent semen (S) viruses. 
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According to the Figure 2.9., the initial population structures (in the inoculum, nasal 
swab and buffy coat viruses) were becoming genetically divergent with the appearance of 
high frequencies of minor variants. This indicates that the presence of a persistent selective 
pressure that continually morphs the population structure. The second important observation 
is the aggregation and fixation of a nonsynonymous variant population in the region of 
genome that encodes for the minor and major structural proteins (between nucleotide 
numbers 10,000 to 12,000) (Figure 2.9.). This indicates that mutations that occurred in this 
region have a greater role in maintaining persistent infections in the stallion reproductive 
tract. In order to investigate this observation further, the pooled semen viruses were 
computed in the analyses to find out whether the evolutionary selection was at a particular 
gene level. This revealed that ORF3 was under positive selection with a ∏n/∏s value of 
1.19. Additionally, the sliding window analyses on pooled semen viruses identified multiple 
regions within nonstructural and structural genes that are under strong positive selection 
(Figure 2.10.).   
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Figure 2.9. Quasispecies population structure during persistent infection (107 to 726 
dpi). Each dot in the figures represents a major and minor SNV population identified 
from the semen viruses of experimentally infected stallions (L136-142) collected during 
persistently infected period; on y-axis population frequencies and x-axis genomic 
position are drawn in 2000 bp intervals. Blue dot (a synonymous SNV), red dot 
(nonsynonymous SNV). SNV population in the semen viruses at (A) 107 dpi, (B) 170 dpi, 
(C) 380 dpi and (D) 726 dpi. 
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Figure 2.10. Quasispecies populations and positive selection in semen viruses. (A) 
SNV identified in semen viruses in the experimental period, each dot in the figures 
represents a major and minor SNV population; on y-axis population frequencies and x-
axis genomic position are drawn in 2000 bp intervals. Blue dot (a synonymous SNV), red 
dot (nonsynonymous SNV). (B) Sliding window analyses for evidence of positive 
evolutionary selections of the sequential viruses from semen, the results were plotted 
against genomic position (x-axis) in 2000 bp intervals.   
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Non-stochastic intra-host evolution of consensus viruses during persistent infection 
in the stallion reproductive tract  
In addition to characterizing the quasispecies population in experimental infection, 
the role of the major variant population was investigated by constructing a consensus 
sequence for each of the 48 viruses examined in this study. Comparative analyses of these 
sequential virus genomes have shown a total of 298 SNV fixed in the consensus genomes, 
and of these changes 68 were nonsynonymous substitutions. Using this information, the 
maximum likelihood and Bayesian phylogenetic trees were generated that show the extent 
of genetic divergence in the sequential viruses (Figure 2.11.A.). These viruses were evolving 
at a rate of 2.5 x 10
 -4
 nucleotide substitutions /site/year.  
A major observation from Bayesian inference analysis was the clustering of viruses 
in the phylogenetic tree in a non-stochastic manner. At the full genome level, the analyses 
have shown that EAV KY84 sequential viruses follow a linearly progressive type of 
evolution; as a result viruses from later dpi had larger branch lengths than their predecessors 
(Figure 2.11.). This was particularly emphasized in those viruses isolated from >107 dpi 
(shaded light brown in the phylogenetic tree), where viruses clustered by their date of 
isolation and the respective stallion. As a result, none of the viruses from two different 
stallions at different dpi clustered together. This observation was further confirmed with root 
to tip divergence analysis that demonstrated the clock-likeness of the sequential viruses by 
fitting the nucleotide substitution rate and date of isolation into a regression model. This 
showed a 0.90 correlation coefficient and R
2
= 0.81 (Figure 2.11.B.). 
 
 
 
 103 
Figure 2.11. Genetic divergence and evolution of EAV KY84 sequential viruses in 
experimental stallions. (A) Full-genome Bayesian phylogenetic tree constructed from all 
sequential viruses in the experimental period (726 dpi) and the numbers in each branch 
showing posterior probabilities calculated from 1000 replicates. Bar under the graph 
indicates the average pairwise distance of the sequential isolates from the original EAV 
KY84 strain described as the nucleotide substitution rate /site. The light brown shaded areas 
showing strict non-stochastic clustering of viral sequence; light blue shaded area shows 
clustering of sequences mostly from the period of acute infection. (B) Root to tip divergence 
analysis justified the use of molecular clock analysis on the sequential isolates in this study.  
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Intra-host evolution and genetic divergence in the structural region of consensus 
viruses during persistent infection 
In order to get a deeper insight on the important genomic region that signifies the 
evolutionary process, the data were systematically analyzed and these changes weighted by 
ORFs. The diversity estimation used to measure evolution was pairwise distance matrix to 
see how these sequential viruses diverged from the inoculum virus (original EAV KY84). 
This analysis at the level of the full genome assumes equal rate of substitution in various 
genomic segments over a period of time and hence was not satisfactory to identify the role 
of a particular region in the evolutionary process. Therefore, the analyses were further 
divided into by different ORFs and calculated a pairwise distance; this showed ORFs 5 and 
3 are the two most evolving regions at rate of 3 x 10
-3 
nucleotide substitutions/site resulting 
in sequence divergence of 1 to 1.4% respectively. ORF1ab and ORF7 were shown to be the 
two most conserved regions with only 0.3 and 0.5 % of divergence from the parental EAV 
KY84 over the two years of the experimental period.  
These changes accumulating in the genomes of sequential isolates have either a 
purifying or a selective role in the evolution of viral populations in the reproductive tract. To 
characterize the changes in such a way, the ORF1ab region was broken down into 
nonstructural protein coding regions (nsp1 to 12) and included the tally of synonymous and 
nonsynonymous substitutions (Figure 2.12.). The analysis showed that despite a higher 
number of synonymous changes occurring in the ORF1ab region, most nonsynonymous 
changes were concentrated in the nsp2 encoding region of ORF1a.  The 1.7 kb-long nsp2 
had undergone 29 synonymous and 14 nonsynonymous substitutions over a period of 726 
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days; this constitutes 42 % of the total nonsynonymous substitutions for the whole of 
nonstructural region. 
 
Figure 2.12. Rate of synonymous and nonsynonymous substitutions across genomic 
regions and ORFs of the sequential viruses. (A) Tally of all nonsynonymous and 
synonymous substitutions in the ORFs and peptide regions of the sequential viruses. (B) 
Graph showing the rate of variation by which nucleotide substitution occurred in the region 
of EAV KY84 sequential genomes, 13 nucleotide substitution/kb in the structural region and 
only 3 substitutions/kb in nonstructural region. 
 
In the structural protein encoding region (ORFs 2-7) of EAV, the sequential isolates 
had a higher rate of nonsynonymous substitution compared to nonstructural region (Figure 
2.12.B.). The data shows that for every kb in the nonstructural region, there were 3.3 
nonsynonymous substitutions over the two year period of the study; whereas there were 12 
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nonsynonymous substitutions /kb in the structural regions, clearly suggestive of a higher rate 
of fitness-associated substitution in the structural region. This observation is also strongly 
supported by ∏s and ∏n analysis, which indicated a strong positive selection in ORF3 and 
also in ORF5 (Figure 2.13.). The result also demonstrated that the nsp2 peptide had 
undergone a positive selection (∏n / ∏s >1) indicating an important role for this region in 
the adaptive evolutionary process.  
 
 
Figure 2.13. Comparison of nonsynonymous to synonymous nucleotide diversity in the 
experimental horses. (A) Nucleotide diversity estimate by regions of the genome ∏n 
(nonsynonymous diversity) ∏s (synonymous diversity). (B) Showing the presence of 
positive selection in ORFs that have ∏n/∏s value > 1.  
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To further investigate which specific codons were under selection pressure, the 
sequences from ORF3 and ORF5 were used for a codon level estimate of positive selection. 
A maximum likelihood reconstruction of ancestral states using a Muse-Gaut model 
employed under MEGA7 was used to test the statistic dN - dS for detecting codons that 
have undergone positive selection, where dS is the number of synonymous substitutions per 
site (s/S) and dN is the number of nonsynonymous substitutions per site (n/N). A positive 
value for the test statistic indicates an overabundance of nonsynonymous substitutions. 
Analysis of ORF3 using this model demonstrated most codon positions in this gene were 
found to be overabundant with nonsynonymous substitutions (Table 2.1.) indicating a 
positive selection pressure in the codons highlighted yellow. However unlike ORF3, ORF5 
contained a higher number of negative dN – dS values per codon site, indicating an 
overabundant synonymous codon site. The values for ORF5 are given in Table 2.2. and the 
overabundant nonsynonymous sites are highlighted in yellow.  
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Table 2.1. Nonsynonymous and synonymous substitution site estimate for ORF3, values shaded in yellow are codon positions that 
have more nonsynonymous substitutions than synonymous substitutions 
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Table 2.2. Nonsynonymous and synonymous substitution site estimate for ORF5, values shaded in yellow are codon positions that 
have more nonsynonymous substitutions than synonymous substitutions 
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Intra-host evolution and genetic diversity of EAV KY84 strain in naturally infected 
stallions over a span of 10 years  
In addition to the experimentally infected horses, there was the opportunity to 
analyze virus sequences from two naturally infected stallions. The two Thoroughbred 
stallions (E and D) were on the farm where the first major EVA outbreak in 
Thoroughbred horses in Kentucky occurred. These two stallions were initially infected 
with EAV KY84 (inoculum virus) that was used for experimental inoculation of the 
seven stallions.  However, the two horses subsequently developed the natural carrier state 
and continued to shed the virus in the semen for a period 7 to 10 years (stallion E, 1984 to 
1991 and stallion D, 1984 to 1994, respectively). In this study, the complete genome of 
four viruses that were isolated from the semen of stallion E in 1984, 1991 and stallion 
D1984, 1994 (these viruses will be referred as E or D followed by year of isolation) were 
sequenced and analyzed.  
Comparative nucleotide and amino acid analyses showed that E84 and D84 
viruses from naturally infected stallions are very similar to the inoculum virus that was 
used for experimental infection of the other stallions. The only differences identified 
were 9 substitutions in the D84 and E84 viruses compared to the EAV KY84 strain used 
to inoculate the stallions. These changes resulted in three nonsynonymous substitutions in 
D84 virus at position (583 T>I (nsp1), 5376 D>A (nsp9) and 10,886 F>L (GP4) and only 
one nonsynonymous substitution in E84 virus at 5376 D>A (nsp9) (Figure 2.14.A.).  
The quasispecies population structures in E84 and D84 viruses have some 
collinearity with what was observed with viruses from the semen of the experimental 
stallions, by having a number of minor variants (Figure 2.15.A and B.). However, the 
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E91 and D94 viruses showed a clearing of the high frequencies of minor variants with a 
new distinct population structure of new minor and new major variants (Figure 2.15.C 
and D.).  
Similar to the observation made in the experimental samples, a higher level of 
nonsynonymous fixation was shown to aggregate in the structural regions of the genome. 
For a detailed characterization of these changes, the consensus sequence was calculated 
as genome-wide pairwise distance for stallion D and E viruses. The results showed 
sequence divergence by 1.6 and 2% over the span of seven year for E91 and ten years for 
D94 (Figure 2.14.B.). 
Previous analyses of viruses from the experimentally infected stallions showed 
that evolution of ORFs occurred at a variable rate. Hence, the extent of evolution was 
investigated between the various ORFs in these four sequential viruses. In agreement 
with earlier observation, different ORFs evolved independently with some accumulating 
more numerous changes than others. In the 10 year period, ORF3 was shown to have a 
4.5% sequence divergence from the original isolates, diverging at a rate of 2 .6 x 10
-2
 
nucleotide substitutions / site (Figure 2.14.B.). By contrast, ORF7 was demonstrated to 
have the lowest evolutionary rate with 2 x 10
-3
 nucleotide substitutions / site, which 
resulted in a 1.2% pairwise sequence divergence from the original EAV KY84 genome 
(Figure 2.14.B.).  
These changes in various ORFs have brought 461 substitutions, which included 
361 synonymous and 96 non-synonymous substitutions (Figure 2.15.C and D.). A higher 
proportion of the nonsynonymous substitutions was shown in the structural protein 
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coding region where 19.3 nonsynonymous substitutions / kb, whereas 4.1 amino acid 
substitutions / kb were seen in the nonstructural region of the EAV genome. 
 
 
Figure 2.14. Sequence alignments and comparison of sequential viruses in naturally 
infected stallions D and E. (A) Multiple genome alignment of four sequential viruses 
with the parental EAV KY84. The genome arrangement with arrowed boxes indicating 
the location of peptides and important genes.  A vertical line indicates disagreement 
between the four viruses from the two naturally infected stallions with the parental EAV 
KY84 strain. (B) Bar graph showing the pairwise similarity of these sequential genomes 
from naturally infected stallions. Genome wide means comparing pairwise distance of 
consensus sequences from stallion D and E viruses. 
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Figure 2.15. Quasispecies population structure in naturally infected stallions D and 
E. The stallions D and E were infected with EAV KY84 strain are very similar to the 
inoculum virus used for experimental infection of the seven stallions. Each dot in the 
figures represents a major and minor SNV population; on y-axis population frequencies 
and x-axis genomic position are drawn in 2000 bp intervals. Blue dot (a synonymous 
SNV), red dot (nonsynonymous SNV) and light green (reference variant). (A) SNV 
population frequencies of E84, (B) SNV population frequencies of D84, (C) SNV 
population frequencies of E91 and (D) SNV population frequencies of D94. 
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To examine these changes and their role in the adaptive evolutionary process, the 
computed ∏n/∏s analysis showed the presence of selection pressure in ORF3 and ORF5 
(Figure 2.16.). However, contrary to what is observed in the experimentally infected the 
stallions, those changes in the nsp2 region were found to be purifying rather than 
associated with evolutionary fitness. Based on these results, further investigation was 
focused on the codon level selection estimate on ORF3 where multiple nonsynonymous 
overabundant codon sites were identified isolates (n=53) of both experimentally and 
naturally infected horses that are highlighted yellow in Table 2.3. 
 
Figure 2.16. Comparison of nonsynonymous to synonymous nucleotide diversity of 
viruses from naturally infected stallions. (A) Nucleotide diversity estimate by regions 
and ORFs in the EAV KY84 genome, ∏n (nonsynonymous nucleotide diversity) ∏s 
(synonymous nucleotide diversity). (B) Showing the presence of positive selection in 
ORFs that have ∏n/∏s value >1. 
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Table 2.3. Nonsynonymous and synonymous substitution site estimate for ORF3 was identified in virus isolates from both 
experimentally and naturally infected horses, values shaded in yellow are codon positions that have more nonsynonymous 
substitutions than synonymous substitutions  
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Mirroring the trend in the comparative evolution between experimentally and 
naturally infected stallions    
As described in the earlier section, one advantage of the sequences from naturally 
infected isolates extended analyses to a ten-year window and enabled us to understand the 
EAV evolutionary process over a longer time period. Hence, the evolutionary rate of EAV 
KY84 was calculated from the combined sequences from the experimental infection with 
isolates from stallion D and E. A full genome multiple alignment of 53 sequential viruses 
was used to perform a Bayesian phylogenetic tree (Figure 2.17.). The result showed that 
EAV KY84 isolates were evolving at rate of 4 x 10
-4 
nucleotide substitutions / site / year. 
This is slightly higher nucleotide substitution rate than that individually estimated for the 
experimental stallions (Figure 2.17.).  
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Figure 2.17. Estimation of evolutionary rate of the sequential viruses. (A) Ancestral 
reconstruction using a Bayesian phylogenetic. (B) Root to tip divergence analysis justifying 
the use of a molecular clock analysis on the sequential isolates in this study.   
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Figure 2.18. Comparative trend in nucleotide diversity and selection between viruses 
from the natural and experimental infections. (A) Collinearity in trends of nucleotide 
diversity in EXPT (sequential viruses from experimental infection), NAT (sequential viruses 
from natural infection). (B) Collinearity in trends of positive and negative selection in EXPT 
(sequential viruses from experimental infection), NAT (sequential viruses from natural 
infection) various genomic region sequential viruses. Horizontal line showing where the 
ratio ∏n/∏s is 1, which indicates equal rate of nonsynonymous and synonymous diversity. 
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In addition, these combined sequences were used to compare and contrast virus 
evolution and selection pressure between experimentally and naturally infected stallions. 
This analysis has showed that the rate of nucleotide substitution / site described as an 
average pairwise distance in Figure 2.18.A. and the diversity estimate ratio of ∏n/∏s 
obtained across all ORFs followed a mirroring trend across genomic regions of viruses from 
experimentally and naturally infected stallions (Figure 2.17.). These comparisons also 
confirmed the previous observation that ORF3 and 5 have a prominent role in the 
evolutionary process of viruses in experimental as well as natural infections.  
In order to visually identify codons or regions of such importance in ORF3 and 5, 
the FUBAR (fast-unconstrained Bayesian approximation for inference of selection) was 
implemented in datamonkey server and fitted the data with a codon substitution model.  This 
method uses an empirical Bayes procedure in the phylogenetic likelihood framework to 
identify codon regions with statistically significant evidence for diversifying and purifying 
selection. The analysis has identified seven sites with diversifying (positive selection) in 
ORF3 with a posterior probability > 0.9 at codon positions 3, 19, 27, 28, 30, 119 and 120 
(Figure 2.19.). It also identified four sites with evidence of purifying (negative selection) at 
posterior probability > 0.9, codon positions 93, 134, 137 and 145 (Figure 2.19.).  
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Figure 2.19. Fast-unconstrained Bayesian approximations for inferring selection 
(FUBAR) analysis of ORF3. (A) A rate class weight analysis of positive and negatively 
selected codon positions with heat map calculated from posterior mean analysis of 
nonsynonymous (beta) over synonymous sites (alpha) by the FUBAR algorithm. (B) Codon 
positions with * (black) are the seven sites with statistically significant evidence for 
diversifying selection at posterior probability of > 0.9 and * (red) the four sites identified 
with statistically significantly purifying selection at posterior probability of > 0.9. 
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Figure 2.20. Fast-unconstrained Bayesian approximations for inferring selection 
(FUBAR) analysis of ORF5. (A) A rate class weight analysis of positive and negatively 
selected codon positions with heat map calculated from posterior mean analysis of 
nonsynonymous (beta) over synonymous (alpha) sites by FUBAR algorithm. (B) The four 
codon positions with * (black) are identified with evidence for diversifying selection at 
posterior probability of > 0.9 and * (red) showing the seven sites identified with purifying 
selection at posterior probability of > 0.9.  
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Similarly in ORF5, FUBAR has identified four statistically significant codon sites 
with diversifying (positive selection) at codon positions 11, 72, 82 and 84 and eight sites (at 
codon positions 2, 109, 110, 111, 117, 121, 138 and 154) with purifying (negative selection) 
at posterior probability of > 0.9 (Figure 2.20.). The analysis by FUBAR was based on 
pooled signals of all the phylogenetic tree branches; however, some studies have suggested 
using the mixed effect model of evolution (MEME) that is more sensitive than FUBAR for 
detection of selection on subsets of viral linages
425–427
. For this reason, ORFs 3 and 5 were 
subjected to MEME analysis as implemented in the adaptive evolution server of 
datamonkey.  By doing so, additional sites of statistically significant value have been 
identified (Table 2.4.). More interestingly, four out of the seven codon sites in ORF3 were in 
concordance for evidence of diversifying positive selection in both FUBAR and MEME 
algorithms (Table 2.4.).  
 
Table 2.4. Analysis of positively selected codon sites in ORF3 and ORF5 of sequential 
viruses 
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By combining the information in Table 2.4. that identifies the sites under 
diversifying selection and localization of the codons in Figure 2.19. and Figure 2.20., it is 
possible to see the pattern of selection in ORF3 and 5. In this regard, the region that contains 
the first 30 codons of ORF3 (an overlapping region with ORF2) is shown to preferentially 
undergo a positive selection pressure, and this may indicate a fitness-associated role in this 
region during persistent infection; whereas in ORF 5, the region between codon positions 
100 to 154 as under significant influence of purifying type of selection, which showed that 
genetic drift is the major driver of evolution in this region.   
 
2.5. Discussion 
Experimental evolutionary models constitute the most powerful means of 
recapitulating natural evolution of viruses, and they have been used to test basic 
theories/hypotheses and elucidate the mechanisms of viral survival and spread in short-
term and long-term viral infections
428–430
. In this study, seven sexually mature stallions 
were used for experimental inoculation of the moderately virulent strain of EAV KY84 
and then these stallions were followed for up to 726 dpi. This appears to be the first study 
to experimentally characterize the intra-host evolutionary process of the prototype 
arterivirus in its natural host. Similar studies for other RNA viruses have been shown to 
elucidate viral evolution across a single transmission event and over the course of the 
infection period
416,431–433
. However, a major strength of this study was the ability to 
follow and sample experimentally and naturally EAV infected horses for relatively long 
periods of time (~up to 2 and 10 years, respectively). The only other study that has 
looked at the evolution of EAV in longitudinal samples was that of Hedges et al. 
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(1999)
142
, where sequential viruses from two naturally infected stallions (D and E) during 
the 1984 EAV outbreak in Kentucky were characterized. However, that study used 
traditional RT-PCR amplification, cloning and Sanger sequencing methods to 
characterize EAV ORFs 2 to 7 in sequential EAV KY84 viruses present in semen. With 
significant improvement on this study, four sequential viruses were included from horses  
(D and E) that were naturally infected during the 1984 EAV outbreak and employed NGS 
technology to evaluate the intra-host evolution and compare it to the analysis from the 
experimental stallions. In total, this study was based on data from 53 sequential viruses 
that have been deep sequenced using an Illumina Miseq technology and used to 
reconstruct the quasispecies population dynamics and overall genetic divergence of EAV 
in the acute and persistent stages of the infection. 
Recent advances in sequencing technology allow viral evolution to be studied 
with deep insight into viral quasispecies populations
429,434
. As a result, investigating intra-
host viral evolutions in longitudinal samples has become a part and parcel of 
pathogenesis studies
285,397,435
. These types of studies have demonstrated that rapidly 
evolving RNA viruses exist as genetically related but highly diverse and complex viral 
populations
436,437
. These observations followed by identification of the viral evolution in 
dynamic population structure indicate that variants undergo temporo-spatial change and 
regulate quasispecies composition that can result in the emergence of new 
phenotypes
438,439
.  
The first reports on identification of EAV quasispecies populations were those 
based on T1 oligonucleotide fingerprinting of viruses isolated from naturally infected 
stallion semen
142
. Subsequently, others characterized the genetic divergence of this virus 
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mainly by targeted sequencing of structural proteins encoding ORFs, mainly ORF5.  In 
this study, the EAV KY84 quasispecies populations in the inoculum and in nasal, buffy 
coat and sequential semen samples were reconstructed. In agreement with observations 
for other RNA viruses, the major and minor variant populations were defined in the 
inoculum virus.  These variants were traced in nasal swabs and buffy coat samples that 
comprised successful establishment of experimental infection from the viral inoculum 
populations.  In the initial samples from the experimentally infected stallion, the founder 
effect had been shown to result in loss of certain populations from the inoculum during 
viral transmission. This might be associated with the efficiency of the nasopharyngeal 
inoculation technique used to infect horses in this study. In larger animal models such as 
horses, the presence of a more extensive surface area in the nasal cavities coupled with a 
high viral challenge dose in the inoculum could facilitate efficient transmission of viral 
populations.  A similar finding has also been reported in the case of intra-host 
evolutionary studies of influenza virus where transmission bottleneck events occurring in 
experimental infections of ferrets and mice were determined by the route of 
inoculation
434,440
.  
The presence of a high rate of mutation in RNA viruses is beneficial for rapid 
adaptation to their microenvironment; at the same time, it has the disadvantage of random 
generation of non-viable viruses
285,439
.  However, contemporary thought on RNA virus 
evolution suggests that a cloud of potentially beneficial mutations occur at the population 
level
285,428,439
 .  An interesting observation from this study was that viruses from nasal 
swabs and buffy coats have distinct quasispecies population sizes and selection patterns.  
This was examined as to how this cell population becomes infected. EAV initially 
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invades the upper respiratory tract and multiplies in the nasopharyngeal epithelium and 
tonsillar tissue as well as in bronchial epithelium and alveolar macrophages. Then, the 
virus infects cells of the monocyte linages and CD3 T
+
 lymphocytes transport the virus to 
the regional lymph nodes, where it undergoes a further cycle of replication before it 
enters into the blood stream
86,87,155,205
.  Based on the initial phase of the pathogenesis of 
EAV, the viral quasispecies in nasal swab samples represent the initial population that 
established infection in the experimental stallions. Analysis of these viruses showed an 
expanded population size as a result of a high rate of de novo mutations. Very 
interestingly, despite an overall purifying type of selection, there was a strong 
diversifying pressure on the nsp9 encoding region of ORF1b (nt 6729 to 6816). This 
suggests that the low frequency mutation on nsp9 may have a regulatory effect on virus 
replication and may be associated with the higher population size in nasal swab viruses. 
Consistent with this observation, shrinkage in population size was detected in the buffy 
coat samples where there was no selection pressure on the indicated site (nt 6729 to 6816) 
of the nsp9 peptide.  
It is also important to note that the virus population being shed by individual 
animals under the same sampling conditions, but from different cell types are distinct in 
their quasispecies composition, selection pattern and population size. The reduction in 
variant population size observed in buffy coat viruses may reflect a transmission 
bottleneck scenario that confers fitness to variants with the right type of mutations to 
infect cells of the monocyte lineages and CD3 T
+
 lymphocytes. 
Similarly, viruses in semen at 5 dpi show a divergent population structure with the 
appearance of several new fixations, reduced population size and multiple sites under 
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positive selection. Given that the neutralizing antibodies first appeared in blood of 
experimental stallions at 8 dpi, the driving force behind the selective sweep in the initial 
semen samples is most likely associated with the fitness cost of adapting to the cells in 
the stallion reproductive tract.  EAV has been demonstrated in a variety of cells in the 
ampullae and other accessory sex glands of stallions
165
. Although these sites of virus 
persistence are not immunologically privileged, there is strong inflammatory cell 
infiltration along with plasma cells producing EAV specific antibodies
441
. These 
observations suggest that infections of various cells in the reproductive tract, as well as 
adaptation to evade local inflammatory and immune responses may be the driving force 
for the selection and reduction of the initial viral variant population in the reproductive 
tract.  
It has been shown that persistent infection with EAV is testosterone dependent 
and castration of stallions leads to clearance of viral persistence
11,209,212
.  How this 
hormone regulates EAV evolution in the reproductive tract, and whether the quasispecies 
population is any different in the presence of variable concentrations of this hormone, is a 
subject for future investigation.  However, some studies have suggested testosterone is 
associated with variable effects on reproductive tissue such as maintenance of susceptible 
host cell population and immune suppression
11,13,209,209
  
The study has also demonstrated the presence of continual positive selection in 
specific regions of the genome that drives evolution of viruses isolated from semen. The 
non-stochastic nature of EAV evolution in persistent infection and the swarm of 
quasispecies populations that shows an atypical high frequency of a minor variant 
population imply ongoing interaction between viral quasispecies populations and the host 
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immune system. Persistent infection with EAV develops in 10 to 70 % of sexually mature 
stallions
11,140,156
. This occurs in the presence of a high level of virus neutralizing 
antibodies in serum that effectively eliminates systemic infection in body tissues with the 
exception of the stallion reproductive tract. Previous studies have showed that natural 
transmission of EAV can occur by aerosol or infective semen, however the quasispecies 
diversity during persistent infection contrasts with the relative genetic stability observed 
in horizontally transmitted disease outbreaks
21,154,267
. There is some evidence from 
natural infection of lactate dehydrogenase-elevating virus and simian hemorrhagic fever 
virus to suggest variants with lower virulence and immunogenicity are selected during 
persistent infection, whereas more virulent variants seem to be favored during 
outbreaks
86,87,205,442
.  
In this study, ORF3 of viruses present in semen have been shown to be under 
selective pressure during persistent infection.  The ORF3 may have some of the T cell 
epitopes of the virus but unfortunately, the T cell epitopes of this virus have not yet been 
characterized. The result is also true for viruses from cases of natural infection suggesting 
an important role for this particular gene in persistent EAV infection. Similar 
observations have been made in previous works that have characterized natural EAV 
infections. However, the observation showed a minimal role for ORF3 in the initial 
stages of infection when viruses first appear in the reproductive tract. The pattern of 
nonsynonymous substitutions at 5 and 9 dpi revealed that selection localizes in the ORF5 
(GP5) and nsp2 peptide regions of ORF1a, suggesting a crucial role for these proteins in 
the initial adaptation process of variant populations in the stallion reproductive tract. The 
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selection of ORF3 variants comes later in the persistent infection period when 
maintenance of persistent infection is needed.  
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CHAPTER THREE 
Genomic, Phylogenetic and Antigenic Characterization of a Novel Field Strain of 
Equine Arteritis Virus Isolated from a Feral Donkey in Chile 
 
3.1. Summary 
Here we describe the isolation and characterization of a new strain of equine 
arteritis virus (EAV donkey VD7634 strain) from the vas deferens of a wild male donkey 
from northern Chile in 2013. The full-length genome sequence of donkey VD7634 was 
obtained using next-generation sequencing (NSG) with Illumina MiSeq technology. 
Comparative nucleotide sequence analysis indicated that the donkey VD7634 virus had 
only 77% and 76.8% nucleotide identity with North American and European strains of 
EAV, respectively. The complete genome of the EAV donkey VD7634 strain was 12,703 
bp in length and consists of ten open reading frames (ORFs) encoding 13 nonstructural 
proteins and eight structural proteins. Comparative nucleotide and amino acid analyses, 
as well as phylogenetic analysis demonstrated that this donkey strain is distinct from 
reference EAV strains due to multiple insertions and deletions. However, the virus 
appears antigenically very similar to the other EAV strains and could be neutralized with 
polyclonal and monoclonal antibodies against EAV.  
 
3.2. Introduction 
Equine arteritis virus (EAV) is the causative agent of equine viral arteritis (EVA), 
a respiratory and reproductive disease affecting members of the family Equidae, which 
include horses, donkeys, mules and zebras. EAV was first isolated from the lung of an 
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aborted fetus following extensive outbreak of respiratory disease and abortion on a 
Standardbred breeding farm near Bucyrus, OH, USA, in 1953. Equine arteritis virus 
(EAV) is a small, enveloped, positive-sense, single-stranded RNA virus that belongs to 
the family Arteriviridae (genus: Equartevirus, order: Nidovirales). The EAV genome is 
approximately 12.7 kb; it contains 10 open reading frames (ORFs) that are flanked by a 5′ 
leader sequence and a 3′ untranslated regions (UTR)
3,17,19,21,64,199
. ORF1a and 1b encode 
two polyproteins (pp1a and pp1ab) that are processed post-translationally by three 
ORF1a-encoded proteinases (nsp1, -2 and -4)
21,55,112
. These polyproteins are cleaved into 
13 nonstructural proteins (nsp1-12, including nsp7α and 7β)
21,36,37,55
. The other eight 
ORFs (2a, 2b and 3, 4, 5a, 5, 6 and 7) encode the envelope proteins E, GP2, GP3, GP4, 
GP5, ORF5a protein and M and nucleocapsid protein, N, respectively
5,21
. The GP5 
protein has been shown to carry the major neutralization determinants of the 
virus
16,20,21,82,443
. Based on ORF5 phylogenetic analysis, EAV field strains can be broadly 
divided into two distinct clades: North American (NA) and European (EU) 
groups
1,40,410,444
. Phylogenetic analysis based on partial ORF5 sequences segregated EAV 
isolates from around the world to North American (NA) and the European (EU) lineages 
and each lineage as further such divided into two North American (NA-1 and NA-2) and 
European (EU-1 and EU-2) clades (Table 3.3.); these sequences segregate into 
independent branch when subjected to phylogenetic analysis
10
.  
In 2013, Servicio Agricola y Ganadero (SAG) identified a large herd of wild 
donkeys naturally infected with EAV in northern Chile. Serum samples from these wild 
donkeys tested positive for anti-EAV antibodies by ELISA and virus neutralization test 
(VNT) assays at SAG. Subsequently, 18 necropsy specimens from two male donkeys 
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(animal ID: Donkeys 7634 and 7635) were collected and these included epididymis, 
prostate, vas deferens, seminal vesicles and conjunctival swabs. Viral nucleic acid was 
extracted from the vas deferens of Donkey 7634 and the partial sequence spanning ORFs 
6 and 7 were obtained by sequencing the RT-PCR products. BLASTn analysis of ORFS 6 
and 7 partial sequences showed 86 % and 90% nucleotide identity with EAV VBS 
(GenBank accession number: DQ846750), respectively. This confirmed that the donkey 
was infected with an EAV strain circulating in the wild donkey population.  Samples 
from donkeys 7634 and 7635 were submitted to the EVA OIE reference laboratory at the 
Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY, 
USA. Here we describe the virus isolation, genetic, phylogenetic and antigenic 
characterization of a novel donkey strain of EAV (EAV donkey VD7634) from a wild 
donkey in northern Chile.   
 
3.3. Materials and methods 
Necropsy specimens 
Eighteen frozen necropsy specimens (epididymis [2], prostate [2], vas deferens 
[2], seminal vesicles [2], conjunctival swab [1] from two donkeys (7634 and 7635) were 
received at the EVA OIE reference laboratory, Maxwell H. Gluck Equine Research 
Center, University of Kentucky, Lexington, KY, USA for EAV testing. 
 
Cells and viruses 
High passage (HP) rabbit kidney 13 cells RK-13 (KY), passage level 399–409 
derived from ATCC
®
 CCL-37™, American Type Culture Collection, Manassas, VA, 
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USA were maintained in Eagle’s minimum essential medium (EMEM, Cellgro
®
, 
Mediatech Inc., Herndon, VA, USA) with 10% ferritin-supplemented calf serum 
(HyClone Laboratories, Inc., Logan, UT, USA), penicillin and streptomycin (100 U/mL 
and 100 μg/mL) and 0.25 μg/mL of amphotericin B (Gibco
®
, Carlsbad, CA, USA). The 
prototype Bucyrus strain of EAV (EAV VBS; ATCC VR-796, Manassas, VA, USA) was 
used as a control virus in the neutralization assay.  
 
Virus isolation  
HP RK-13 (KY) cells were used for isolation of EAV from reproductive tract 
tissues and the conjuctival swabs, as previously described. Briefly, 10% tissue 
homogenates of necropsy specimens were prepared, centrifuged at 2,500 x g for 15 min, 
and the supernatant serially ten-fold diluted (10
-1
 to 10
-3
). The conjunctival swab was 
immersed in 5 mL of EMEM and the medium filtered through a 0.45 µm filter.  One mL 
of each tissue homogenate and conjunctival filtrate was inoculated in duplicate 25-cm
2
 
flasks containing confluent monolayers of HP RK-13 (KY) cells. Additionally, 1 mL of 
each undiluted tissue homogenate was inoculated in duplicate 25-cm
2 
flasks. After 1 hour 
(h) adsorption at 37°C, monolayers were overlaid with EMEM supplemented with 0.75% 
carboxymethylcellulose, incubated for 4 days at 37°C and checked for the appearance of 
cytopathic effect (CPE). If there was no detectable CPE, a second blind passage was 
performed. After decanting the medium, monolayers were stained with a 1% crystal 
violet solution, and viral titers were expressed as plaque-forming units per gram of tissue 
(PFU/g). The tissue culture fluids (TCFs) were subjected to a one-way serum 
neutralization assay using polyclonal anti-EAV equine serum against the prototype VBS 
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strain of EAV to confirm the identity of the isolates as previously described
223
.  The 
isolates were further confirmed by EAV specific TaqMan
®
 real-time RT-PCR assay as 
previously described
232
. 
 
Microneutralization test  
The neutralization phenotypes of the EAV donkey isolate was determined by a 
microneutralization assay using a panel of neutralizing monoclonal antibodies (mAbs; 
5G11, 6D10, 7E5, 10F11, 1H7, 1H9, 5E8, 6A2, 7D4 and 10B4)
15–17,78
 and polyclonal 
equine antisera against EAV VBS, commercial live-attenuated vaccine strain of EAV 
(MLV, ARVAC
®
; Zoetis, Kalamazoo, MI, USA), EAV KY84 strain and EAV CW01 
strain were performed as previously described
15,78
. The non-neutralizing mAbs 12A4 
(specific for EAV non-structural protein-1 [nsp-1]) and 3E2 (specific for N protein) and 
normal equine serum were used as negative controls.  Briefly, duplicate serial two-fold 
dilutions of each equine antiserum sample from 1:4 to 1:8192 were made in 
supplemented EMEM containing 10% guinea pig complement (25 µl per well; Rockland 
Immunochemicals, Gilbertsville, PA, USA) and tested in 96-well plates. Ascitic fluid 
containing each mAb was diluted from 1:16 to 1:32,384 in unsupplemented EMEM 
without 10% guinea pig complement as previously described
15–17,78
. An equal volume 
containing 200 TCID50 of the EAV donkey VD7634 strain was added to each well.  
Plates were incubated at 37°C in 5% CO2 for 1 h.  After incubation, a suspension of HP 
RK-13 (KY) cells (125 µl per well) was added to each well, and the plates were 
incubated for 72 hours at 37
°
C until CPE had fully developed in the virus control wells.  
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The titer of a sample was recorded as the reciprocal of the highest serum dilution that 
provided at least 50% protection of the monolayer. 
 
Real-time RT-qPCR  
The nucleic acids extracted from the reproductive tract tissue samples (10% tissue 
suspensions), TCFs and conjunctival swabs were tested by an EAV specific TaqMan
®
 
real-time RT-PCR assay as previously described 
232
. Briefly, viral RNA was directly 
isolated from 50 µl of 10% tissue suspension or TCF using a commercial RNA isolation 
kit (MagMAX
TM
 -96 Viral RNA Isolation Kit, Thermo Fisher, Waltham, MA, USA) 
according to the manufacturer’s instructions. Viral RNA was eluted in 50 l of nuclease-
free water and stored at -80°C.  RNA extracted from TCF derived from HP RK-13 (KY) 
cells inoculated with semen samples that were negative for EAV, as well as from 
nuclease-free water were included as negative controls. Viral RNA extracted from TCF 
containing the EAV VBS was used as a positive control.  A one-tube TaqMan
®
 real-time 
RT-PCR assay was performed as described in Miszczak et al. (2011)
223
. 
 
Sanger sequencing  
Viral RNA was extracted from the TCF containing EAV donkey D7634 strain 
using MagMax
TM
-96 viral RNA Isolation Kit (Thermo Fisher, Waltham, MA, USA). The 
sequences of the PCR products were determined by the Sanger method. The extracted 
viral RNA was first reverse-transcribed into cDNA using SuperScript
TM
 III Reverse 
Transcriptase (Thermo Fisher, Waltham, MA, USA) with gene specific primer 
(BN12707N) following the manufacturer’s instruction, and amplified by Qiagen 
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HotStarTaq
®
 DNA polymerase using forward and reverse primers described in 
Supplementary Table 3.1. Fourteen new primers were designed based on published EAV 
donkey sequences from South Africa
405
. In addition, fifteen EAV specific primers were 
used for primer walking. ORFs 2-7 sequences including the flanking 5' ORF1b and 3'-
UTR (2912 bp) were determined. A similar approach was used to amplify the partial 
ORF1ab regions (1-1087 [1087 bp], 1592-2093 [502 bp], 4152-4721 [570 bp] and 6436-
6923 [488 bp] encoding the nsp1, partial nsp2, partial nsp5, nsp6, partial nsp7 and partial 
nsp9, respectively. The PCR products were gel-purified using a high pure PCR product 
purification kit (Roche). Both sense and antisense strands were sequenced. About 5559 
base pairs (43.75%) of the entire genome were sequenced by Sanger methods. Then, 
Illumina MiSeq next-generation sequencing technology was used to obtain the complete 
genome sequence of EAV donkey D7634 strain.  
 
Next-generation sequencing 
Total RNA was isolated from HP RK-13 (KY) cells infected with the EAV 
donkey VD7634 strain using a total RNA isolation kit (Norgen Biotek Corp., Niagara-on-
the-Lake, Ontario, Canada). The RNA was quantified with a Qubit 2.0 spectrophotometer 
(Life Technologies, Carlsbad, CA, USA) and purified RNA was stored at -80°C. The 
complete genome sequence of EAV donkey VD7634 strain was determined by using 
next-generation sequencing (NGS) technology on an Illumina MiSeq platform according 
to previously established procedures445. Briefly, the cDNA libraries were constructed 
from 100 ng of total RNA using a TruSeq Stranded total RNA sample preparation kit 
(Illumina, San Diego, CA, USA) according to the manufacturer’s instructions and 
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previously described protocol . Multiplex libraries were prepared using barcoded primers 
and a median insert size of 340 base pairs (bp). Libraries were analyzed for size 
distribution using a Bioanalyzer and quantified by quantitative RT-PCR using a Kapa 
library quantification kit (Kapa Biosystems, Boston, MA, USA); relative volumes were 
pooled accordingly. The pooled libraries were sequenced on an Illumina MiSeq platform 
with 150 bp end-reads following standard Illumina protocols. Sequences were mapped to 
all known EAV strains and mapped read-sets were used for de novo assembly using 
ABySS, v.1.3.7 (BC Cancer Agency, Vancouver, Canada) and Geneious 7.0.6 software 
(Biomatters Ltd., Auckland, New Zealand). Sequences obtained by NGS technique were 
mapped to all available published genome sequences of the family Arteriviridae 
(currently 550 genomes are available at http://www.ncbi.nlm.nih.gov/) using BWA-
MWM (v0.7.5a). Sequence ID of mapped reads were extracted using SAMtools (v0.1.19).  
 
Sequence analysis  
The new paired-end read sets were extracted from the original paired-end fastq 
files using seqtk with the list of mapped ID to insure both reads of one pair were selected. 
The raw reads in FASTA formats were imported into IGV_2.3.79 for mapping and paired 
using the default parameter for Illumina short read. Comparative nucleotide (nt) and 
amino acid (aa) sequence alignment, maximum likelihood (ML) phylogenetic 
reconstruction were performed using Geneious v.7.0.6 (Biomatters Ltd., Auckland, New 
Zealand) and MEGA v.7.0.26 (http://www.megasoftware.net).  
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Phylogenetic analysis 
Phylogenetic trees were constructed by using the maximum likelihood method 
based on the Tamura-Nei model
446
, applying Neighbor-Join and BioNJ algorithms to a 
matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) 
distance with Gamma-distributed rates, pairwise gap deletion and boopstrap resampling 
(1,000 replications)
447
. 
 
3.4. Results 
Virus isolation and RT-qPCR testing of the reproductive tissues from donkeys 
EAV was isolated from the epididymis, prostate, vas deferens and seminal 
vesicles of donkey number 7634, but not from the tissues of the donkey number 7635 
(Supplementary Table 3.2.). The viral isolates were further confirmed by TaqMan
®
 real-
time RT-qPCR specific for EAV ORF7. These data unequivocally confirmed that virus 
isolates from epididymis, prostate, vas deferens and seminal vesicles of VD7634 as EAV.  
Viral RNA extracted from 10% tissue homogenates were also tested directly by EAV-
specific RT-qPCR.  Of the nine samples tested from donkey 7634 (Supplementary Table 
3.2.), only three samples gave positive results with EAV RT-qPCR (epididymis, vas 
deferens and seminal vesicles). All the necropsy samples from donkey 7635 were 
negative for EAV nucleic acid by RT-qPCR.  This further confirmed that the donkey 
7635 was not persistently infected with EAV. 
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Analysis of genomic sequence of EAV donkey VD7634 strain 
The full-length genome sequence of the EAV donkey VD7634 strain isolated 
from the vas deferens of donkey 7634 was determined by NGS. The complete genome of 
EAV donkey VD7634 strain was 12,703 bp in length with ten ORFs which encode 13 
nonstructural proteins (nsp) and eight structural proteins (sp) common to all known EAV 
strains. The annotation of EAV donkey VD7634 strain was predicted based on NCBI-
referenced EAV sequence (EAV Utr; accession numbers: NC002532), then compared to 
both NCBI-referenced EAV sequence and our prototype virulent Bucyrus virus strain 
(EAV VBS; accession numbers: DQ846750) to determine its general genome features
1
. 
The sequence of EAV donkey VD7634 strain was deposited in GenBank under the 
accession number MF598091.   
The complete genome sequence of EAV donkey VD7634 strain was 1nt shorter in 
length and had 75.6 % nucleotide identity to both EAV VBS and EAV Utr (GenBank 
Accession numbers DQ846750 and NC002532, respectively).  The nucleotide and amino 
acid differences in ORF1a and ORF1b are shown in Table 3.1. The nsp2, nsp3 and nsp12 
of donkey VD7634 had 1-3 amino acid deletions as compared to the EAV VBS and EAV 
Utr. The leader sequence of EAV donkey VD7634 strain is 211 nucleotides, and its 5´ 
UTR is 6 nt longer than the other two EAV strains. The ORF1a and ORF1ab start codon 
of EAV donkey VD7634 strain is located at nucleotide position 231.  
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Table 3.1. Comparative nucleotide and amino acid sequence analysis of donkey VD7634 
strain of EAV and published EAV sequences (EAV Utr [NC002532] and EAV VBS 
[DQ846750] 
ORF Protein 
EAV donkey VD7634 strain 
(MF598091) nucleotide sequence 
(Start…End)
EAV donkey 
VD7634 strain 
(MF598091) 
nucleotide 
position (nt) 
EAV donkey 
VD7634 
strain protein 
length (aa)
EAV Utr (NC002532) nucleotide 
sequence  (Start...End) 
EAV Utr 
(NC002532) 
nucleotide 
position (nt) 
EAV Utr 
(NC002532) 
protein length 
(aa) 
EAV VBS (DQ846750) nucleotide 
sequence  (Start...End)
EAV VBS  
(DQ846750) 
nucleotide 
position (nt)
EAV VBS  
(DQ846750) 
protein length 
(aa)
5' TTR - 1-230 - 1-224 - - -
Leader sequence 1-211 - 1-211 - - -
ORF1a 1a polyprotein ATGGCAACCT…GTTAAACTGA 231-5405 1724 ATGGCAACCT…GTTAAACTGA 225-5408 1727 ATGGCAACCT…AGTGAATCAG 225-5399 1725
ORF1b - CTGAGAGCGC…ACCCGTGTGA 5402-9748 1448 CTGAGAGCGC…GCCCGTGTGA 5405-9751 1448 CTGAGAGCGC…GCCCGTGTGA 5405-9751 1448
ORF1ab 1ab polyprotein ATGGCAACCT…ACCCGTGTGA 231-9748 3172 ATGGCAACCT…GCCCGTGTGA 225-9751 3175 ATGGCAACCT…GCCCGTGTGA 225-9751 3175
nsp1 ATGGCAACCT…GAACTACGGT 231-1010 260 ATGGCAACCT…CAACTACGGC 225-1004 260 ATGGCAACCT…CAACTACGGC 225-1004 260
nsp2 GGGTACAACC…GTTGATTGGA 1011-2714 568 GGCTACAATC…GCTGATAGGT 1005-2717 571 GGCTACAATC…GCTGATAGGT 1005-2717 571
nsp3 GGGTGGACCT…TGGTGTTTGA 2715-3412 232 GGATGGATTT…GGTGTTTGAA 2718-3416 233 GGATGGATTT…GGTGTTTGAA 2718-3416 233
nsp4 GGGCTTGTTC…CAACAGAGAG 3413-4025 204 GGGCTATTCA…CAATAGAGAG 3417-4028 204 GGGCTATTCA…CAATAGAGAG 3417-4028 204
nsp5 AGTAGCCTTT…CTTCCTTGAG 4026-4511 162 AGCAGCCTTT…CTTCCTGGAG 4029-4514 162 AGCAGCCTTT…CTTCCTGGAG 4029-4514 162
nsp6 GGAGGTGTGA…CACTCAAGAA 4512-4577 22 GGAGGAGTGA…TACCCAGGAG 4515-4580 22 GGAGGAGTGA…TACCCAGGAG 4515-4580 22
nsp7 AGTTTGACCG…CAGTTATGAA 4578-5252 225 AGTCTCACTG…GAGCTATGAA 4581-5255 225 AGTCTCACTG…GAGCTATGAA 4581-5255 225
nsp8 GGGTTAGACA…CCAGTTAAAC 5253-5402 50 GGCCTAGATC…TCAGTTAAAC 5256-5405 50 GGCCTAGATC…TCAGTTAAAC 5256-5405 50
nsp9 GGGTTAGACA…GCAGTACGAG 5253-7330 693 GGCCTAGATC…GCAGTATGAG 5256-7333 693 GGCCTAGATC…GCAGTATGAG 5256-7333 693
nsp10 GCGGCTGTAT…GGAAAAACAG 7331-8731 467 AGTGCCGTGT…GGAAAAGCAA 7334-8734 467 AGTGCCGTGT…GGAAAAGCAA 7334-8734 467
nsp11 TCAAACAAAG…TGTCCAGGAG 8732-9388 219 TCCAACAAAA…TGTCCAAGAG 8735-9391 219 TCCAACAAAA…TGTCCAAGAG 9835-9391 219
nsp12 GGGATTGATG…AATTGGACCC 9389-9742 118 GGTGTTGATG…CATTGGGCCC 9392-9745 118 GGTGTTGATG…TGGGCCCGTG 9392-9748 119
Slippary sequence GTTAAAC 5398-5404 - GTTAAAC 5399-5405 - GTTAAAC 5399-5405 -
ORF2a E ATGGGCTTAG…ACCTCTTTAA 9748-9951 67 ATGGGCTTAG…ACCTGTTTAA 9751-9954 67 ATGGGCTTAG…ACCTGTTTAA 9751-9954 67
ORF2b GP2 ATGCTGTGCT…GATTTTGTAG 9821-10504 277 ATGCAGCGCT…GATTTTGTAG 9824-10507 227 ATGCAGCGCT…GATTTTGTAG 9824-10507 227
ORF3 GP3 ATGGATTATG…AAGCTCGTAA 10303-10794 163 ATGGGTCGTG…AGGCTCGTAA 10306-10797 163 ATGGGTCGTG…AGGCTCGTAA 10306-10797 163
ORF4 GP4 ATGAAGAACT…TTATCTATGA 10697-11155 152 ATGAAGATCT…TTATCTATGA 10700-11158 152 ATGAAGATCT…TTATCTATGA 10700-11158 152
ORF5a ORF5a ATGTTCTTCT…TGCGCTATGA 11109-11288 59 ATGTTCTTTT…TGCGATATGA 11112-11291 59 ATGTTCTTTT…TGCGATATGA 11112-11291 59
ORF5 GP5 ATGTTATCTA…GGAGCCATAG 11143-11910 255 ATGTTATCTA…GGAGCCATAG 11146-11913 255 ATGTTATCTA…GGAGCCATAG 11146-11913 255
ORF6 M ATGGGAGCCA…GTTACAATGA 11898-12386 162 ATGGGAGCCA…GCTACAATGA 11901-12389 162 ATGGGAGCCA…GCTACAATGA 11901-12389 162
ORF7 N ATGGCGTCAA…AGGGCCGTAA 12310-12642 110 ATGGCGTCAA…AGGGCCGTAA 12313-12645 110 ATGGCGTCAA…AGGGCCGTAA 12313-12645 110
3' TTR - GACGTGGATA…AAGTATCCAG 12643-12703 - GACGTGGATA…CCCAGGAACC 12646-12704 - GACGTGGATA…CCCAGGAACC 12646-12704 -
 
Characterization of nucleotide hallmarks of EAV donkey VD7634 strain as 
compared with other EAV strains  
  Comparative nucleotide sequence analysis of the full-length genome of VD7634 
sequence and twenty-nine EAV strains in GenBank determined unique insertions and 
deletions (Table 3.2.). These included four North American strains and twenty-five 
European strains (EU-1 [CW and S numbered strains] and EU-2 [French strains]) that 
were selected by BLASTn analysis. The nucleotide identity with North American and 
European strains varied from 77% and 76.8%, respectively. Analysis identified a number 
of unique insertions and deletions that were present in 5´ UTR, 3´ UTR, ORF1a (nsp2 
coding region) and ORF3 of EAV donkey VD7634 strain (Table 3.2.). 
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Table 3.2. Insertion and deletion positions in full-length genome alignments of EAV 
isolates from North America and Europe 
ORF
EAV donkey 
VD7634 strain          
nucleotide position 
Nucleotide 
substitution 
length (bp)
Nucleotide substitution Description 
5' UTR 6 1 C Insertion
26 1 G Insertion
88-89 2 GT Consecutive nucleotide insertions 
123 1 T Insertion, similar to F27, F60, F61, F62, F63 strains
124 -1 T Deletion, except F27, F60, F61, F62, F63 strains
127 -1 G Deletion
164 1 C Insertion, similar to CW01, CW96, F27, F60, F61, F62, F63 strains
224 1 T Insertion
nsp2 1399-1401 -3 AAC* Deletion
1460-1462 3 AAC Insertion, similar to CW01, CW96, F60, F61, F62, F63, F27 strains
1478-1480 3 AGA Insertion
1515-1517 3 TTG Insertion
1565-1579 - 15
CGTCCACAGTGGTCT*
Insertion except EAV donkey VD7634 strain, CW01, CW96, F60, 
F61, F62, F63, F27, HK25, HK116, VBS, ARVAC strains
1621-1635 - 15 GGCGTGTGGCCAAAA* Deletion
GP3 10,653-10,664 - 12 TGCGAAACCACT Insertion in F61, F62, F63 strains
10658-106659 2 AG Insertion
10,684-10,695 - 12 
AGTGCATTTGGA*
Insertion except EAV donkey VD7634 strain, CW01, CW96, F60, 
F61, F62, F63, F27, HK25, HK116, VBS, ARVAC strains
10,669 -10,670 -2 GG Deletion
3' UTR 12685 1 G Insertion
12703 1 C Insertion
 
*Most common deletion sequence is shown out of three different deletion sequences in 
the nucleotide comparison among EAV referenced sequences. 
 
The 5´-leader sequence of the EAV donkey VD7634 strain had three single 
nucleotide insertions (C-6, G-26 and T-224), one single nucleotide deletion (G-127 based 
on the EAV VBS sequence) and two consecutive nucleotide insertions (G-88 and T-89).  
In addition, there was a single nucleotide insertion at T-123 of the EAV donkey VD7634 
strain sequence that is similar to some of the French strains (F27, F60-F63). There was 
one insertion followed by one consecutive single nucleotide deletion compared to the 
earlier described French strains.  Finally, there was a single nucleotide insertion in the 5´ 
leader sequence at position C-164, which is similar to some of the European strains 
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(CW96, CW01; F27, F60-F63). The donkey EAV strain had two single nucleotide 
insertions in the 3´ UTR (G-12,685 and C-12,703).  
Interestingly, there was a consecutive 3-nucleotide deletion in the nsp2 of EAV 
donkey VD7634 strain at nucleotide positions 1399-1401 based on the EAV VBS 
sequence position numbering (AGC [CW96, CW96, HK25, HK116, Bucyrus and 
ARVAC] or CGC [F27 and F60-F63] or AAC [S-3685, S-3685, S-3699, S-3711, S-3712, 
S-3817, S-3854, S-3861, S-3886, S-3943, S-3961, S-4007, S-4216, S-4417, S-4421, S-
4227, S-4333 and S-4445]). Then, there were three consecutive nucleotide insertions 
encoding region of ORF1a at three positions (A-1460, A1461 and C-1462; A-1478, G-
1479 and A-1480; and T-1515, T-1516 and G-1517).  Seven other EAV strains also had 
three consecutive nucleotide insertions at nucleotide positions 1460-1462 (CGT [CW96 
and CW01] GGG [F27, F60-F63]). The consecutive 15-nucleotide insertion in nsp2 
encoding region of ORF1a was presented by S-numbered EAV strains in nucleotide 
positions at 1565-1579; CGTCCACAGTGGTCT [S-3685, S-3699, S-3711, S-3712, S-
3854, S-3861, S-3886, S-3943, S-3961, S-4007, S-4227, S-4333, S-4421 and S-4445] or 
CGTCCACAGTGGTCC [S-3685, S-3817 and S-4216] or CATCCACAGTGGTCT [S-
4417]. Based on the EAV VBS sequence position numbering, EAV donkey VD7634 
strain had a consecutive 15-nucleotide deletion at 1621-1635; GGCGCGTGACTAAAA 
[CW01 and CW96] or GGCGCGTGACAAAGA [F27 and F60-63] or 
GGCGTGTAGCCAAAA [S-4417] or GGCGTGTGGCCAAAA [HK25, HK116, 
Bucyrus, ARVAC, S-3685, S-3685, S-3699, S-3711, S-3712, S-3817, S-3854, S-3861, S-
3886, S-3943, S-3961, S-4007, S-4216, S-4421, S-4227, S-4333 and S-4445].  
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Two consecutive 12-nucletide insertions (10,653-10,664; TGCGAAACCACT 
[F61] or TGCGAAACCAYT [F62] or TGCRAAACCAYW [F63]; and 10,684-10,695; 
AGTGCATTTGGA [S-3583, S-3817, S-3685, S-3699, S-3711, S-3712, S-3854, S-3869, 
S-3943, S-40007, S-4417, S-4445, S-3961 and S-4216] or TAGTGTATTTGGA [S-3886, 
S-4333 and S-4421] or AGTGCACTTGGA [S-4227]) in some of the European strains 
were not present in the ORF3 of EAV donkey VD7634 strain and the rest of the EAV 
sequences available in GenBank.  ORF3 of EAV donkey VD7634 strain had two unique 
nucleotide insertions (A-10,658 and G-10,659) and two unique nucleotide deletions (G-
10,669 and G-10,670; according to EAV VBS sequence position numbering). 
 Additionally, the percentage identity (%) of nucleotide and amino acid sequence 
alignment among EAV donkey VD7634 strain and other EAV sequences from GenBank 
(n=29) were calculated and used to create bar graphs (Figure 3.1. and supplementary 
table 3.5.). The average nucleotide and amino acid identity are 65.55% and 70.72% in 
ORF1a (nsp2 coding region) and nsp2, respectively (Figure 3.1.A.). Similarly, the 
average nucleotide identity and amino acid identity were 78.18% and 74.21% in ORF3 
and GP3, respectively (Figure 3.1.B.). In nucleotide similarity, ARVAC, HK116, HK25 
and Bucyrus NA strains showed 80.8% to 81.4% highest nucleotide identity in ORF3, as 
well as 77% to 78.2% of amino acid identity in GP3. EAV isolates CW01, CW96, F27 
and F60 strains showed second highest nucleotide identity from 78.1% to 79.6% in ORF3 
and 72.7% to 73.9% amino acid identity in GP3. 
EAV donkey VD7634 strain showed 81.3% to 81.5% and 93% nucleotide identity 
and amino acid identity to partial ORF5 and GP5 gene from donkey isolates from 
Republic of South Africa (RSA), respectively (Figure 3.1.C.). Even though two of the 
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EAV donkey referenced sequences isolated from Italy presented low nucleotide identity 
from 74.3% to 74.7%, respectively, these two sequences showed 86.6% amino acid 
identity, which is the second highest similarity in partial GP5. The other EAV sequences 
had 75.54% nucleotide identity and 86.34% amino acid identity in partial GP5 compared 
to the EAV donkey VD7634 strain. There were no insertions or deletions in partial ORF5 
sequences analyzed from donkeys.  
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Figure 3. 1. Based on percentage homology among EAV 29 EAV strains; nucleotide 
sequence identity (%) and amino acid sequence identity (%) analyses were used to 
create bar graphs. (A) nsp2, (B) GP3 and (C) partial GP5. Blue bar indicates nucleotide 
identity (%) and red bar indicates amino acid identity (%).  
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Comparison of partial ORF5 sequence of EAV donkey VD7634 strain and other 
EAV donkey strains  
Nine partial donkey EAV ORF5 sequences (nt 11,295-11,812 [518 bp in length]
10
 
available in GenBank were compared to the EAV donkey VD7634 strain (Supplementary 
Table 3.3.).  The data showed that the EAV donkey VD7634 strain shared variable 
nucleotide and amino acid identity with other EAV donkey strains: 74.3% to 81.5% 
nucleotide identity and 86.7% to 93.4% amino acid identity. Phylogenetic analysis was 
carried out on partial ORF5 sequences (Figure 3.2.). The maximum likelihood 
phylogenetic tree was clearly divided into two lineage groups: Republic of South Africa 
(RSA) and Italy.  
 
Figure 3.2. Phylogenetic tree based on the partial ORF5 of EAV donkey VD7634 
strain and nine EAV donkey reference strains. Phylogenetic trees constructed based 
on nucleotide sequences of partial ORF5 (nt 11,295-11,812 [518 bp]) of EAV donkey 
VD7634 strain using the maximum likelihood method implemented in MEGA7.0. 
Bootstrap values for 1,000 replicates are shown at the nodes. The bar indicates genetic 
distance.  
 J1-931125 RSA |AY956596.1|
 J2-931125 RSA |AY956597.1|
 J3-931209 RSA |AY956598.1|
 J7-931125 |AY956602.1|
 J5-940309 RSA |AY956600.1|
 J6-940309 RSA |AY956601.1|
 J4-931209 RSA |AY956599.1|
EVA donkey Republic of South Africa (RSA)
 EAV donkey VD7634
 1489V96 Italy |AF099829.1|
 3308V96 Italy |AF099830.1|
EAV donkey Italy
100
100
66
50
0.05
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Both sequence identity and phylogenetic tree indicate that EAV donkey VD7634 
strain was more closely related to Republic of South African (RSA) strains than the 
Italian strains. According to Stadejek et al. (2006), the RSA EAV donkey strains 
sequenced from the semen of naturally infected donkeys were different from reference 
sequences obtained from viruses in horses in North American and European groups
10
. In 
contrast, ORF5 sequences of Italian EAV donkey strains were clustered in European 
groups, indicating that these donkeys had probably become infected from horses
227,412
.  
 
Phylogenetic analysis of EAV donkey VD7634 strain 
Twenty-nine EAV full-length genome sequences from GenBank were 
downloaded and used in phylogenetic analysis (Figure 3.3.). These sequences included 
EAV strains from both North American (NA) and European (EU) lineages. In addition, 
partial ORF5 sequences from EAV and donkey isolates from South Africa and Italy were 
included in the analysis. Phylogenetic analysis was conducted using maximum likelihood 
based on the Tamura-Nej model and neighbor-joining methods
446
. As the result, EAV 
donkey VD7634 strain was presented as more diverged than other referenced EAV 
strains.  
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Figure 3.3. Phylogenetic analyses of EAV were inferred based on primary 
nucleotide alignment. (A) Whole genome of 29 referenced strains and EAV donkey 
VD7634 strain and amino acid alignment of (B) ORF1a, nsp2 encoding region, (C) ORF3 
and (D) Partial GP5 includes nine additional strains of EAV donkey reference strains.  
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Phylogeny based on full-length genome  
Based on BLASTn analysis of GenBank database, twenty-nine EAV whole 
genome sequences were selected to perform sequence alignment and phylogenetic 
analysis (Figure 3.3.A.). The EAV donkey VD7634 strain is 12,703 nucleotides in length, 
slightly shorter than EAV CW strains (12,708 nucleotides; EU-1), EAV French strains 
(12,710 to 12722 nucleotides; EU-2), EAV North American strains (12704 nucleotides; 
NA) and EAV S numbered strains (12,731 nucleotides; EU-1). The EAV donkey 
VD7634 strain shares average homology of 75.37% at the nucleotide level among 29 full 
genomes of EAV referenced sequences (Supplementary table 3.4.). Analyzing homology 
at the amino acid level for specific ORFs, least similarity was noted across ORF1a and 
ORF3 which encode nsp2 and GP3 at 70.72% and 74.21%, respectively. These proteins 
were previously described with nucleotide hallmarks of unique insertions and deletions. 
The greatest similarity at the amino acid level was ORF7, which encode nucleocapsid (N) 
protein at 95.67% among 29 full genomes of EAV referenced sequences (Supplementary 
table 3.4.). Phylogenetic analysis did not cluster EAV donkey VD7634 with the other 
EAV full-length genome sequences and segregated it into an independent lineage.   
 
Phylogeny based on ORF1a nsp2 coding region and ORF3  
EAV donkey VD7634 strain has unique genetic hallmarks in nsp2 and ORF3, 
thus these protein sequences at the amino acid level were analyzed phylogenetically to 
compare among each genome of 29 EAV referenced sequences (n=29) (Figure 3.3. B and 
C). In these analyses, EAV donkey VD7634 strain segregated into an independent lineage 
similar to the full-length genome sequences. (Figure 3.3.A.)  
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Phylogeny based on ORF5 partial sequences including other EAV donkey strains 
Phylogenetic analysis of the EAV partial ORF5 sequences including other EAV 
donkey sequences from Italy (n=2) and Republic of South Africa (n=7) was carried out 
(Figure 3.3.D.). Interestingly, EAV donkey VD7634 strain was clustered with EAV 
donkey strains from the Republic of South Africa, and this clustering was supported by a 
bootstrap value of 99%. It suggests that EAV donkey VD7634 strain was most closely 
related to EAV donkey strains that originated in the Republic of South Africa. Not 
surprisingly, partial ORF5 sequences of Italian EAV donkey strains were clustered in the 
European group (EU-1), but were distantly related to other EU-1 virus isolates in this 
phylogenetic subgroup.  
 
Neutralization phenotype of EAV donkey VD7634 strain 
A panel of 12 monoclonal antibodies (mAbs) and a panel of 6 of polyclonal 
equine antisera were used to characterize the neutralization phenotypes of EAV donkey 
VD7634 strain (Table 3.3.). EAV donkey VD7634 strain was neutralized by mAbs 5G11, 
6D10, 7E5, 10F11 and 6A2. Especially, mAbs 6D10, 7E5 and 6A2 neutralized the 
donkey virus to a higher titer. In contrast, mAbs 1H7, 1H9, 5E8, 7D4 and 10B4 did not 
neutralize EAV donkey VD7634 strain. Only anti-KY84 and anti-CW96 polyclonal 
equine antisera were able to neutralize the EAV donkey VD7634 strain to a higher titer. 
Interestingly, anti-ARVAC and anti-VBS polyclonal equine sera did not neutralize 
donkey VD7634 to a high titer. Furthermore, anti-EAV NVSL sera failed to neutralize 
the donkey strain.  
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Table 3.3. Serum neutralization test titers of mAbs and polyclonal equine antisera against 
EAV donkey VD7634 strain and other EAV isolates 
Virus 
EAV donkey VD7634 strain CW96
a
CW01
a
EAV 030
a
ATCC
a
ARVAC
b 
S3583
b
S4216
b
S3685
b
S3861
b
S3854
b
S4333
b
S3943
b
S4445
b
mAbs 
5G11 GP5/102 and 104 [D] 512 512 4096 4096 >4096 <32 1024 512 2048 2048 1024 2048 1024 1024
6D10 GP5/99 [D] 4096 4096 >4096 >4096 >4096 512 4096 2048 2048 4096 4096 >4096 4096 4096
7E5 GP5/102 [D] 512 32 256 256 256 32 128 128 512 128 512 128 256 256
10F11 GP5/ND [D] 4096 4096 >4096 >4096 >4096 2048 2048 1024 4096 4096 4096 4096 4096 4096
1H7 GP5/49 [A] 16 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32
1H9 GP5/69 [C] <16 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32
5E8 GP5/61 [B] <16 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32
6A2 GP5/69 [C] 2048 128 <32 <32 <32 <32 256 64 1024 256 2048 512 1024 32
7D4 GP5/69 [C] <16 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32
10B4 GP5/62-101 deleted [C and D] 32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32
Control mAbs
3E2* N 16 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32
12A4* nsp1 <16 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32 <32
Polyclonal equine sera
anti-ARVAC NA 16 <8 8 128 8 256 16 64 32 32 32 16 8 16
anti-VBS NA 64 64 16 512 512 256 128 128 128 128 128 64 128 128
anti-KY84 NA 1024 512 32 >1024 >1024 64 256 64 128 512 128 64 512 128
anti-CW96 NA 1024 ND ND ND ND ND ND ND ND ND ND ND ND ND
Control polyclonal 
equine sera 
anti-EAV NVSL positive NA 16 32 16 128 64 128 64 16 32 32 32 32 32 16
anti-EAV NVSL negative NA <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 <8
Protein specificity/epitope location  
(amino acid no. and site) 
Antibody 
Virus of SNT result from Balasuriya et al. (2004)
a
Virus SNT result from Zhang et al. (2010)
b
 
Neutralization titers are expressed as the inverse of the antibody dilution providing 50% 
protection of RK-13 cell monolayers against 200 TCID50 of virus. Significant differences 
in neutralization titers (four-fold or greater) are indicated by bold numbers. ND, not 
determined. NA, not applicable. EAV donkey VD7434 strain SNT result was compared 
to previously published data. 
*
mAb to the nucleocapsid (N) protein and nonstructural protein 1 (nsp1) of EAV was 
used as negative control 
a 
Viruses of neutralization test result titers were from Balasuriya et al. (2004)
17
 
b 
Viruses of neutralization test result titers were from Zhang et al. (2010)
21
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Previously published data described neutralization phenotypes of the same panel 
of mAbs and polyclonal equine antisera (exception of anti-CW96 polyclonal equine sera) 
against different EAV strains: CW96, CW01, EAV030, ATCC, ARVAC, S3583, S4216, 
S3685, S3861, S3854, S4333 and S3943
17,21
. Interestingly, 6A2 showed significant 
variability in its ability to neutralize different EAV isolates, but the same mAb 
neutralized the EAV donkey VD7634 strain to a higher neutralization titers
17,21
. In 
summary, these neutralization data suggest that EAV donkey VD7634 strain has a 
distinct neutralization phenotype. Comparative amino acid sequence analysis of the 
critical neutralization regions of the GP5 protein of this isolate are shown in Figure 3.4.  
 
Figure 3.4. Comparative amino acid substitution of ORF5 of EAV donkey VD7634 
to 29 full-length EAV strains according to the serum neutralization test (SNT) result 
by mAb. 
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 Interestingly, the GP5 protein of the EAV donkey VD7634 strain had an amino 
acid substitution in neutralization site B (aa 61), 13 amino acid substitutions in site C (aa 
67, 69-73, 79, 81-82, 84-85, 89 and 90) and 4 amino acid substitutions in site D (aa 100-
101, 104 and 106) compared to 29 EAV referenced sequences. These amino acid 
substitutions in GP5 may contribute to its distinctive neutralization phenotype 
(Supplementary table 3.6.). 
 
3.5. Discussion 
We have successfully determined the complete genome sequence of the novel 
EAV donkey strain isolated from a naturally infected wild donkey in northern Chile. In 
this study, we demonstrated the full genomic, phylogenetic and antigenic characterization 
of the EAV donkey VD7634 strain. The complete genome of EAV donkey VD7634 
strain was 12,703 bp in length, which was 1nt shorter in length and had 75.6% nucleotide 
identity to both NCBI reference EAV sequence and our prototype virus EAV VBS. 
Comparisons of the EAV donkey VD7634 strain to both NCBI referenced EAV sequence 
and our prototype EAV VBS defined its genomic annotation. Further sequence alignment 
among 29 EAV referenced full-genome sequences determined nucleotide and amino acid 
percentage homology (%) and revealed a unique number of insertions and deletions in 
both 5′ and 3′ UTRs, nsp2 and GP3.  
Six insertions and two deletions were found in the 5′ UTR and two insertions 
were found in 3′ UTR in EAV donkey VD7634 strain by comparison with 29 EAV 
referenced sequences. It is known that the 5′ and 3′ UTRs of PRRSV play important roles 
in viral replication, subgenomic RNA transcription and infectivity
448–450
. Even though 5′ 
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and 3′ UTR sequences are highly conserved, the unique presence of insertions and 
deletions have been frequently identified in both North American and European 
genotypes of PRRSV
450,451
. A previous study demonstrated that a deletion of either one or 
two consecutive nucleotides had occurred in both 5′ and 3′ UTRs in highly pathogenic 
PRRSV isolates from China
452
. In contrast, a single-nucleotide deletion observed in an in 
vitro serial cell culture passaged PRRSV strain that was overattenuated from a highly 
pathogenic PRRSV strain
453
. These studies indicate that both 5′ and 3′ UTR sequences of 
Arteriviruses are involved in viral virulence and these may also affect EAV donkey 
VD7634 strain. 
In this study, we determined that the EAV donkey VD7634 strain has a number of 
insertions and deletions in ORF1a (particularly in the encoding region of nsp2 replicase 
subunit) and ORF3. Very interestingly, EAV donkey VD7634 strain has similar unique 
patterns of insertions and deletions to EAV CW strains and French strains
17,19
. For 
instance, the consecutive 15-nucleotide insertion in ORF1a nsp2 encoding region 
(nucleotide position at 1565-1579) was present in S-numbered EAV isolates, but EAV 
donkey VD7634 strain and EAV CW and French strains did not have this particular 
insertion.  
According to previous studies, the ten ORFs of EAV evolve at different rates 
during persistent infection. Most variations occur among the ORFs encoding viral 
structural proteins ORF3 and ORF5, which encode GP3 and GP5 enveloped 
glycoproteins of the virus, respectively
17,19,21
. For instance, EAV F61-63 strains have 
been shown to have a consecutive 12-nucleotide insertion in ORF3; this was not present 
in the EAV donkey VD7634 strain at nt location 10,653-10,664
19
. Molecular 
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characterization of the EAV S-numbered isolates revealed a unique consecutive 12-
nucleotide insertion feature at nt position 10,684-10,695 that had not been observed in 
GP3 of EAV donkey VD7634 strain as well as CW, French and NA strains of EAV. 
Interestingly, EAV donkey VD7634 strain had two additional unique nucleotide deletions 
(G-10,669 and G-10,670) following this consecutive 12-nucleotide insertion in S-
numbered isolates of EAV.  
The GP5 protein, encoded by ORF5, consists of the known neutralization 
determinants of EAV
15,16,78
. Previous studies determined that the individual amino acid 
substitutions within the GP5 ectodomain occur during persistent infection of stallions. 
This results in the emergence of viruses with different neutralization phenotypes
142,164,166
. 
Neutralization testing with a large panel of well-characterized mAbs and polyclonal 
equine sera confirmed different phenotypes and demonstrated the nucleotide variations of 
ORF5 in EAV donkey VD7634 strain compared to other strains of EAV (CW96, CW01, 
EAV030, ATCC, ARVAC, S3583, S4216, S3685, S3861, S3854, S4333 and S3943
21,82
. 
EAV donkey VD7634 strain was found to have a distinct neutralization phenotype. This 
virus was highly neutralized by any of the mAbs that neutralized other isolates (mAbs: 
6D10, 7E5, 10F11 and 6A2) as well as neutralized to a significantly high titers by 
polyclonal equine sera (anti-KY84) compared with other isolates. Interestingly, the 
comparative amino acid sequence analysis of GP5 protein determined that EAV donkey 
VD7634 strain had an amino acid substitution in neutralization site B (aa 61), 13 amino 
acid substitutions in site C (aa 67, 69-73, 79, 81-82, 84-85, 89 and 90) and 4 amino acid 
substitutions in site D (aa 100-101, 104 and 106) compared to 29 EAV referenced 
sequences. These amino acid substitutions in GP5 may correlate to this unique 
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neutralization phenotype of EAV donkey VD7634 strain associated with EAV 
persistency, however this needs to be investigated further. 
In conclusion, there are approximately 3,000 wild donkeys living in small herds in 
the Huasco province, Atacama Region, Chile
454
. In the 16
th
 century, Spanish settlers 
introduced donkeys in Chile for transportation
454
. In order to evaluate the health status of 
infectious diseases in these animals, SAG collected 312 serologic specimens from 
randomly selected wild donkeys and subjected them to serum neutralization testing
454
. As 
result of a serological survey for animal health monitoring, neutralizing EAV antibodies 
were found in 53% of the obtained samples giving a statistically significant p-value of 
0.001. This finding indicates that the virus circulates in the wild donkey population
454
. 
Yet, EAV has not been detected in domestic horses in Chile
455
. EAV strains have been 
spread globally through the international movement of equids or shipment of semen and 
on occasion, have been responsible for epidemics of major economic consequences
266
. 
Also, EAV outbreaks appear only periodically, hence it is hard to trace the historic origin 
so we assume that EAV has been in circulation long before it’s first isolation
48
. 
Phylogenies may be used for epidemiologically tracing the virus origin. For instance, 
EAV Gb_Glos_2012 strain from Great Britain was reported as presumably transferred 
from an imported Spanish stallion
48
.  
By reviewing the historical background of wild donkeys in Chile and the 
relationship of EAV donkey VD7634 strain to other EAV donkey strains and horse 
strains based on the phylogeny of ORF5, the origin of EAV donkey VD7634 strain may 
be closely related to EAV donkey strains from Republic of South Africa. The history of 
donkey movement by Spanish settlers would suggest that EAV donkey VD7634 strain 
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and EAV donkey strains from Republic of South Africa might have originated from each 
other or another source centuries ago.  
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CHAPTER FOUR 
Complete Genome Sequence of a Noncytopathic Strain of Bovine Viral Diarrhea 
Virus 1 (BVDV-1), a Contaminant of the High Passage RK-13 Cell Line  
Published in ASM Genome Announc. 3(5): e01115-15. 
Modified with permission 
 
4.1. Summary 
It has been previously reported that the rabbit kidney continuous cell line (RK-13; 
ATCC CCL-37 cell line, ATCC, Manassas, VA, USA) and its derivative high passage 
RK-13 cell line (HP-RK-13[KY]) is contaminated with a noncytopathic bovine viral 
diarrhea virus (ncpBVDV). Our laboratory has been using the HP-RK-13 (KY) cell line 
for isolation of equine arteritis virus from clinical specimens for many years. In this study, 
we report the complete genome sequence of the noncytopathic bovine viral diarrhea virus 
1 (ncpBVDV-1) contaminating the HP-RK-13 (KY) cell line. The complete genome of 
this ncpBVDV strain (ncpBVDV HP-RK-13) is 12,271 nucleotides (nts) in length; it 
contains a single open reading frame (ORF) made up of  11,697 nts [387-12,083]) 
encoding 3898 amino acid polyproteins. Phylogenetic analysis indicated that this strain 
belongs to BVDV group 1b.   
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4.2. Introduction 
 Bovine viral diarrhea virus (BVDV) is a non-enveloped, positive-sense, single-
stranded RNA virus whose genome size is approximately 12.3-12.5 kb. The virus is a 
member of the genus Pestivirus in the family Flaviviridae which also includes Border 
disease virus and classical swine fever virus
456,457
. Two major genotypes of BVDV are 
recognized (type 1 [BVDV-1] and 2 [BVDV-2]). BVDV-1 strains are genetically 
subdivided into at least 17 subtypes (a to q) and BVDV-2 strains into four subtypes (a to 
d)
458–461
. In addition, two distinct biotypes within each genotype have been identified: 
cytopathic viruses (cpBVDV) that cause cytopathic effects in cultured cells and 
noncytopathic viruses (ncpBVDV) that do not cause cytopathic effects in cultured cells 
(7-10). It has previously been reported that a number of cell lines (e.g. of cattle, sheep, 
goat, deer, bison, rabbit and domestic cat origin) including the RK-13 cell line (CCL-37; 
American Type Culture Collection [ATCC], Manassas, VA, USA) are persistently 
infected with ncpBVDV resulting from the use of BVDV contaminated fetal bovine 
serum in cell culture media
462–466
. Many laboratories use the RK-13 cell line from the 
ATCC or it derivatives for research and laboratory confirmation of various viral agents. 
Our laboratory has been using high passage RK-13 cells (P399-409; HP-RK-13 [KY]) for 
routine laboratory diagnostic investigation for over 50 years
467
. In this study, we 
determined the complete genome sequence of ncpBVDV virus present in the HP-RK-13 
(KY) cells (P404) using next-generation sequencing (NGS) technology on an Illumina 
MiSeq platform according to previously established procedures
445
.  
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4.3. Materials and methods 
Cells and viruses 
High passage rabbit kidney 13 (HP399-409; HP-KY-RK-13 [KY]; derived from 
ATCC
®
 CCL-37™, American Type Culture Collection) cells were maintained in Eagle’s 
minimum essential medium (EMEM, Cellgro
®
, Mediatech Inc., Herndon, VA, USA) 
with 10% ferritin-supplemented calf serum (HyClone Laboratories, Inc., Logan, UT, 
USA), penicillin and streptomycin (100 U/mL and 100 μg/mL) and 0.25 μg/mL of 
amphotericin B (Gibco
®
, Carlsbad, CA, USA).  
 
Next-generation sequencing 
 Total viral RNA was extracted from the tissue culture fluid following freeze thaw 
of HP-RK-13 (KY) cell monolayers (P404) in 25-cm
2
 flasks using a total RNA 
purification kit (Catalog no. 17200, Norgen Biotek Corp., Ontario, Canada). The RNA 
was quantified with a Qubit 2.0 spectrophotometer (Life Technologies, Carlsbad, CA, 
USA) and purified RNA was stored at -80°C. The complete genome sequence of 
ncpBVDV HP-KY-RK13 strain was obtained by next-generation sequencing (NGS) 
technology on an Illumina MiSeq platform following a previously established protocol
445
. 
Briefly, cDNA libraries were constructed from 100 ng of total RNA using a TruSeq 
Stranded total RNA sample preparation kit (Illumina, San Diego, CA, USA) according to 
the manufacturer’s instructions and previously described protocol. Multiplex libraries 
were prepared using barcoded primers and a median insert size of 340 base pairs (bp). 
Libraries were analyzed for size distribution using a Bioanalyzer and quantified by 
quantitative RT-PCR using a Kapa library quantification kit (Kapa Biosystems, Boston, 
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MA, USA); relative volumes were pooled accordingly. The pooled libraries were 
sequenced on an Illumina MiSeq platform with 150 bp end reads following standard 
Illumina protocols.  
 
Sequence analysis  
 Sequences were mapped to all known BVDVs and mapped read sets were used 
for de novo assembly using ABySS, v.1.3.7 (BC Cander Agency, Vancouver, Canada) 
and Geneious 7.0.6 software (Biomatters Ltd., Auckland, New Zealand). The new paired-
end read sets were extracted from the original paired-end fastq files using seqtk with the 
list of mapped ID to insure both reads of one pair were selected. The raw reads in FASTA 
formats were imported into IGV_2.3.79 for mapping and paired using the default 
parameter for illumine short read. Comparative alignment analysis of nucleotide (nt) and 
amino acid (aa) sequences was performed through Geneious 7.0.6 software (Biomatters 
Ltd., Auckland, New Zealand).  
 
Phylogenetic analysis 
Phylogenetic trees were constructed by using the Maximum Likelihood method 
based on the Tamura-Nei model
446
, applying Neighbor-Join and BioNJ algorithms to a 
matrix of pairwise distances estimated using the Maximum Composite Likelihood (MCL) 
distance with Gamma-distributed rates, pairwise gap deletion and boopstrap resampling 
(1,000 replications)
447
. 
 
 
 
 162 
4.4. Results and discussion 
 The complete genome of ncpBVDV contaminating the HP-RK-13 (KY) cell line 
(ncpBVDV HP-KY-RK13 strain) is comprised of 12,271 nucleotides (nt) and contains a 
5′ untranslated region (UTR; 386 nts), a single open reading frame (ORF; 11,697 nt [387-
12,083]) and a 3′ UTR (188 nt). The single ORF encodes a 3,898 amino acid polyprotein 
which is predicted to be cleaved into 12 proteins (Table 4.1.
468
). The polyprotein is 
cleaved into 12 proteins that are respectively enumerated from amino acids to carboxyl 
terminus as follow: NH2-N
pro
-C-E
rns
-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-
COOH. Specifically, the polyprotein is cleaved by the viral protease into four structural 
proteins (C, E
rns
, E1 and E2) and eight nonstructural proteins (N
pro
, P7, NS2, NS3, NS4A, 
NS4B, NS5A and NS5B). Based on the putative cleavage sites of structural and 
nonstructural proteins of other BVDVs (Table 4.1.), the ncpBVDV HP-KY-RK13 strain 
UTRs and genes were annotated to the following nucleotide positions in the genome: 5′ 
UTR, 1-386 (386 nt); N
pro
, 387-887 (501 nt); C, 888-1,196 (309 nt); E
rns
, 1,197-1,877 
(681 nt); E1, 1,878-2,462 (585 nt); E2, 2,463-3,584 (1,122 nt); P7, 3,585-3,794 (210 nt); 
NS2, 3,795-5,153 (1,359 nt); NS3, 5,154-7,202 (2,049 nt); NS4A, 7,203-7,394 (192 nt); 
NS4B, 7,395-8,435 (1,041 nt); NS5A, 8,436-9,923 (1,488 nt); NS5B, 9,924-12,083 
(2,160 nt); 3′ UTR, 12,084-12,271 (188 nt) (Table 4.2.).  The complete genomic sequence 
of ncpBVDV HP-KY-RK13 strain has been submitted to GenBank under accession 
number: KT355592.  
 Comparative nucleotide sequence analysis showed that the ncpBVDV HP-KY-
RK-13 strain had 85.2% to 99.7% identity with 11 strains of BVDV-1b and 68.6% to 
70.9% identity with eight strains of BVDV-2. This further demonstrated that the 
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ncpBVDV HP-KY-RK13 strain is very closely related to the previously described 
ncpBVDV present in the RK-13 cells from Japan (RK13/E
-
 strain [GenBank accession 
number: JX419397.1; 12064 nt, 99.7% identity])
469
. The ncpBVDV HP-KY-RK13 strain 
was compared with eleven other BVDV-1b subtypes available in GenBank; P7 and  
NS5A proteins are the most variable (78.1% to 99.0% and 79.1% to 99.6%, respectively), 
whereas the E
rns
, NS3, NS4A and NS4B proteins are the most conserved. The ncpBVDV 
HP-KY-RK13 strain had several nucleotide insertions and deletions compared to several 
of the other BVDV-1b strains (Table 4.3.). However, the specific insertion(s) and/or 
deletion(s) that are predictable for pathogenesis and establishment of persistent infection 
in the HP-RK-13 (KY) cell line have not been determined.  
A phylogenetic tree was constructed using the complete genome sequence of 
ncpBVDV HP-KY-RK13 strain along with 34 BVDV strains available in GenBank 
(Figure 4.1.). The phylogenetic analysis determined that ncpBVDV HP-KY-RK13 strain 
belongs to BVDV-1b genotype. 
 
Acknowledgements 
This study was supported by the Agriculture and Food Research Initiative competitive 
grant no.2013-68004-20360 from the United States Department of Agriculture National 
Institute of Food and Agriculture (USDA-NIFA). The next-generation sequencing using 
an Illumina Miseq technology was collaborated by Dr. Ganwu Li and Ms. Ying Zheng at 
the Department of Veterinary Diagnostic and Production Animal Medicine, College of 
Veterinary Medicine, Iowa State University.  
 
 
 
 
164 
Table 4.1. Cleavage sites between structural and nonstructural proteins of reference BVDV strains and HP-KY-RK13 strain  
 
Cleavage sites of SH-28, XJ-04, 890, NADL, ZM-95 strains of BVDV from Tao et al. (2013)
468
. 
Table 4.2. Nonstructural and structural proteins of BVDV strains  
 
Table	1.	Cleavage	sites	between	structural	and	nonstructural	proteins	of	reference	BVDV	strains	and	HP-KY-RK13	strain
ORF N
pro
C E
rns
E1 E2 P7 NS2 NS3 NS4A NS4B NS5A NS5B
SH-28 -LWVTS CSDEG-QLVTG ENIT-FGAYA ASPYC-TGAQG FPECK-QIAMG ARVNT-GVVKA SKTNT- QVTGL STAEN-ELKEL QKIKE-KIRNL SSNYL-YTMKL SSWST-
XJ-04 -LWVTS CSDEG-QLVEG ENIT-FGAYA ASPYC-TGAQS FPECK-QIAMG ARVNT-GLVKA REINT- -QVTGL STAEN-ELKEL AVGDL-KIRNL SSNYL-YTMKL SSWST-
890 -LWVTS CSDEG-QLVTG ENITQ-FGAHA ASPYC-TGVQG FPECK-QMAMG AGVNT-GAVKA IPPEE- -QVTGL STAEN-ELKEL AVGDL-KIRNL SGNYI-YTMKL SSWST-
NADL -LWVTT CSDTK-QVTMG ENIT-FGAYA ASPYC-TGVQG KKLFD-QKALG IQYGS-DVVKA DSGGQ- -QVTGL SSAEN-ELKEL ASGDV-KIRNL SGNYI-YAMKL SSWFL-
ZM-95 MELIS-LWVTS CSDTK-QVTAG ENIT-FGAYA ASPYC-TGAQG YPDCK-QRASG TQCGA-GAVKA ESGTQ-HLGWI LRGPA-QVAGL SSAEN-ELKEL ALGDV-KIRNL SGNYI-YTMKL SSWFM-VGASS
SD0803 MELIS-WVASC SDPKN-QVTMG ENIT-FGAYA ASPYC-TGVQG IPECR-QKASG AQCGA-GAVKA DSETQ-GWILR GPAVC-QVVGL SSAEN-ELKEL ALGDT-KIRNL SGNYI-YTMKL SSWFL-VNASS
CC13B MELIT-LWVSS CSDTK-QVTMG ENTI-FGAYA ASPYC-TGAQG YPDCK-QMALG AQYGS-GMVKA EPGTK-GWILR GPAVC-QVVGL SSAEN-ELKEL AVGDL-KIRNL SGNYV-YTMKL SSWFL-VGASS
 HP-KY-RK13 MELIT-LWISS CSDTK-QVTVG ENIT-FGAYA ASPYC-TGVQG YPDCK-QMASG AQYGA-GMARA EPGAQ-GWILR GPAVC-QVVGL SSAEN-ELKEL AVGDL-KIRNL SGNYV-YTMKL SSWFL-VGASS
Cleavage	sites	of	SH-28,	XJ-04,	890,	NADL,	ZM-95	Strains	of	BVDV	from	Tao	et	al.	Virus	Genes	(2013)	46:81–87
Table	2.	Nonstructural	and	structural	proteins	of	BVDV	strains
BVDV strain 
(GenBank 
accession 
number)
Full-length 
genome (nt)
1 ORF amino 
acid sequence 
length (aa)
ORF
Nucleotide length 
(nt)
Amino acid 
length (aa)
Nucleotide length 
(nt)
Amino acid 
length (aa)
Nucleotide length 
(nt)
Amino acid 
length (aa)
Nucleotide length 
(nt)
Amino acid length 
(aa)
Nucleotide length 
(nt)
Amino acid length 
(aa)
5′ UTR 1-386 (386) - (128) 1-388 (388) - (129) 1- 380 (380) - (126) 1-388 (388) - (129) 1-329 (329) - (109)
Npro 387-887 (501) 1-167 (167) 389-892 (504) 1-168 (168) 381-881 (501) 1-167 (167) 389-892 (504) 1-168 (168) 330-833 (504) 1-168 (168)
C 888-1196 (309) 168-270 (103) 893-1198 (306) 169-270 (102) 882-1190 (309) 168-270 (103) 893-1198 (306) 169-270 (102) 834-1145 (312) 169-272 (104)
E
rns
1197-1877 (681) 271-497 (227) 1199-1879 (681) 271-497 (227) 1191-1871 (681) 271-497 (227) 1199-1879 (681) 271-497 (227) 1146-1826 (681) 273-499 (227)
E1 1878-2462 (585) 498-692 (195) 1880-2464 (585) 498-692 (195) 1872-2456 (585) 498-692 (195) 1880-2464 (585) 498-692 (195) 1827-2411 (585) 500-694 (195)
E2 2463-3584 (1122) 693-1066 (374) 2465-3586 (1122) 693-1066 (374) 2457-3578 (1122) 693-1066 (374) 2465-3586 (1122) 693-1066 (374) 2412-3536 (1125) 695-1069 (375)
P7 3585-3794 (210) 1067-1136 (70) 3587-3796 (210) 1067-1136 (70) 3579-3788 (210) 1067-1136 (70) 3587-3796 (210) 1067-1136 (70) 3537-3746 (210) 1070-1139 (70)
NS2 3795-5153 (1359) 1137-1589 (453) 3797-5155 (1359) 1137-1589 (453) 3789-5147 (1359) 1137-1589 (453) 3797-5155 (1359) 1137-1589 (453) 3747-5099 (1353) 1140-1590 (451)
NS3 5154-7202 (2049) 1590-2272 (683) 5156-7204 (2049) 1590-2272 (683) 5148-7196 (2049) 1590-2272 (683) 5156-7204 (2049) 1590-2272 (683) 5100-7154 (2055) 1591-2275 (685)
NS4A 7203-7394 (192) 2273-2336 (64) 7205-7396 (192) 2773-2336 (64) 7197-7388 (192) 2273-2336 (64) 7205-7396 (192) 2773-2336 (64) 7155-7346 (192) 2276-2339 (64)
NS4B 7395-8435 (1041) 2337-2683 (347) 7397-8437 (1041) 2337-2683 (347) 7389-8429 (1041) 2337-2683 (347) 7397-8437 (1041) 2337-2683 (347) 7347-8387 (1041) 2340-2686 (347)
NS5A 8436-9923 (1488) 2684-3179 (496) 8438-9925 (1488) 2684-3179 (496) 8430-9917 (1488) 2684-3179 (496) 8438-9925 (1488) 2684-3179 (496) 8388-9875 (1488) 2687-3182 (496)
NS5B 9924-12083 (2160) 3180-3898 (719) 9926-12085 (2160) 3180-3898 (719) 9918-12077 (2160) 3180-3898 (719) 9926-12085 (2160) 3180-3898 (719) 9876-12035 (2160) 3183-3901 (719)
3′ UTR 12084-12271 (188) - (62) 12086-12271 (186) - (62) 12078-12265 (188) - (62) 12086-12271 (186) - (62) 12036-1220(185) - (61)
122271 nt
3898 aa
BVDV HP-KY-RK13 (KT355592.1) BVDV SD0803 (JN400273.1)
12271 nt
3898 aa
BVDV ZM-96 (AF526381.3)
12220 nt
3901 aa
BVDV CC13B (KF772785.1)
12265 nt
3898 aa
BVDV 1 Japan (JX419397.1)
12064 nt
3898 aa
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Table 4.3. Insertion and deletion positions in full-length genome alignments of BVDV-
1b strains  
 
 
 
 
Table	3.	Insertion	and	deletion	positions	in	full	length	genome	alignments	of	BVDV-1b	strains	
Compared strain HP-KY-RK13
(GenBank accession number) Insertion/Deletion
JL-1  5′ UTR 11 A deletion
|KF501393.1| 17 T deletion
45-48 AAAA insertion
75-76 AA insertion
E2 2719-2721 GAA insertion
NS2 5010-5021 AATATCCTTCAG deletion
CP7 strain  5′ UTR 45-47 AAA deletion
|U63479.1|
NS2 4358-4384 GGGTGTTCCTTATCCGGACCCTCAAAC deletion
3156  5′ UTR 45-47 AAA insertion
|JN704144.1| 75-76 AA insertion
NS5A 9406 A insertion
9411 A deletion
9800-9803 GGGC insertion
9812-9815 AAGT deletion
NS5B 11960 A deletion
11976 A insertion
 3′ UTR 12090-12092 AAT insertion
12116-12120 GAATT deletion
12125-12129 TGTAT insertion
12168-12176 CCTCAAAAG deletion
12185-12206 CTCAACATACACAGCTAAACAG deletion
12210-12215 TTGAGA deletion
Germini E2 2469-2471 GAC insertion
|JX297516.1|  2720-2725 AAGAAA insertion
 3′ UTR 12033 C insertion
Nucleotide 
position 
Nucleotide  substitutionORF
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Figure 4. 1. Phylogenetic analyses of whole genome of 34 reference BVDV strains 
obtained from GenBank and the ncpBVDV HP-KY-RK13 strain identified with a 
black dot.   
  
 50 BVDV 1b |KF835698.1| 50 strain
 50a BVDV 1b |KF835699.1| 50a
 AU526 BVDV 1b |KF835697.1|
 526 BVDV 1b |HQ174294.1|
 6151 BVDV 1b |JN380083.1|
 BVDV HP-KY-RK13 |KT355592|
 RK13/E- BVDV1b |JX419397.1|
 RK13/E+ BVDV 1b |JX419398.1|
 Gemini BVDV 1b |JX297516.1|
 CP7 BVDV1b |U63479.1|
 CC13B BVDV 1 |KF772785.1|
BVDV 1b
 12F004 BVDV 1 |KC963967.1|
 890 BVDV 1 |U86599.1|
 JL-1 BVDV 1b |KF501393.1|
 KE9 BVDV 1 |EF101530.1|
 GX4 BVDV 1 |KJ689448.1|
 Av69 VEDEVAC BVDV 1 |KC695814.1|
 3156 BVDV 1b |JN704144.1|
 NADL BVDV 1 |AJ133739.1|
 Oregon C24V BVDV 1 |AF091605.1|
 GS5 BVDV 1 |KJ541471.1|
 10JJ-SKR BVDV 1 |KC757383.1|
 ZM-95 BVDV 1 |AF526381.3|
 SD0803 BVDV 1 |JN400273.1|
 camel-6 BVDV 1 |KC695810.1|
 uwaCp BVDV 1 |KC853441.1|
 SuwaNcp BVDV 1 |KC853440.1|
BVDV 1
 SD1301 BVDV 2 |KJ000672.1|
 Hokudai-Lab/09 BVDV 2 |AB567658.1|
 HLJ-10 BVDV 2 |JF714967.1|
 SH-28 BVDV 2 |HQ258810.1|
 XJ-04 BVDV 2 |FJ527854.1|
 KZ-91-CP BVDV 2 |LC006970.1|
 C413 BVDV 2 |NC 002032.1|
 11F011 BVDV 2 |KC963968.1|
BVDV 2
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CHAPTER FIVE 
Summary of Research Findings 
Chapter one provides a review of the current literature on equine arteritis virus 
(EAV) and equine viral arteritis (EVA) which includes viral classification, genome 
organization, replication cycle and neutralization determinants and the disease caused by 
the virus including epidemiology, modes of transmission, immune response, clinical 
signs, pathogenesis, persistent infection in the stallion, diagnosis, treatment, prevention 
and control. Also, a brief overview of RNA virus quasispecies theory and viral 
evolutionary mechanisms is provided. Viruses are infectious particles that cannot self-
replicate without susceptible and permissive host cells. Like other RNA viruses, the EAV 
RNA-dependent RNA polymerase enzyme lacks proofreading capability (error-prone), 
which results in the generation of a large number of viral genomes with mutations. The 
viral population size, number of mutations and quasispecies effect drive RNA virus 
evolution. RNA viruses evolve close to their error threshold at a high mutation rate 
during a short period of viral replication and produce a large viral population and enough 
mutants to enhance viral survival. Viral populations exist as a dynamic mutant 
distribution (mutant swarms) that is called quasispecies. The viral quasispecies 
population constantly evolves in the face of selection pressures to adapt to a given 
environment. When the virus fitness decreases, the viral population loses the ability to 
adapt to its environment and it experiences a bottleneck event, which is a sharp reduction 
in the size of a population due to environmental events such as selective pressure and 
viral fitness.  
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In chapter two, EAV evolution was studied during long-term persistent infection 
established following experimental infection of seven stallions with the KY84 strain of 
EAV. In addition, two stallions naturally infected with the EAV KY84 strain for a period 
of 7 to 10 years were also included in the study. This was the first study where the 
evolution of the full-length EAV genome was studied during long-term persistent 
infection using next-generation sequencing. The sequencing data were analyzed using 
contemporary sequence and phylogenetic analysis software. The statistical analyses were 
performed to measure the intra-host evolutionary dynamics, quasispecies diversity, rate 
of evolution and selection pressure among viral populations from the ancestral strain (the 
initial inoculum) through the evolutionary time scale (acute and persistent infection 
periods).  Analysis of viral sequences in nasal secretions and buffy coat cells revealed a 
lack of extensive positive selection; however, characteristics of the mutant spectra were 
different in the two sample types. By contrast, virus populations in semen during the 
acute infection phase were under selective pressure and subjected to bottleneck events, 
which was reflected in a reduction in population size and the positive selection of viral 
genomes. During long-term persistent infection, virus evolved in the reproductive tract of 
the stallions; as a result, a non-stochastic evolutionary process with many atypical high-
frequency minor variants was identified. This indicates that an active selection pressure 
continually morphs EAV quasispecies population structures and dynamics during 
persistent infection. Comparative analysis of the evolution in experimentally infected 
stallions with that of naturally infected stallions showed a higher degree of correlation in 
the rate of sequence divergence through time and mirrored the patterns of selection 
between experimental and naturally infected stallions.  In summary, this study 
 
169 
 
demonstrated the genetic bottleneck event and selection during the acute infection period 
and intra-host quasispecies diversification during persistent infection in the stallion 
reproductive tract. 
A total of 53 sequential isolates made during acute and persistent infection were 
analyzed and compared to the of EAV KY84 strain present in the inoculum. Major and 
minor viral populations were identified in the inoculum used for experimental infection 
of the seven stallions. The more homogenous virus populations with major and minor 
variants were demonstrated in the inoculum virus and viruses isolated during the acute 
infection period. A distinct quasispecies population size and selection pattern were 
observed during the initial establishment of the viral population in nasal swab and buffy 
coat samples. For instance, the reduction in variant population size observed in buffy coat 
virus isolates may reflect a transmission bottleneck scenario. The results indicate that the 
selective bottleneck event happens during virus migration from the upper respiratory tract 
to the regional lymph nodes via the blood stream until EAV reaches its final destination 
in the male reproductive tract. In the virus population during acute infection period, 
strong negative evolutionary selection was observed at nucleotide positions of nsp9 
located at aa 6729-6816, which play a role in RdRp function and in assembly of the viral 
replication complex. This suggested that the conserved nsp9 region with low frequency 
mutation might have a regulatory effect on viral replication.  
In contrast, the presence of continual positive selection resulting in quasispecies 
diversity was observed in specific regions of the genome that drives the evolution of 
semen virus isolates made during persistent infection. For instance, an atypical high 
frequency minor variant population implies an ongoing interaction between the viral 
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qausispecies population and the host immune system. Even though 10 to 70% of stallions 
become persistently infected carriers, the presence of high levels of serum virus 
neutralizing antibodies effectively eliminates systemic infection in body tissues except 
for the reproductive tract of the stallion. The strong diversifying selection was observed 
especially in ORF3 and ORF5. The results suggest that quasispecies diversity may play a 
significant role in establishment of persistent infection and the pathogenesis of EAV. 
 In conclusion, this study identified virus evolution with the dynamic population 
in sequential samples from both experimentally and naturally infected stallions during 
acute and persistent infection. Questions to emerge from the research findings are as 
follows: What leads to persistent infection of EAV in the stallion reproductive tract? 
Supplementary tables 2.2. and 2.3. may provide a key to understanding the major amino 
acid changes in structural proteins, particularly GP5, which contains the major 
neutralization sites of EAV. What will happen to pathogenesis of the virus as it evolves 
over time? Does the phenomenon of the virus quasispecies population occur similarly in 
mares?  Due to the lack of resources, this in vivo study could not be extended to include 
breeding trials with experimental mares to define the pathogenesis of the infection. 
However, supplementary tables 2.4. and 2.5. suggest the presence of distinctive 
neutralizing phenotypes; further investigation of the latter may well help in understanding 
in pathogenesis of the virus as well as persistent infection of EAV in the stallion 
reproductive tract.   
 Chapter three was devoted to a study of the isolation and characterization of a 
novel field strain of EAV from a persistently infected donkey in northern Chile, described 
as EAV donkey VD7634 strain. This is the first full-length genome sequence of EAV 
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obtained from a wild male donkey. The annotation of EAV donkey VD7634 strain was 
predicted based on the NCBI referenced EAV sequence (accession numbers: NC002532). 
There are only partial ORF5 sequences (nucleotide location: 11,295-11,812 [518 bp in 
length]) of donkey EAV isolates available from GenBank. Both sequence identity and 
phylogenetic analyses indicated that the partial ORF5 sequence of EAV donkey VD7634 
strain was closely related to that of a donkey isolate from the Republic of South Africa 
(RSA). However, further phylogenetic analysis using 29 full-length EAV strains from 
horses grouped the EAV donkey VD7634 strain with French and CW strains (EU-2 
subgroup). Although EAV donkey VD7634 strain diverged from both NA and EU 
subgroups of 29 referenced EAV sequences of horses, phylogenetic analysis including 
other arteriviruses indicated that EAV donkey VD7634 strain belongs to the genus 
Equartevirus (Family: Arteriviridae and Order: Nidovirales). Neutralization testing with 
a large panel of well-characterized mAbs and polyclonal equine sera confirmed antigenic 
cross reactivity of this strain. The newly identified EAV donkey VD7634 strain had a 
unique neutralization phenotype compared to other EAV strains.  
 Even though EAV has not yet been detected from domestic horses in Chile, this 
is the first isolate of EAV from a carrier male donkey originating from a wild herd for an 
unknown period of time. It is very difficult to imagine how these feral donkeys survive, 
some persistently infected with EAV, in Huasco province, Atacama region in Chile, that 
is geographically surrounded by arid desert, salt lakes and felsic lava that flows towards 
the Andes mountains
470
. There are very large deposits of sodium nitrate in the region, 
which could serve as fertilizer and may enable plants to grow as a food source for the 
feral donkeys. Although the geographical location limits the possibility of contact of 
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EAV positive feral donkeys with domestic equids including donkeys and horses, this 
study might suggest that there could be the potential for an outbreak of EVA. 
Accordingly, implementation of prevention and control measures against EVA are highly 
recommended to protect the domestic equine population in Chile from the risk of such an 
event.   
Chapter four, the full-length genome sequence of a noncytopathic bovine diarrhea 
virus 1 (ncpBVDV-1) contaminating the high passage rabbit kidney continuous cell line 
(HP-RK-13 [KY]). It has been repeatedly reported that the RK-13 cell line is 
contaminated with noncytopathic bovine viral diarrhea virus (ncpBVDV) as a result of 
the use of BVDV contaminated fetal bovine serum in cell culture media. This laboratory 
has been using the HP-RK-13 (KY) cell line for isolation of EAV from clinical 
specimens for many years.  
In this study, the complete genome of ncpBVDV-1 (ncpBVDV HP-KY-RK13 
strain) was determined and the genome organization predicted by comparing cleavage 
sites to other published BVDV sequences. Several nucleotide insertions and deletions 
were observed in the ncpBVDV HP-KY-RK13 strain by comparing it to several other 
BVDV-1b strains; however, its role in the pathogenesis and establishment of persistent 
virus infection has to be determined. Phylogenetic analysis determined that the 
ncpBVDV HP-KY-RK13 strain belongs to the BVDV-1b genotype. 
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APPENDIX 1 
List of Abbreviations 
°
C Celsius 
3CLSP 3C-like serine proteases 
TCID50 50% tissue culture infective dose 
R
2
 Accuracy of the linear regression analysis 
COOH Acidic carboxylic group 
Vero or MA-104 African green monkey kidney  
APRAV-1 African pouched rat arterivirus 
AAEP American Association for Equine Practitioners 
ATCC American Type Culture Collection 
AVMA American Veterinary Medical Association 
aa Amino acid 
BHK-21 Baby hamster kidney-21 
bp Base pair 
NH2 Basic amino group 
BVDV Bovine viral diarrhea virus 
BC Buffy coat 
HS or HT-7 Canine hepatitis virus-transformed hamster tumor  
CO2 Carbon dioxide 
CMC Carboxymethylcellulose 
CD Cluster of differentiation 
CF Complement-fixing 
cDNA Complementary DNA 
Cys Cysteine 
CP Cysteine protease 
cp Cytopathic 
cpBVDV Cytopathic BVDV  
CPE Cytopathic effect 
dpi Days post-infection 
DNA Deoxyribonucleic acid  
DIVA Differentiate vaccinated from infected animals 
DMV Double-membrane vesicle 
EMEM Eagle's minimum essential medium 
ER Endoplasmic reticulum 
E Enveloped protein 
ELISA Enzyme-linked immunosorbert assay 
EAV Equine arteritis virus 
C-X-C motif Equine chemokine 
EqCXCL16 Equine chemokine ligand 16 
ECA11 Equine chromosome 11 
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EEC Equine endothelial cell 
EO Equine ovary cell 
EVA Equine viral arteritis 
ERGIC ER-Golgi intermediate compartment 
EU European 
FUBAR 
Fast unconstrained Bayesian analysis for inferring 
selection  
FMDV Foot-and-mouth disease virus 
GP Glycoprotein 
GnRH Gonadotropin releasing hormone 
h Hour 
H Hemagglutinin 
HmLu Hamster lung 
HS Heparin sulfate 
HAV Hepatitis A virus 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HP-RK-13 (KY) High passage RK-13 (KY) 
hpi Hours post-infection 
huCXCL16 Human chemokine ligand 16 
HIV Human immunodeficiency virus 
HyPhy Hypothesis testing using phylogenies 
ARTERVAC® Inactivated EAV vaccination 
pEAVrMLVB Infectious cDNA clone of the MLV strain of EAV 
IACUC Institutional Animal Care and Use Committee 
iiRT-PCR Insulated isothermal RT-PCR 
IFN Interferon 
IL Interleukin 
ICTV International Committee for Taxonomy of Viruses 
KY Kentucky 
KY84 Kentucky 84 strain 
kb Kilobase 
kDa Kilodalton 
L Liter 
LDV Lactate dehydrogenase-elevating virus 
LTH Leader TRS hairpin 
MCL Maximum composite likelihood 
ML Maximum likelihood 
M Membrane protein 
mRNA Messenger RNA 
μg/mL Microgram per milliliter 
µL  Microliter 
MIA Microsphere immunoassay 
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MEME Mixed effect model of evolution 
ARVAC® Modified live attenuated EAV vaccination 
MLV Modified live attenuated vaccination 
mAbs Monoclonal antibodies 
NS Nasal swab or nasal secretion 
NAHMS National Animal Health Monitoring System 
NCBI National Center for Biotechnology Information 
N Neuraminidase 
NGS Next-generation sequencing 
NendoU Nidoviral-endonuclease specific for U 
ncp Noncytopathic 
ncpBVDV noncytopathic BVDV 
nsp Nonstructural protein 
NS3 Nonstructural protein 3 
n Nonsynonymous 
∏n Nonsynonymous nucleotide diversity 
n/N Nonsynonymous substitutions per site 
NA North American 
N protein Nucleocapsid protein 
NTPase Nucleoside-triphosphatase 
nt Nucleotide 
∏ Nucleotide diversity 
dN Number of n/N 
dS Number of s/S 
ORF Open reading frame 
p P-value 
PCP Papain-like cysteine protease 
P1 Passage 1 
P-PMO Peptide-conjugation to the PMO 
PMO Phosphorodiamidate morpholino oligomer 
PFU/mL Plaque-forming units per milliliter 
PCR Polymerase chain reaction 
pp Polyprotein 
PRRSV Porcine reproductive respiratory syndrome virus 
RK-13 Rabbit kidney-13 
qRT-PCR Real-time RT-PCR 
rRT-PCR Real-time RT-PCR 
RTC Replication/transcription complex 
RSA Republic of South Africa 
RVN Reticulovesicular network 
RT-PCR Reverse transcription-polymerase chain reaction 
RNA Ribonucleic acid 
RdRp RNA-dependent RNA polymerase 
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RT-nPCR RT-nested PCR 
S Semen 
SP Serine protease 
SAG Servicio Agricola y Ganadro 
SHFV Simian hemorrhagic fever virus 
SNV Single nucleotide variant 
ss Single stranded 
SH2 Src homology 2 
sp Structural protein 
sg mRNA Subgenomic viral messanger RNA 
s Synonymous 
∏s Synonymous nucleotide diveresity 
s/S Synonymous substitutions per site 
TCF Tissue culture fluid 
TRS Transcription regulating sequence 
TNF Tumor necrosis factor 
USDA-APHIS 
United States Department of Agriculture Animal and 
Plant Health Inspection Service 
USA United States of America 
U/mL Units per milliliter 
UTR Untranslated region 
VS Vas deferens 
VN Viral neutralizing 
VBS Virulent Bucyrus strain 
VI Virus isolation 
VNT Virus neutralization test 
VRP Virus replicon particle 
VLP Virus-like particle 
WPDV Wobbly possum disease virus 
OIE World Organisation for Animal Health 
ZF Zinc finger 
ZBD Zinc-binding domain 
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APPENDIX 2 
Glossary Relevant to the Virus Evolution 
Adaptation 
The constant steady replication of large viral populations results in a 
consequence of high fitness 
Antigenic drift  
 
One of the main mechanisms that is a result of point mutations in 
influenza virus genes, encoding HA and NA that cause alternations 
in the structure of the main viral surface antigens. This is a slow 
process that is on-going and which causes antigenic differences in 
strains of influenza virus 
Bottleneck event 
 
Modification of viral population sizes resulting in the heterogeneous 
and dynamic nature of viral populations that are suitable in the 
environment by fitness gain 
Defectors  
 
Types of defective mutants that are associated with virus extinction 
caused by lethal mutagenesis 
Drug resistance  
 
A general phenomenon and the selection of a drug-resistant mutant 
against a specific antiviral drug is evidence of the phenomenon 
Error-threshold 
 
The value that is determined by the replication accuracy and the 
virus fitness of the dominant or master sequence corresponding to 
the mean fitness value of the error copies 
Exonuclease 
activities  
The DNA-dependent DNA polymerases have proofreading ability 
that are enable them to modify or correct any such mistakes 
Lethal 
mutagenesis 
A process of suppression in the replication of a high fitness variants 
Molecular clock  
 
The neutral theory of molecular evolution that means the rates of 
evolution reflect mutation rates 
Mutant spectra  
 
The ensemble of genomes that forms a viral quasispecies and its 
complexity and formation are closely related to its biological 
environment.  
Mutation 
frequency  
 
The proportion of mutant viruses in a population, and is affected by 
many biochemical and environmental selective factors 
Mutation rate  
 
The frequency of occurrence of a mutation during genome 
replication that can be calculated by mutations per site per 
replication. It is a value that is an independent of the fitness of the 
parental and mutated genomes 
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Negative 
selection  
The process of removing a genotype in an evolving population that 
causes the negative evolution of phenotypic traits expressed by 
individuals 
Next-generation 
sequencing  
The application of modern technologies to study the virus evolution 
and viral quasispecies population 
Non-equilibrium  
A mutant spectrum in variable fitness landscapes, a theoretical 
construction of the evolutionary process 
Nonsynonymous 
mutation  
A nucleotide mutation that changes the amino acid sequence of a 
protein 
Population 
equilibrium  
An important role in maintaining a constant consensus sequence in 
viral populations 
Positive selection  
 
The process of a dominant genotype resulting in the positive 
evolution of phenotypic traits expressed by the individuals of the 
evolving population 
Quasispecies  
 
Also known as mutant swarms or mutant clouds; a continuous 
process of genetic variations in RNA viruses is responsible for 
heterogeneous mutant distributions in virus population 
Quasispecies 
dynamics  
 
RNA viruses evolve as a consequence of disequilibria of mutant 
distributions instead of linear accumulation of mutations 
Quasispecies 
memory  
 
The presence of maintaining virus subpopulations in the mutant 
spectrum at high frequencies than mutation rates  
Rate of evolution 
 
Viral quasispecies parameter which is the number of accumulated 
mutations in viral genomes through a time point 
Reassortant 
 
When a susceptible host cell is coinfected by two strains of a virus, 
the progeny virus may have a mixture of genome segments from the 
two parental strains of a virus 
Recombination  
 
Viruses evolve by rearranging their genomes or functional parts 
among different viruses 
RNA-dependent 
RNA polymerase 
 
Most RNA viruses encode for a low fidelity polymerase enzyme that 
encoded by most RNA viruses that can result in a mutation rate of 
10
3
 to 10
5
 errors per nucleotide per replication cycle. 
Selective 
constraints  
 
Antiviral drugs, immune components of the innate or the adaptive 
immune response including those induced by vaccination and 
interfering RNAs 
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Synonymous 
mutations  
A nucleotide mutation that does not change the amino acid sequence 
of a protein 
Viral fitness  
 
A major parameter which results in a viral population adapting to a 
specific environment and producing infectious progeny under the 
formulation of quasispecies theory and the error threshold 
relationship 
Viral quasispecies  
 
It allows RNA viruses to adapt to a given environment with the 
advantages of dynamics of infection, virus spread, attenuation and 
virulence, complexity and self-organization 
Virus extinction  
 
Mutant spectrum complexity occurs by an increase in the mutation 
rate above an extinction threshold.  
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APPENDIX 3 
Supplementary Tables 
Supplementary table 2.1. GenBank submission information of 53 sequential isolates of 
EAV KY84 strain from this study 
Sample 
Number
Sample ID
GenBank Submission 
Name
Collection 
dpi
Specimen Type GenBank ID
1 EAV KY84 strain KY84 0 Tissue culture fluid MG137429
2 L136 (A) NS D6 KY84-L136A-NS6 6 Nasal swab MG137434
3 L137 (B) NS D6 KY84-L137B-NS6 6 Nasal swab MG137443
4 L138 (C) NS D6  KY84-L138C-NS6 6 Nasal swab MG137448
5 L139 (D) NS D6 KY84-L139D-NS6 6 Nasal swab MG137453
6 L140 (E) NS D6 KY84-L140E-NS6 6 Nasal swab MG137460
7 L141 (F) NS D6 KY84-L141F-NS6 6 Nasal swab MG137469
8 L142 (G) NS D6 KY84-L142G-NS6 6 Nasal swab MG137476
9 L136 (A) BC D6 KY84-L136A-BC6 6 Buffy coat MG137435
10 L137 (B) BC D6 KY84-L137B-BC6 6 Buffy coat MG137444
11 L138 (C) BC D6 KY84-L138C-BC6 6 Buffy coat MG137449
12 L139 (D) BC D6 KY84-L139D-BC6 6 Buffy coat MG137454
13 L140 (E) BC D6 KY84-L140E-BC6 6 Buffy coat MG137461
14 L141 (F) BC D6  KY84-L141F-BC6 6 Buffy coat MG137470
15 L142 (G) BC D6 KY84-L142G-BC6 6 Buffy coat MG137477
16 L136 (A) S D5 KY84-L136A-S5 5 Semen MG137436
17 L137 (B) S D5 KY84-L137B-S5 5 Semen MG137445
18 L138 (C) S D5 KY84-L138C-S5 5 Semen MG137450
19 L139 (D) S D5 KY84-L139D-S5 5 Semen MG137455
20 L140 (E) S D5 KY84-L140E-S5 5 Semen MG137462
21 L141 (F) S D5 KY84-L141F-S5 5 Semen MG137471
22 L142 (G) S D5 KY84-L142G-S5 5 Semen MG137478
23 L136 (A) S D9 KY84-L136A-S9 9 Semen MG137437
24 L137 (B) S D9 KY84-L137B-S9 9 Semen MG137446
25 L138 (C) S D9 KY84-L138C-S9 9 Semen MG137451
26 L139 (D) S D9 KY84-L139D-S9 9 Semen MG137456
27 L140 (E) S D9 KY84-L140E-S9 9 Semen MG137463
28 L141 (F) S D9 KY84-L141F-S9 9 Semen MG137472
29 L142 (G) S D9 KY84-L142G-S9 9 Semen MG137479
30 L136 (A) S D107 KY84-L136A-S107 107 Semen MG137438
31 L137 (B) S D107 KY84-L137B-S107 107 Semen MG137447
32 L138 (C) S D107 KY84-L138C-S107 107 Semen MG137452
33 L139 (D) S D107 KY84-L107D-S107 107 Semen MG137457
34 L140 (E) S D107 KY84-L140E-S107 107 Semen MG137464
35 L141 (F) S D107 KY84-L141F-S107 107 Semen MG137473
36 L142 (G) S D107 KY84-L142G-S107 107 Semen MG137480
37 L136 (A) S D170 KY84-L136A-S170 170 Semen MG137439
38 L139 (D) S D170 KY84-L139D-S170 170 Semen MG137458
39 L140 (E) S D170 KY84-L140E-S170 170 Semen MG137465
40 L141 (F) S D170 KY84-L141F-S170 170 Semen MG137474
41 L142 (G) S D170 KY84-L142G-S170 170 Semen MG137481
42 L139 (D) S D345 KY84-L139D-S345 345 Semen MG137459
43 L141 (F) S D345 KY84-L141F-S345 345 Semen MG137475
44 L136 (A) S D380  KY84-L136A-S380 380 Semen MG137440
45 L140 (E) S D380  KY84-L140E-S380 380 Semen MG137466
46 L136 (A) S D548 KY84-L136A-S548 548 Semen MG137441
47 L140 (E) S D548 KY84-L140E-S548 548 Semen MG137467
48 L136 (A) S D726 KY84-L136A-S726 726 Semen MG137442
49 L140 (E) S D726  KY84-L140E-S726 726 Semen MG137468
50 Stallion D84 KY84 Stallion D84 - Semen MG137430
51 Stallion D94 KY84 Stallion D94 - Semen MG137431
52 Stallion E84 KY84 Stallion E84 - Semen MG137432
53 Stallion E91 KY84 Stallion E91 - Semen MG137433
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Supplementary table 2.2. Comparative amino acid substitution analysis of both nonstructural and structural proteins between 
inoculum and semen viruses of EAV KY84 strain from the experimentally infected carrier stallions during acute and persistent 
infection periods 
Amino acid 
position
O-EAV 
KY84
L136 (A) 
S D5
L136 (A) 
S D107
L136 (A) 
S D170
L136 (A) 
S D380
L136 (A) 
S D548
L136 (A) 
S D726
L140 (E) 
S D5
L140 (E) 
S D9
L140 (E) 
S D107
L140 (E) 
S D170
L140 (E) 
S D380
L140 (E) 
S D548
L140 (E) 
S D726
Amino Acid  Substution: 1 1 2 5 11 21 3 1 1 4 6 7 13
ORF 1ab (255-9751) nsp1: Met1-Gly260 (260) - - - - - - - - - - - - - -
nsp2: Gly261-Gly831 (571) 265 Pro (P) Leu (L)
411 Asp (D) Gly (G)
447 Ala (A) Thr (T)
458 Thr (T) Ile (I)
462 Ser (S) Leu (L)
489 Ser (S) Cys (C)
509 Thr (T) Ile (I)
549 Ala (A) Thr (T)
nsp3: Gly832-Glu1064 (233) - - - - - - - - - - - - - - -
nsp4: Gly1065-Glu1268 (204) 1148 His (H) Arg (R)
nsp5: Ser1269-Glu1430 (162) - - - - - - - - - - - - - - -
nsp6: Gly1431-Glu1452 (22) 1439 Ala (A) Thr (T) Thr (T)
nsp7: Ser1453-Glu1677 (225) - - - - - - - - - - - - - - -
nsp8: Gly1678-Asn1727 (50) - - - - - - - - - - - - - - -
nsp9: Gly1678-Arg2370 (693) 226 Asp (D) Gly (G) Gly (G) Gly (G)
582 Ile (I) Val (V) Val (V)
nsp10: Ser2371-Gln2837 (467)
842 Glu (E) Ala (A)
863 Ser (S) Cys (C) Cys (C)
nsp11: Ser2838-Glu3056 (219)
- - - - - - - - - - - - - - -
nsp12: Gly3057-Val3175 (119)
- - - - - - - - - - - - - - -
ORF2a (9751-9954) E (67) - - - - - - - - - - - - - - -
ORF2b (9824-10507) GP2 (227) 81 Ala (A) Tyr (Y) Tyr (Y) - - - - - - -
ORF3 (10306-10797)
†
GP3 (163)
†
3 His (H) Tyr (Y) Tyr (Y) Tyr (Y) Tyr (Y) Tyr (Y) Tyr (Y)
19 Arg (R) Cys (C) Cys (C) Cys (C) Cys (C) Cys (C) Cys (C)
22 Phe (F) Ser (S)
28 Asp (D) Asn (N) Asn (N)
30 Ile (I) Thr (T) Thr (T)
84 Phe (F) Leu (L)
116 His (H) Gln (Q)
118 His (H) Arg (R) Arg (R) Arg (R)
119 Leu (L) Ser (S) Ser (S) Ser (S) Ser (S) Ser (S) Pro (P) Pro (P) Pro (P)
ORF4 (10700-11158) GP4 (152) 14 Ala (A) Val (V)
116 Lys (K) Gln (Q)
ORF5a (11112-11291) ORF5a protein (59) 13 Ala (A) Val (V)
ORF5 (11146-11913) GP5 (255) 71 Glu (E) Asp (D)
73 Ile (I) Val (V) Val (V) Val (V) Val (V) Val (V) Val (V) Val (V) Val (V)
82 Asp (D) Asn (N) Asn (N) Asn (N)
84 Tyr (Y) His (H) His (H) His (H) His (H) His (H) His (H)
104 Asp (D) Gly (G)
173 Leu (L) Pro (P)
ORF6 (11901-12389) M (162) 88 Ile (I) Met (M) Met (M)
135 Lys (K) Arg (R)
ORF7 (12313-12645) N (110) - - - - - - - - - - - - - - -
Open Reading 
Frames (ORFs) 
Protein (aa length)
Amino Acid Substitutions Amino Acid Substitutions
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Supplementary table 2.3. Comparative amino acid substitution analysis of both nonstructural and structural proteins between 
inoculum and semen viruses of EAV KY84 strain from the experimentally infected stallions that stopped shedding the virus 
Amino acid 
position
O-EAV 
KY84
L137 (B) 
S D5
L137 (B) 
S D9
L137 (B) 
S D107
L138 (C) 
S D107
L139 
(D) S D5
L139 
(D) S D9
L139 
(D) S 
D170
L139 
(D) S 
D345
L141 (F) 
S D5
L141 (F) 
S D107
L141 (F) 
S D170
L141 (F) 
S D345
L142 
(G) S D5
L142 
(G) S 
D107
L142 
(G) S 
D170
Amino Acid  Substution: 1 1 3 4 1 1 6 15 2 6 6 10 2 1 3
ORF 1ab (255-9751) nsp1: Met1-Gly260 (260) 145 Val (V) Met (M)
nsp2: Gly261-Gly831 (571) 404 Ser (S) Arg (R)
411 Asp (D) Gly (G)
470 Lys (K) Arg (R)
495 Phe (F) Ser (S)
497 Ala (A) Thr (T)
511 Thr (T) Ile (I)
705 Thr (T) Ala (A)
nsp3: Gly832-Glu1064 (233) 844 Val (V) Ile (I)
873 Thr (T) Ile (I) Ile (I)
nsp4: Gly1065-Glu1268 (204) - - - - - - - - - - - - - - - - -
nsp5: Ser1269-Glu1430 (162) - - - - - - - - - - - - - - - - -
nsp6: Gly1431-Glu1452 (22) - - - - - - - - - - - - - - - - -
nsp7: Ser1453-Glu1677 (225) - - - - - - - - - - - - - - - - -
nsp8/9: Gly1678-Asn1727 (50) 1681 Gln (Q) Arg (R)
nsp9: Gly1678-Arg2370 (693) 200 Val (V) Ala (A)
441 Ser (S) Gly (G) Gly (G)
nsp10: Ser2371-Gln2837 (467) 819 Val (V) Phe (F)
1039 Ser (S) Gly (G)
nsp11: Ser2838-Glu3056 (219) 1142 Leu (L) Phe (F)
1168 Leu (L) Phe (F) Phe (F)
1190 Thr (T) Ala (A)
1234 His (H) Tyr (Y) Tyr (Y)
nsp12: Gly3057-Val3175 (119) 1379 Ala (A) Val (V)
ORF2a (9751-9954) E (67) - - - - - - - - - - - - - - - - -
ORF2b (9824-10507) GP2 (227) 9 Tyr (Y) Cys (C) Cys (C)
10 Leu (L) Ser (S)
217 Ser (S) Phe (F)
ORF3 (10306-10797)
†
GP3 (163)
†
3 His (H)
Tyr (Y)
19 Arg (R) Cys (C) Cys (C) Cys (C) Cys (C) Cys (C)
27 Ser (S) Cys (C)
28 Asp (D) Tyr (Y)
118 His (H) Arg (R)
119 Leu (L) Ser (S) Ser (S) Ser (S) Pro (P)
120 Thr (T) Ile (I)
121 Thr (T) Met (M)
ORF4 (10700-11158) GP4 (152) 3 Thr (T) Ile (I)
145 Arg (R) His (H) His (H) His (H) His (H)
ORF5a (11112-11291) ORF5a protein (59) 8 Val (V) Ile (I) Ile (I) Ile (I) Ile (I)
13 Ala (A) Val (V)
ORF5 (11146-11913) GP5 (255) 6 Val (V) Ala (A)
70 Asp (D) Asn (N) Asn (N)
73 Ile (I) Val (V) Val (V)
82 Asp (D) Asn (N)
84 Tyr (Y) His (H) His (H)
ORF6 (11901-12389) M (162) 66 Val (V) Phe (F)
ORF7 (12313-12645) N (110) - - - - - - - - - - - - - - - - -
Amino Acid SubstitutionsAmino Acid Substitutions
Open Reading 
Frames (ORFs) 
Protein (aa length)
Amino Acid Substitutions Amino Acid Substitutions
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Supplementary table 2.4. Serum neutralization test titers of mAbs against semen viruses of EAV KY84 strain from both 
experimentally and naturally infected stallions during acute and persistent infection periods 
5G11 6D10 7E5 10F11 1H7 1H9 5E8 6A2 7D4 10B4 3E2 12A4
L136 d5 16 16 16 <16 <16 <16 <16 32 <16 16 <16 <16
L136 d9 16 16 64 16 <16 <16 <16 64 <16 <16 <16 <!6
L136 d107 16 <16 <16 <16 <16 <16 <!6 16 <16 <16 <16 <16
L136 d170 <16 <16 <16 <!6 <16 <16 <16 32 <!6 16 <16 <16
L136 d380 32 256 512 1024 <16 <16 <16 512 <16 <16 <16 <16
L136 d548 32 64 128 512 <16 <16 <16 256 <16 <16 <16 <16
L136 d726 16 16 16 256 16 <16 <16 <16 <16 <16 <16 <16
L139 d5 <16 <16 <16 <16 <16 <16 <16 <16 <16 <16 <16 <16
L139 d9 16 <16 16 16 <16 <16 <16 16 16 16 <16 <16
L139 d107 32 32 32 32 <16 <16 <16 64 <16 <16 <16 <16
L139 d170 32 16 32 16 <16 <16 <16 64 <16 <16 <16 <16
L139 d345 16 16 32 128 <16 <16 <16 128 <16 16 16 16
L140 d5 16 <16 <16 128 64 <16 <16 128 <16 32 32 <16
L140 d9 32 32 64 32 16 <16 <16 32 <16 <16 16 <16
L140 d107 <16 <16 <16 <16 <16 <16 <16 16 <16 <16 <16 <16
L140 d170 <16 <16 <16 16 <16 <16 <16 16 <16 <16 <16 <16
L140 d380 <16 64 64 16 <16 16 <16 16 <16 <16 <16 <16
L140 d548 64 128 128 256 <16 16 <16 128 <16 <16 <16 <16
L140 d726 16 512 128 2048 16 <16 <16 1024 <16 16 <16 <16
L141 d5 32 16 32 <16 16 Ab toxic <16 64 Ab toxic Ab toxic Ab toxic <16
repeated 16 16 <16 <16 <16 <16 16 <16 <16 <16 <16
L141 d9 16 <16 16 <16 16 16 <16 32 <16 16 32 <16
L141 d107 32 64 2048 16 16 16 <16 64 16 32 32 <16
repeated <16 16 <16 <!6 <16 <16 32 <16 <16 <!6 <!6
L141 d170 16 16 32 32 <16 16 <16 256 <16 Ab toxic 16 <16
repeated 16 16 <16 <16 <16 <16 16 <16 <16 <16 <16
L141 d345 <16 <16 16 16 <16 <16 <16 <16 <16 <16 <16 <16
L142 d5 32 16 32 Wrong <16 32 <16 256 16 16 16 <16
repeated <16 32 <16 <16 <16 <16 32 <16 <16 <16 <16
L142 d9 16 16 16 <16 <16 <16 <16 32 16 16 16 16
L142 d107 32 256 128 32 32 <16 <16 128 <16 <16 <16 <16
L142 d170 16 32 128 128 <16 <16 <16 64 <16 16 16 <16
EAV KY84 2048 4096 2048 2048 <16 <16 <16 <16 <16 <16 <16 <16
EAV VBS 1924 8192 1024 4096 64 <16 <16 256 <16 <16 <16 <16
EAV ARVAC 256 1024 128 1024 <16 <16 <16 <16 <16 <16 <16 <16
EAV KY84 D84 2048 2048 256 4096 <16 <16 <16 128 <16 <16 <16 <16
EAV KY84 D94 64 512 64 64 <16 <16 <16 <16 <16 <16 <16 <16
EAV KY84 E84 32 <16 <16 32 <16 <16 <16 <16 <16 <16 <16 <16
EAV KY84 E91 1024 2048 256 4096 16 <16 <16 64 <16 <16 <16 <16
EAV Strain
Neutralizing mAbs Control mAbs
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Supplementary table 2.5. Serum neutralization test titers of polyclonal equine antisera against semen viruses of EAV KY84 strain 
from both experimentally and naturally infected stallions during acute and persistent infection periods 
Control Serum
d14 d726 Anti-KY53 Anti-KY84 Anti-ARVAC Anti-EAVNVSL NVSLNEG
L136 d170 1:64 1:32 1:128 1:128 1:8 <1:4 1:8
L136 d380 1:32 1:16 1:32 1:32 1:8 <1:4 1:4
L136 d548 1:8 1:16 1:16 1:16 <1:4 <1:4 <1:4
L136 d726 1:16 1:16 1:32 1:32 1:16 <1:4 <1:4
EAV KY84 1:16 1:32 1:16 1:64 <1:4 <1:4 <1:4
EAV VBS 1:128 1:128 1:64 1:64 <1:4 1:4 <1:4
EAV ARVAC 1:128 1:64 1:128 1:128 <1:512 1:32 <1:4
L139 d5 1:4 1:8 1:16 1:16 1:8 <1:4 <1:4
L139 d345 1:16 1:8 1:32 1:64 1:8 <1:4 <1:4
EAV KY84 1:16 1:32 1:8 1:16 <1:4 <1:4 <1:4
EAV VBS 1:32 1:32 1:64 1:256 <1:4 1:4 <1:4
EAV ARVAC 1:256 1:64 1:128 1:256 1:128 1:16 <1:4
L140 d5 1:4 1:16 1:8 1:8 1:4 <1:4 <1:4
L140 d170 1:4 1:8 1:8 1:8 <1:4 <1:4 <1:4
L140 d380 1:4 1:16 1:8 1:16 <1:4 <1:4 <1:4
L140 d548 1:8 1:8 1:8 1:16 1:4 <1:4 <1:4
L140 d726 1:16 1:16 1:64 1:64 1:4 <1:4 <1:4
EAV KY84 1:8 1:32 1:16 1:64 <1:4 <1:4 <1:4
EAV VBS 1:128 1:16 1:32 1:256 <1:4 1:32 <1:4
EAV ARVAC 1:16 1:32 1:64 1:64 1:256 1:8 <1:4
L141 d170 1:8 1:8 1:8 1:16 <1:4 <1:4 <1:4
L141 d345 1:16 1:16 1:8 1:32 <1:4 <1:4 <1:4
EAV KY84 1:8 1:8 1:4 1:32 <1:4 <1:4 <1:4
EAV VBS 1:256 1:128 1:128 1:64 <1:4 <1:4 <1:4
EAV ARVAC 1:256 1:128 1:128 1:256 1:128 1:8 <1:4
L142 d107 1:32 <1:4 1:16 1:8 <1:4 <1:4 <1:4
L142 d170 1:64 1:32 1:8 1:16 <1:4 <1:4 <1:4
EAV KY84 1:64 1:32 1:8 1:32 <1:4 <1:4 <1:4
EAV VBS >1:512 1:128 1:64 1:128 <1:4 1:4 <1:4
EAV ARVAC 1:128 1:258 1:128 1:128 1:128 1:16 <1:4
EAV Strain
Isolate Equine Sera Polyclonal Equine Antisera
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Supplementary table 3.1. Primers used for reverse transcription and PCR amplification 
Numbers Primer Polarity Position Nuleotide sequence (5'-3')
1 BN1P + 1-21 GCTCGAAGTGTGTATGGTGCC
2 BD501P + 501-520 CTTGAGCTGTTGCAACACCC
3 JQ548N - 548--568 CTTGCCTCTTCAATGGCTAAC
4 BD800N - 800-781 AGTTCGTTGTTCGCGGTAGT
5 JQ1100N - 1124-1103 AGCCAACTCATCATCACACCAC 
6 JQ1524P + 1524-1542 CAGGCGCCCATCCCAGCACC
7 JQ2106N - 2140-2121 ACAGTGCAAGGAACATAAGC
8 JQ4002P + 4002--4021 CTGATTGATGGCTTATCCAA
9 BD4546N - 4546-4527 GGCGGTGACACTCTCTTTCA
10 JQ4600N - 4619-4600 GTCATCATCAGTGAGGGCAG
11 JQ6077P + 6077-6096 GCTGACATCAGCTGTGACGC
12 JQ6577N -
13 JQ9745P + 9745-9767 CGTGTGATGGGCTTAGTGTGGTC
14 BD10330N - 10330-10311 TTGGCCTAGCGTTGGCATAA
15 BD10449P + 10449-10468 TAATGTCACCTTCCCGTCGC
16 BD10507N - 10507-10488 CTACAAAATCTTGCGCCGCG
17 BD10621N - 10621-10602 AGCATACACAGTGACAGGCC
18 BD10764P + 10764-10783 TGCACTTTCTACCCATGCCA
19 BD11148N - 11148-11125 GTTGAGCCCAACGTACCAGT
20 BN11220P + 11187-11207 GCCATCACATGCTTACTTCTC
21 UB11255P + 11272-11293 GCCAATTTGCTGCGATATGATG
22 BD11284N - 11284-11264 GCAGCAAATTGGCAATAACGC
23 BD11361P + 11361-11380 AGTCATCACCTTCGGCACAG
24 BD11619P + 11619-11638 TGTACAGCGGGGCTTACTTG
25 BD11800N - 11800-11781 GCAACTGGCAAACTGGGATC
26 N11877P +
27 BN12707N - 12698-12679 TTGGATCCTGGGTGGCTAATAACTACTT
28 UB12296P +
29 BD12322N - 12305-12286 TTACCAACTGCGGTGTACCC
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Supplementary table 3.2. List of total clinical specimens from two male donkeys and 
results of EAV confirmation test 
Virus isolation qPCR Virus isolation qPCR 
Epididymis 1* -** + (very weak) - -
Epididymis 2* + (1 pfu each in 3 of 4 flasks) - - -
Prostate 1* + (1-4 pfu in all 4 flasks) - - -
Prostate 2* + (1 pfu each in 3 of 4 flasks) - - -
Vas deferens 1* + (1.35x10E4pfu/mL in all 4 flasks) + - -
Vas deferens 2* + (2.15x10E4pfu/mL in all 4 flasks) + (very weak) - -
Seminal vesicles 1* + (1 pfu in 1 of 4 flasks) - - -
Seminal vesicles 2* + (5.2x10E1pfu/mL in all 4 flasks) - - -
Conjunctival swab 1 -** - - -
Donkey 7634 Donkey 7635 Animal ID           
Clinical specimens
 
*1 mL of 10% tissue suspension into 4 x 25-cm
2
 flasks of RK-13 (KY) cells. All virus 
isolations detected on 1st passage in cell culture  
**Negative for virus after 3 blind passages in RK-13 (KY) cells 
 
Supplementary table 3.3. Partial GP5 sequence identities (%) of the novel EAV donkey 
VD7634 strain to EAV donkey reference strains 
Nucleotide position of partial GP5 located at 11,295-11,812 (518 bp in length) 
Strain in GenBank with the 
highest similarity 
Nucleotide 
identity (%)
Amino acid 
identity (%)
Origin
GenBank accession 
number 
J1-931125 81.5 93.0 RSA |AY956596.1|
J2-931125 81.5 93.0 RSA |AY956597.1|
J3-931209 81.5 93.0 RSA |AY956598.1|
J4-931209 81.5 93.0 RSA |AY956599.1|
 J7-931125 81.5 93.0 RSA |AY956602.1|
J5-940309 81.3 93.0 RSA |AY956600.1| 
J6-940309 81.3 93.0 RSA |AY956601.1|
1489V/96 74.7 86.6 Italy |AF099829.1|
3308V/96 74.3 86 Italy |AF099830.1|  
*Republic of South Africa (RSA) 
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Supplementary table 3.4. Nucleotide and amino acid sequences of average pairwise identity of EAV donkey VD7634 compared to 
29 full-length EAV strains  
Average pairwise 
identity of nucleotide 
alignment (%) n=2
Average pairwise 
identity of aimino acid 
alignment (%) n=2
Average pairwise 
identity of nucleotide 
alignment (%) n=5
Average pairwise 
identity of aimino acid 
alignment (%) n=5
Average pairwise 
identity of nucleotide 
alignment (%) n=4
Average pairwise 
identity of aimino acid 
alignment (%) n=4
Average pairwise 
identity of nucleotide 
alignment (%) n=18
Average pairwise 
identity of aimino acid 
alignment (%) n=18
Full length - - - 75.37 - 75.15 - 75.36 - 75.35 - 75.41 -
5' TTR - 1-230 - 67.56 - 66 - 67.62 - 66.68 - 67.91 -
Leader sequence 1-211 - - - - - - - - - - -
ORF1a 1a polyprotein 231-5405 1724 72.91 84.12 72.55 84.2 72.72 83.88 72.95 84.05 72.99 84.19
ORF1b - 5402-9748 1448 75.29 88.4 75.35 88.6 75.2 88.34 74.98 88.68 75.37 88.34
ORF1ab
1ab 
polyprotein 
231-9748 3172 74 - 73.8 - 73.86 - 73.85 - 74.09 -
nsp1 231-1010 260 78.16 88.41 77.35 89.4 89.12 77.2 77.9 87.8 78.57 88.23
nsp2 1011-2714 568 65.55 70.72 65.6 71 65.16 69.6 65.68 71.55 65.62 70.81
nsp3 2715-3412 232 75.74 90.19 75.7 89.7 75.18 89.2 76.65 90.3 75.71 90.5
nsp4 3413-4025 204 74.37 37.81 73.45 35.8 75.74 40.1 73.86 40.1 74.21 37.33
nsp5 4026-4511 162 78.37 91.86 77.05 92 76.7 92.48 77.45 90.55 79.18 91.97
nsp6 4512-4577 22 82.47 92.33 79.55 90.9 89.56 95.5 84.8 95.5 90.9 80.3
nsp7 4578-5252 225 76.2 93.18 76.15 94.2 76.56 94.7 75.2 92.53 76.32 92.79
nsp8 5253-5402 50 74.48 94.7 74.7 92 75.46 91.62 78.7 94 73.24 96
nsp9 5253-7330 693 75.38 44.62 75.25 43.8 75.34 43.34 75.65 44.58 75.34 45.08
nsp10 7331-8731 467 75.8 90.63 75.8 89.5 75.68 90.6 75.15 90.75 75.98 90.74
nsp11 8732-9388 219 74.83 84.95 75.55 84.95 74.56 84.68 74.08 85.7 74.99 84.86
nsp12 9389-9742 118 73.27 85.31 73.3 86.6 73.92 85.96 73.3 85.7 73.08 84.9
Slippary 
sequence 
5398-5404 - - - - - - - -
ORF2a E 9748-9951 67 80.96 78.45 81.15 82.1 81.02 80.06 80.4 80.6 81.04 77.6
ORF2b GP2 9821-10504 277 83.46 87.39 82.3 87.2 83.36 88.68 83.45 85.03 83.61 87.57
ORF3 GP3 10303-10794 163 78.17 74.21 78.75 73.3 78.28 72.24 81.08 77.9 77.44 74.03
ORF4 GP4 10697-11155 152 77.99 84.06 77.2 82.25 78.72 82.14 78.28 83.75 77.81 84.86
ORF5a ORF5a 11109-11288 59 91.09 87.05 89.4 84.7 92.72 89.84 92.08 87.68 90.6 86.4
ORF5 GP5 11143-11910 255 78.1 86.1 78.1 86.1 78.34 84.84 77.78 84.1 78.09 85.28
ORF6 M 11898-12386 162 83.83 86.98 83.4 86.4 83.98 87.7 83.75 86.4 83.86 86.97
ORF7 N 12310-12642 110 88.97 95.67 89.05 95.95 88.68 94.04 89.28 94.28 88.97 96.4
3' TTR - 12643-12703 - 80.92 - 81.7 - 83.3 - 81.7 - 80 -
EAV donkey and CW strains (EU-1) EAV donkey and French strains (EU-2) EAV donkwy and NA strains (NA) EAV donkey and S numbered strains (EU-1)
ORF Protein 
EAV donkey 
VD7634 strain 
nucleotide position 
(bp) 
EAV donkey 
VD7634 strain 
protein length 
(aa)
Average pairwise identity 
of nucleotide alignment 
(%) n=29
Average pairwise identity 
of aimino acid alignment 
(%) n=29
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Supplementary table 3.5. Percent homology (%) of nucleotide and amino acid 
sequences of EAV donkey VD7634 compare to 29 full-length EAV strains used for bar 
graph  
(A) nsp2 (B) GP3 (C) Partial GP5
EAV 
donkey 
VD7634
nt (%) aa (%)
EAV 
donkey 
VD7634
nt (%) aa (%)
EAV donkey 
VD7634
nt (%) aa (%)
CW01 65.4 70.8 CW01 79.4 73.9 RSA J7-931125 81.5 93.4
CW96 65.8 70.8 CW96 78.1 72.7 RSA J3-931209 81.5 93.4
F27 65.4 70.8 F27 79.4 73.7 RSA J2-931125 81.5 93.4
F62 65.1 70.8 F62 77.3 70.5 RSA J1-931125 81.5 93.4
F63 65 70.8 F63 77.3 71.1 RSA J6-940309 81.3 93.4
F61 65.3 70.8 F61 77.8 72.1 RSA J5-940309 81.3 93.4
F60 65 70.8 F60 79.6 73.8 RSA J4-931209 81.5 93.4
S3583 65.7 70.8 S3583 77.7 74.3 Italy 3308V/96 74.3 86.7
S3817 65.7 70.8 S3817 77.7 74.3 Italy 1489V/96 74.7 86.7
S4216 65.7 70.8 S4216 77.7 74.3 CW01 74.1 85.5
S3685 65.6 71 S3685 77.5 74.3 CW96 75.3 85.5
S3854 65.6 71 S3854 77.5 74.3 F27 73 84.3
S3711 65.5 71 S3711 77.1 73.7 F62 73.6 84.3
S3712 65.5 71 S3712 77.3 73.7 F63 73.9 84.3
S3699 65.7 70.6 S3699 77.3 74.3 F61 74.3 84.9
S3961 65.7 70.6 S3961 77.3 74.3 F60 74.3 84.9
S4333 65.6 70.6 S4333 77.7 74.3 S3583 74.7 84.9
S4227 65.5 70.8 S4227 77.6 73.7 S3817 75.1 85.5
S3886 65.6 71.7 S3886 77.5 74.3 S4216 74.7 85.5
S4421 65.6 71.7 S4421 77.5 73.7 S3685 74.3 84.9
S3943 65.7 71.5 S3943 77.5 74.3 S3854 74.3 84.9
S4445 65.7 71.3 S4445 77.5 74.3 S3711 74.3 84.9
S3861 65.6 70.1 S3861 76.9 73.1 S3712 74.3 84.9
S4007 65.5 69.5 S4007 77.3 73.1 S3699 74.3 84.9
S4417 65.7 69.3 S4417 77.3 74.3 S3961 74.7 85.5
HK25 65.7 68.8 HK25 81.2 78.2 S4333 74.5 84.9
HK116 65.6 70.3 HK116 80.9 78.2 S4227 74.7 84.9
Bucyrus 65.7 71 Bucyrus 81.4 78.2 S3886 74.1 85.5
ARVAC 65.7 71 ARVAC 80.8 77.0 S4421 74.4 85.5
1900.9 2050.8 2267.1 2152 S3943 74.5 84.9
65.5483 70.7172 78.17586 74.2069 S4445 74.1 84.3
S3861 74.3 84.9
S4007 73.9 83.1
S4417 74.5 84.9
HK25 73.7 83.7
HK116 73.4 82.5
Bucyrus 73.9 84.3
ARVAC 72.2 80.7
2870.5 3280.9
75.53947 86.33947
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Supplementary table 3.6. Comparative amino acid substitutions of ORF5 of EAV 
donkey VD7634 to 29 full-length EAV strains and SNT result mAb that explains Figure 
3. 4. 
EAV other 
strains/isolates
Donkey
aa 49         
(site A)
None - -
aa 61        
(site B)
1 61 K E
All of EAV S numbered isolates and NA strains are very different to EAV 
donkey VD7634 strain 
? E EAV F61-63 straisn (? Is undetermined amino acid sequence from GenBank)
Q E EAV F27 strain
R E EAV F60 strain
F E EAV CW01 isolate
V E EAV CW96 isolate
aa 67-90 
(site C)
13 67 V T
All of EAV S numbered isolates and French strains are very different to EAV 
donkey VD7634 strain 
E T EAV S3817, S4227, S4216, S3961, S4417, S4445 and S4007 isolates
? T EAV F60 strain (? Is undetermined amino acid sequence from GenBank)
T T NA and CW strains 100% identity to EAV donkey VD7634 strain
69 P L EAV ARVAC strain
70 N D EAV S4417 and S4007 isolates
71 D E EAV CW01 isolate
72 K Q EAV ARVAC strain
73 I V
S3699, S3861, S3712, S3711, S3854, S3685, S3583, S3886, S3817, S4216, 
S4007, F60 and NA strains are very different to EAV donkey VD7634 strain
? V EAV F61 strain (? Is undetermined amino acid sequence from GenBank)
V V Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
79 D G Rest strains are very different to EAV donkey VD7634 strain   
G G
EAV S3886, S4421 and CW strains  are 100% identity to EAV donkey VD7634 
strain
81 D N EAV HK116, HK25, and ARVAC (laboratory NA strains)
82 D N Rest of all strains are different to EAV donkey VD7634 strain 
N N
EAV S3817, S4216, S3961 and S4417 isolates and F60-61 strains are 100% 
identity to EAV donkey VD7634 strain
84 D Y EAV S4007 isolate
I Y EAV F27, F60-63 strains and CW01 isolate
F Y EAV CW96 isolate 
Y Y Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
85 T S EAV S4007 and S4445 isolates
A S EAV F27, 60-63 and NA strains
S S Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
89 A S
All EAV NA strians (HK25, HK116, Bucyrus and ARVAC) are differnet to EAV 
donkey VD7634 strain 
S S Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
90 T V all S numbered EAV isolates are different to EAV donkey VD7634 strain  
E V
All EAV NA strians (HK25, HK116, Bucyrus and ARVAC) are differnet to EAV 
donkey VD7634 strain 
? V
EAV F62 and F63 strains (? Is undetermined amino acid sequence from 
GenBank)
L V EAV F27 strain
V V EAV F60, F61, CW01, CW96 are 100% identity to EAV donkey VD7634 strain
aa 98-106 
(site D)
4 100 G S EAV HK116 and ARVAC strains are differnet to EAV donkey VD7634 strain 
S S Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
101 V T Rest of all strains are very different to EAV donkey VD7634 strain 
T T CW96 and CW01 strains are 100% identity to EAV donkey VD7634 strain
104 G D EAV HK116 and ARVAC strains
D D Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
106 V M EAV ARVAC strain
M M Rest of all EAV strains are 100% identity to EAV donkey VD7634 strain
Amino acid substitution  
Variant sequences of EAV strains (Description)
Amino acid 
substitution 
position 
Specific 
amino acid 
substitution 
site in GP5 
Amino 
acid 
change 
numbers
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APPENDIX 4 
Experimental Methods 
Our standard laboratory protocol for commonly used tissue culture media recipes  
Rabbit kidney-13 high passage and low passage from Dr. William McCollum, UKY 
Laboratory designated name: RK-13 HP #399-409 and RK-13 LP #194-204 
Eagle’s minimum essential medium (EMEM;              500 mL 
with Earle’s salts and L-glutamine; GIBCO# 11095-080) 
Cosmic calf serum 10% (HYCLONE# SH30087.03)               50 mL 
Penicillin and streptomycin (GIBCO# 15140-122)         5 mL 
 
Rabbit kidney 13 (ATCC# CCL-37) 
Laboratory designated name: CCL-37-RK13 
Eagle’s minimum essential medium (EMEM;                    500 mL 
with Earle’s salts and L-glutamine; GIBCO# 11095-080)    
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)    50 mL 
Penicillin and streptomycin (GIBCO# 15140-122)       5 mL 
1.0 mM Sodium pyruvate (100 mM [100X]; GIBCO# 11360-070)     5 mL 
0.1 mM Non-essential amino acids (10 mM [100X]; GIBCO# 11140-050)    5 mL 
 
Equine pulmonary artery endothelial cells (EPAEC) 
Laboratory designated name: EPAEC, currently EEC 
Dulbecco’s modified Eagle medium (DMEM;         1 L 
With high glucose [4.5 g/L], without L-glutamine; CELLGRO# 15-013-CM) 
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)             110 mL 
Penicillin and streptomycin (10,000 U/mL and μg/mL; GIBCO# 11140-050) 11 mL 
0.1 mM Non-essential amino acids (10 mM [100x]; GIBCO# 11140-050)  11 mL 
2 mM L-glutamine (200 mM [100X]; GIBCO# 25030)    10 mL 
 
Equine derm cells (ATCC# CCL-57) 
Laboratory designated name: ED (Equine derm) 
Eagle’s minimum essential medium (EMEM;               500 mL 
with Earle’s salts and L-glutamine; GIBCO# 11095-080)    
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)    50 mL 
Penicillin and streptomycin (GIBCO# 15140-122)       5 mL 
1.0 mM Sodium pyruvate (100 mM [100X]; GIBCO# 11360-070)     5 mL 
0.1 mM Non-essential amino acids (10 mM [100X]; GIBCO# 11140-050)    5 mL 
 
Baby hamster kidney-21 (ATCC# CCL-10) 
Laboratory designated name: BHK-21 
Eagle’s minimum essential medium (EMEM;                500 mL 
with Earle’s salts and L-glutamine; GIBCO# 11095-080)    
Fetal bovine serum 10% (FBS; HYCLONE# SH30396.03)     50 mL 
Tryptose phosphate broth (TPB)        50 mL 
Penicillin and streptomycin (GIBCO# 15140-122)        5 mL 
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Cell lines grown with EMEM 10% FSCS in incubator without CO2 
Rabbit kidney-13 high passage and low passage (RK-13 HP #399-409 and RK-13 LP 
#194-204) from Dr. William McCollum, UKY, Equine derm cells (ATCC Cat# CCL-57) 
and Baby hamster kidney-21 (ATCC Cat# CCL-10) 
 
10 L stock cell culture media, EMEM 10% FSCS 
Materials  
Eagle’s minimum essential medium (EMEM;          10 L/bottle 
NEAA, L-glutamine; MEDIATECH #50-011-PB; 10 L/bottle)               
Ferritin supplemented calf serum (FSCS; HYCLONE# SH30072.03)         1,000 mL 
Penicillin and streptomycin (10,000 U/mL and μg/mL; GIBCO# 11140-050)        100 mL 
Fungizone (SIGMA A-9528; one vial)      10 mL 
 Fungizone (Amphotericin B; 1,000 μg/mL)     50 mg 
 Sterile distilled water        50 mL 
Dissolve fungizone in dH2O and dispense in 10 mL aliquots. Store at -20°C 
Unreconstituted vial should be stored at 4°C 
Sodium bicarbonate (NaHCO3; SIGMA# S5761-500 g)      6.0 g 
Glass fiber prefilter (MILLIPORE# AP2012450) 
Durapore
®
 membrane filters (0.45 μm; MILLIPORE# HVLP14250)  
 
Materials in order 
EMEM           96.1 g 
NaHCO3             6.0 g 
Penicillin and streptomycin                  100 mL 
Fungizone (Amphotericin 1,000 μg/mL)                  10 mL 
Ferritin supplemented calf serum (FSCS)             1,000 mL 
dH2O (tissue culture grade water)                       q.s. to 10,000 mL  
 
Method 
1. Autoclave and sterilize the containers, filter with membrane filters, hose, 12 
bottles (1 L). 
2. Add 8 L dH2O to 12 L bottle wit stir bar. 
3. Place on stirrer/hotplate and turn stirrer to setting #3. Make sure stir bar is 
standing middle in the bottom of 12 L bottle. 
4. Add EMEM bottle quickly without losing powder. Rinse twice with dH2O. Let it 
mix well until dissolved in about 15 min. 
5. Add sodium bicarbonate (color should change from yellow to red), penicillin and 
streptomycin, fungizone and serum (rinse each container twice with dH2O). 
6.  Final concentration of penicillin and streptomycin 100 U/mL and 100 μg/mL and 
fungizone 1 μg/mL.  
7. Instead of #4-5, anti-anti (1 bottle [100X GIBCO# 15240]) can be used.  
8. Add dH2O to 10 L and mix 5 min. 
9. In cell culture room, filter through sterile Millipore filter unit using a prefilter. 
Dispense 1 L/sterile 1 L bottle.  
10. Perform sterility check. Store at 4°C. 
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Carboxymethylcellulose (CMC) overlay media (1.3X EMEM 10% FSCS) 
Materials 
Carboxymethylcellulose, medium viscosity (SIGMA# C4888)             6.0 g 
Distilled water (dH2O)                 140 mL 
 
Method 1 
1. Add 140 mL of dH2O to a 1 L bottle (12), swirl while adding 0.75% 
carboxymethylcellulose (CMC) and then shake if necessary. 
2. Let stand (12 bottles) overnight at room temperature (shake occasionally). 
3. Autoclave for 20 min at 121°C (liquid setting). 
4. When cooled to approx. 40°C, add filtered 1.3X EMEM 10% FSCS to the 800 
mL mark. 
 
10L stock CMC overlay media (1.3X EMEM 10% FSCS) 
Materials  
EMEM           96.1 g 
NaHCO3             6.0 g 
Penicillin and streptomycin                  100 mL 
Fungizone (Amphotericin 1,000 μg/mL)                  10 mL 
Ferritin supplemented calf serum (FSCS)             1,000 mL 
dH2O (tissue culture grade water)                         q.s. to 7,800 mL 
 
Method 2 
Prepare method 1 a day before making the CMC stock  
Prepare EMEM 10% FSCS by following the protocol except start with 6 L dH2O and q.s. 
to 7.8 L 
 
5. Shake the bottle to dissolve cooled carboxymethylcellulose dilution. 
6. Perform sterility check. Store at 4°C. 
7. Before using, add 0.8 mL gentamicin/bottle (working concentrationg – 50 μg/mL). 
 
Virus transport medium  
Hanks’s balanced salt solution with phenol red 1X (INVITROGEN# 14170112) 500 mL 
HEPES buffer (final concentration 25 mM; INVITROGEN# 15630080)            20 mL 
Bovine serum albumin V (final concentration 0.5%; SIGMA# A9647)           2.5 g 
Antibiotic-Antimycotic (100X, Penicillin, Steptomycin & Amphotericin B;             5 mL 
INVITROGEN# 15240112) 
Gentamicin sulfate (final concentration 250 mg/L; CELLGRO# 30-005-CR)        2.5 mL 
  
Freezing media 
Dimethylsulfoxide (DMSO; SIGMA# D-2650)     10% 
EMEM 10% FSCS         90% 
 
Method 
5 mL of DMSO + 95 mL of complete medium (depending on which cell lines) 
Generally, 1 x 10
6
 cell/mL DMSO/1vial 
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Or 
Recovery
TM
 cell culture freezing medium (GIBCO# 12648-010) 
Cells from T-75 = averages 8.4 x 10
6
 cells/mL DMSO/1vial, makes 5 vials 
 
Dublecco’s phosphate-buffered saline (PBS) 
Materials 
PBS (GIBCO# 21600-069)      95.5 g (1 bottle) 
Sterile distilled water (dH2O)             q.s. to 10,000 mL 
 
Method 
1. Add 9 L dH2O to 12 L bottle with stir bar. Place on stirrer/hotplate and turn stirrer 
to setting #3. Make sure stir bar is standing middle in the bottom of 12 L bottle. 
2. Add PBS bottle quickly (rinse twice with water) and mix for 10 min. 
3. Distribute evenly into each 1 L bottle 1 L for about 800ml. Autoclave the PBS 
contained bottles for 20 min at 121°C (liquid setting). 
4. Cool bottles down to room temperature before tightening caps and labeling. 
Perform sterility check. Store at room temperature. 
 
Trypsin EDTA solution (0.5%) 
Materials 
PBS (sterile 1X)              180 mL (900 mL) 
Trypsin EDTA (no phenol red [10X]; GIBCO# 15400-054)           20 mL (100 mL) 
 
Aliquot out 45 mL in 50 mL conical tube and store at -20°C (for long term) and store at 
4°C (for current use). 
 
Guinea pig complement  
Material 
100 mL/bottle (ROCKLAND# C300-0100).  
 
Method 
Thaw and dispense (on ice) into 1 or 2 mL volumes and store at -70°C. 
 
Antibiotics for cell culture  
Gentamicin MEDIATECH# 30-005-CR 
Gentamicin sulfate, 50 mg/mL, 10 mL/vial and store at 4°C 
 
Fungizon SIGMA A-9528 
Amphotericin B (1,000 μg/mL) 
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C 
 
Penicillin/Streptomycin GIBCO# 11140-050 
10,000 μg/mL Pen and 10,000 μg/mL Strep 
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C 
 
Antibiotic-Antimycotic (Anti-Anti 100X) GIBCO# 15240 
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L-Glutamine 100X GIBCO 25030 
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C 
 
MEM NEAA 100X GIBCO 11140 MEDIATECH #50-011-PB 
Aliquot out 11 mL in 15 mL conical tubes and store at -20°C 
 
Miscellaneous 
70% Ethanol  
  95% Ethanol    dH2O    Total     
      147 mL     53 mL             200 mL 
      368 mL   132 mL            500 mL 
    2,944 mL            1,056 mL          4,000 mL 
 
Roccal 
Maintain at 1:1200 dilution (20 mL of Roccal : 4 L of dH2O) 
 
Our standard laboratory protocol for commonly used bacterial media recipes 
Liquid media 
LB Medium (Luria-Bertani Medium; 500 mL) 
Materials 
Deionized water                 500 mL 
Bacto-trypto            5 g 
Bacto-yeast extract                   2.5 g 
NaCl             5 g 
 
Method 
1. Stir until the solutes have dissolved. Adjust the pH to 7.0 with 5N NaOH. 
2. Sterilize by autoclaving for 20 min on liquid cycle. 
 
Psi Broth (500 mL) 
Materials 
Bacto-trypto             5 g 
Bacto-yeast extract         2.5 g 
NaCl              5 g 
5 mM MgSO4 
10 nM KCl 
dH2O                 to 500 mL 
Autoclave liquid cycle 30 min. 
 
Media containing agar 
LB Agar plates 
Materials 
Deionized water                   500 mL 
Bacto-trypto             5 g 
Bacto-yeast extract         2.5 g 
NaCl              5 g 
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Method 
1. Prepare LB medium according to the above recipe. Just before autoclaving, add 
7.5 g of Bacto agar. Sterilized by autoclaving for 20 min on liquid cycle. 
2. When the medium is removed from the autoclave, swirl it gently to distribute the 
melted agar throughout the solution (need to be very careful, the media may bio 
over when swirled). Allow the medium to cool to 45-50°C before adding 
antibiotic*.  
3. To avoid air bubbles, mix the medium by swirling. Pour 20-25 mL of medium in 
a petri dish (use the tissue culture hood and florescent light should be off). 
4. When medium has hardened completely, invert the plates and wrap in aluminum 
foil and store them at 4°C until needed. The plates should be removed from 
storage 1-2 hours before they are used and allow them to dry.  
 
*Antibiotics solutions 
Antibiotic     Working concentration    
Ampicillin      50 μg/mL 
Streptomycin     50 μg/mL 
Tetracycline     50 μg/mL 
Kanamycin     50 μg/mL 
Carbenicillin     50 μg/mL 
Chloramphenicol     170 μg/mL 
 
Stock solutions should be stored at -20°C. Avoid repeated freezing thawing and exposure 
to light. Magnesium ions are antagonists of tetracycline. Use media without magnesium 
salts for selection of bacteria resistant to tetracycline.  
 
Our standard laboratory protocol for commonly used solutions and buffers for 
molecular biology 
0.5 M EDTA (pH 8.0) 
Deionized water                    115 mL 
EDTA (di-sodium)              27.918 g 
5N NaOH               15,825 μL 
Bring the volume to 150 mL with deionized water 
 
5.0 M Sodium chloride 
NaCl                  29.22 g 
Distilled water                     100 mL 
 
1M Tris HCl(pH 8.0) 
Tris HCl  Tris base   Molarity 
4.44 g/1 mL  2.65 g/1 mL  0.05 M 
88.8 g/1 mL  53.0 g/1 mL    1.0 M 
8.88 g/100 mL 5.30 g/100 mL    1.0 M 
17.76 g/200 mL 10.6 g/200 mL   1.0 M 
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1M Tris HCl (per liter) 
Tris base          121.1 g 
Add deionized water to 800 mL 
Desired pH                 Volume of HCl 
pH 7.4          70 mL 
pH 7.6          60 mL 
pH 8.0          42 mL 
Add deionized water to 1 L 
 
TE buffer  
pH 8.0    pH 7.6    pH 7.4  
10 mM Tris HCl (pH 8.0) 10 mM Tris HCl (pH 7.6) 10 mM Tris HCl (pH 7.4) 
  1 mM EDTA (pH 8.0)     1 mM EDTA (pH 8.0)     1 mM EDTA (pH 8.0) 
 
TAE (Tris-acetate; 50X concentrated stock solution [per L]) 
Tris base          242 g 
Glacial acetic acid        57.1 mL 
0.5 M EDTA (pH 8.0)       100 mL 
Deionized water        q.s.  
Working concentration 1X (dilute 10 mL in 490 mL of deionized water) 
 
TAE (50X to 1X) 
50mL of 50X TAE buffer + 1960 mL dH2O = 2 L 
 
TAE (10X to 1X) 
200 mL of 50X TAE buffer + 1800 mL of dH2O = 2 L 
100 mL of 50X TAE buffer + 900 mL of dH2O = 1 L 
50 mL of 50X TAE buffer + 450 mL of dH2O = 500 mL 
 
Ethidium bromide (EtBr; 10 mg/mL) 
Method 
1. EtBr in agarose: 5.0 μL of EtBr (10 μg/μL) solution per 100 mL of agarose. 
2. EtBr staining solution (1XTAE with 0.5 μg/mL EtBr): 25 μL of EtBr stock 
solution in TAE buffer. 
 
25 bp ladder (INVITROGEN# 10597-011) 
25 bp DNA ladder (1 μg/μL)           50 μL 
6X loading buffer        100 μL 
Nuclease free water        450 μL 
 
100 bp ladder (INVITROGEN# 15628-019) 
100 bp DNA ladder (1 μg/μL)        50 μL 
6X loading buffer        100 μL 
Nuclease-free water        450 μL 
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1 Kb ladder (INVITROGEN# 15615-024) 
1 Kb plus DNA ladder (1 μg/μL)          50 μL 
6X loading buffer        100 μL 
Nuclease-free water        450 μL 
 
PCR products 
PCR products          10 μL 
6X loading buffer           2 μL 
 
PCR products to estimate concentration 
PCR products            2 μL 
6X loading buffer           2 μL 
Nuclease-free water           8 μL 
 
Our standard laboratory protocol for commonly used stains 
Crystal violet stain (10X stock solution) 
Crystal violet (MALLINCKRODT# 8839)       12 g 
Methanol (FISHER# A412-20)      600 mL 
 
Method  
Large volume of crystal violet (10X stock)  
1. Measure 1200 mL of methanol, add 24.0g of crystal violet  
2. Stir well with a pipet. Aliquot equally 400 mL to 1 L bottles (3)  
3. Store at room temperature 
 
Crystal violet stain (working solution) 
1 part of crystal violet (stock solution)     100 mL 
9 parts of 10% buffered formalin (FISHER 23-245-685)   900 mL 
 
Our standard laboratory protocol for commonly used antibodies 
EAV specific antibodies  
Monoclonal antibodies  Protein specificity/epitope location 
5G11      GP5/102 and 104 [D] 
6D10      GP5/99 [D] 
7E5      GP5/102 [D] 
10F11      GP5/ND [D] 
1H7      GP5/49 [A] 
1H9      GP5/69 [C] 
5E8      GP5/61 [B] 
6A2      GP5/69 [C] 
7D4      GP5/69 [C] 
10B4      GP5/62-101 deleted [C and D] 
Control monoclonal antibodies 
3E2       N 
12A4       nsp1 
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Polyclonal equine sera 
Anti-ARVAC      NA 
Anti-VBS      NA 
Anti-KY84      NA 
Anti-CW96      NA 
Anti-EAV NVSL positive    NA 
Anti-EAV NVSL negative     NA 
 
Our standard laboratory protocol for commonly used for tissue culture techniques 
Maintenance of continuous cell line  
Materials  
Trypsin EDTA (keep in the water bath for few min at 37°C) 
Confluent T-75 flask of cells 
Appropriate cell culture medium 
 
Method 
1. Check the cell under the microscope to verify cells are confluent and ready to be 
passaged (3-7 days old). 
2. Pour off media from the flask. 
3. Rinse cells 2-3 times with PBS (pH 7.4). 
4. Add 1 mL (25-cm2 flask; T-25), 2 (3) mL (75-cm2 flask; T-75), 4 (5) mL (150-cm2 
flask; T-150) trypsin-EDTA, and rock gently for 30 sec, then let the flask(s) sit at 
room temperature for 1 min. 
5. Pour off trypsin-EDTA (optional) and incubate the flask(s) another 7-8 min at 
37°C. 
6. When cells are visualized on the bottom of flask, bang the flask hard to remove 
cells. 
7. (Option) Add media (T-25: 5 mL; T-75: 10 mL; T150: 20 mL) into flask and 
aliquot out into conical tube. Centrifuge it at 800 rpm for 5 min to get the cell 
pellet. Throw the media out in the conical tube and break the pellet cell by collide 
with pipet tube. Add fresh EMEM media (T-25: 8 mL; T-75: 10 mL; T-150: 20 
mL) and mix it well to evenly distribute 1:5 dilution of the cell into new flask. Fill 
up the fresh EMEM media to appropriate amount of media up to 10 mL (T-25), 
30 mL (T-75), 60 mL (T-150). 
8. Add appropriate amount of media (EMEM 10% FSCS for 1:5 split) up to 10 mL 
(T-25), 30 mL (T-75), 60 mL (T-150). 
 
Once a week split cells: 150-cm
2 
flask with confluent RK-13 cells is made up to approx. 
300 - 335 mL EMEM 10% FSCS.  
10 mL (T-25), 30 mL (T-75), 60 mL (T-150) 
Note: to get a confluent monolayer within 24-36 hours transfer 2 mL of cell suspension 
into a T-75 flask and add 20 mL of complete medium to the flask (1:5 split). 
Generally one T-75 flask is sufficient to seed five 96-well plates for neutralization or 
microtitration assays. 
For specific cell lines: One T-75 flask of RK-13 cells (confluent) is sufficient within 3-4 
days for 96-well plates. 
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Freezing cells 
Materials 
Freezing medium 
Cells in log phase of growth 
Trypsin EDTA (keep in the water bath for few min at 37°C) 
Nalgene
TM
 Cryo 1°C freezing container (NALGENE# 5100-0001) 
 
Method 
1. Pour off the media.  
2. Add 3-4 mL of trypsin EDTA solution and rinse the cells (this is to remove the 
fetal bovine serum). 
3. Add 3-4 mL of fresh trypsin EDTA solution and leave it for 3-4 min (preferably 
at 37°C) and bang on the flask to detach the cells from the surface. 
4. Add 10-12 mL of complete medium (the medium contains 10% fetal bovine 
serum and this will inhibit trypsin) and pour into a 50 mL conical tube. 
5. Centrifuge at 1,100 or 1,300 rpm (200 x g) in a tabletop centrifuge for 5 min at 
25°C. 
6. Aspirate the supernatant and resuspend the cell pellet in freezing medium at 
approx. 10
7
 cells/mL.  
7. Freeze cells first in NalgeneTM Cryo 1°C freezing container with isopropanol at -
80°C for 1 day. 
8. Transfer frozen cell vials to liquid nitrogen container.  
 
Recovery of frozen cells 
Materials 
Frozen cells (-70°C) in aliquots 
Growth medium 
 
Method 
1. Rapid thawing of the cells is necessary. Thaw the cells in the water bath at 37°C, 
by swirling the tube (do not submerge the lid to avoid contamination of the cells). 
2. Resuspend in 15 mL of growth medium and centrifuge at 1,200 or 1,300 rpm (200 
x g) in a tabletop centrifuge for 5min at 25°C. 
3. Aspirate the supernatant and resuspend the cells in 10 mL of growth medium. 
Transfer the cell suspension into a T-75 flask and add 10 mL of medium. Incubate 
at 37°C for 2-3 days. 
 
Our standard laboratory protocol for commonly used classical virology techniques 
Processing of nasal swabs for virus isolation 
Materials 
10 mL syringes 
Autoclaved plastic forceps 
0.45 μm syringe filter CORNING#431220 or MILLIPORE Millex#SLHA033SB 
1.7 mL screw cap tubes SARDSTEDT# 72.694.996 (color) #72.694.006 (clear) 
15 mL conical tubes 
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Method 
1. Thoroughly swab the nasopharyngeal area with a sterile rayon swabs (1/2” x 1”) 
with plastic shafts (16”). 
2. After collection, the rayon tip of each swab is cut off into 7 mL of virus transport 
medium (Hank’s balanced salt solution with penicillin, streptomysin, gentamicin 
sulfate and amphotericin B; LIFE TECH). 
3. Squeeze the swab to recover maximum amount of media and centrifuge at 300 x g 
for 10 min to remove debris. 
4. Transfer individual nasal swabs in transport medium to the barrel of a 12 mL 
disposable syringe and express through 0.45 μm syringe filter (Millipore). 
5. Collect the filtrate into a 15 mL conical tube. Bring up the sample volume to 7 
mL with plain MEM to normalize samples (e.g. after filtration usually approx. 6 
mL is recovered). Leave approx. 2 mL for virus isolation and aliquot the 
remaining filtrate (approx. 1 mL x 2) into tubes. Freeze at -70°C until tested. 
6. Aspirate off media from confluent RK-13 cells in 6-well plates and inoculate 500 
μL specimen/well in duplicate. 
7. Incubate plates at 37°C in presence of 5% CO2 for 1-2 hours. 
8. Add 10 mL CMC overlay to each flask and incubate at 37°C in the presence of 5% 
CO2 for 5 days.  
9. Do second passage on day 4 using the same cells. Stain cells on day 5 with crystal 
violet. Archive the TCF at -80°C.  
 
Processing of buffy coat for virus isolation (without gradient purification) 
Method 
1. Draw blood by venipuncture into vacutainer tubes containing sodium citrate or 
EDTA and mix thoroughly. 
2. Allow blood to stand for 1-2 hours or sediment at 600-700 rpm (100 x g) for 10 
min at 4°C. Remove layer and sediment at 2,000 rpm for 10 min at 4°C. The few 
red blood cells in pellet cause no apparent concern.  
3. Aspirate off supernatant; resuspend pellet in 5 mL EMEM 10% FSCS and vortex 
thoroughly. If desired, pellet can be washed with PBS before resuspending in 
EMEM media. Freeze or inoculate.  
4. Process as in steps 5-8 above. 
For buffy coat from the EDTA tube   
1. Centrifuge 700 rpm for 10 min at 4°C. You will see plasma, white blood cells 
and red blood cells from top to bottom in the tube.  
2. Centrifuge 2,000 rpm for 10 min at 4°C.  
3. Remove yellow top plasma and save white blood cells at the bottom (pellet 
cell).  
4. Add 5 mL of media, mix it well.  
5. Aliquot out 0.5 mL for DNA extraction and save rest.  
6. 1 mL goes for RK-13 LP, RK-13 HP and EEC cells for virus isolation.  
 
Collecting PBMC from buffy coat 
Peripheral blood mononuclear cell (PBMC) 
 
 201 
1. Spin the sample at 700 rpm for 10 min (1st). 
2. Remove plasma only. 
3. Spin plasma for 1,900 rpm for 10 min (2nd). 
4. Pour out the plasma. Break and mix PBMC (pellet cell) with MEM.  
5. Aliquot out in 1.5 mL tube.  
6. Freeze at -80°C. 
 
Serum processing  
Materials 
Vacutainer needles  
Vacutainer adapters (TERMUNO, VENOJECT II# P-1316R) 
15 mL BD vacutainer tubes (KENDALL MONOJECT [no additive]# 8881 301819) 
1.7 mL screw cap tubes (SARDSTEDT# 72.694.006) 
Transfer disposable pipets for serology (SAMCO SCIENTIFIC# 202-1S) 
 
Methods 
1. Collect blood into vacutainer tubes via jugular venipuncture (about 15 mL blood). 
2. Transport blood tubes to the lab. Spray tubes with diluted Roccal-D (1:200). 
Rinse tubes and dry with paper towel. Let stand at room temperature for 4-5 hours 
or for 1 hour at 37°C (water bath works faster). 
3. Sediment blood cells at 2,000 rpm (300 x g) for 10 min. 
4. Collect serum and aliquot into tubes (1.4 mL x 4). Freeze at -20°C until tested for 
virus or antibody. 
5. Process as in steps 5-8 above.  
   
Virus isolation from semen 
Protocol 
1. Thaw 15 mL tube containing semen sample in warm tap water, then place on ice.  
2. Label 8 flasks (T-25) [4 RK-13 (KY) ”high passage” and 4 RK-13 (ATCC-
CCL37)”low passage”]/semen, 2x10
-1
, 1x10
-2
, 1x10
-3
 for high passage and 2x10
-1
, 
1x10
-2
, 1x10
-3
 for low passage.  
3. Sonicate (output 20 #4.5 on dial) samples on ice 3 x 15 sec; let vials set on ice for 
15 sec. 1 min between sonications (dilute small volumes to 5 mL). Clean 
sonicator probe with 95% EtOH 2X between each sample. Spin 300 x g (1,900 
rpm) for 10 min to remove sperm and debris, save and use supernatant (SSP). 
4. Set up 3 tubes (10-1 to 10-3) for each sample, 4.5 mL EMEM 10% FSCS per tube.  
5. Aspirate off media from T-25 (3-6 day old RK-13 monolayers). Do not rinse. 
Make 10
-1
 (0.5 mL sample in 4.5 mL diluent), vortex; with new pipet add 0.5 mL 
of 10
-1 
to tube #2 (10
-2
) and 1 mL to each of 4 flasks marked 10
-1
. Continue the 
same way with dilutions 10
-2
 and 10
-3
 (2 flasks each). 
      
 10
-1   
        10
-2   
       10
-3
 
(2.7) 4.5 mL EMEM (2.7) 4.5 mL EMEM (2.7) 4.5 mL EMEM 
(0.3) 0.5 mL SSP (0.3) 0.5 mL SSP (0.3) 0.5 mL SSP 
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6. Incubate all flasks at 37°C in air incubator (incubator without CO2) with caps 
closed for 1 hour (2 hours maximum). 
7. Add 10 mL of CMC overlay to each flask and incubate at 37°C in air incubator 
(incubator without CO2) with caps closed. 
8. Check for CPE on day 4. If bacterial contamination occurs, redo after 
bacteriological examination and sensitivity testing to find out which antibiotics to 
used in the tissue culture media. Repeat test as above and also note contamination. 
Specimen may be filtered through a 0.45 μm filter using 5 or 10 cc syringe, if 
necessary. 
9. If negative, a second passage is performed on day 4 (2nd passage). 
10. If sample is toxic, this material is passaged as is (2nd passage). 
11. If positive, supernatant is usually harvested from a 10-2 flask showing viral 
activity (store at -20°C) and a reverse SNT is performed against known positive 
and negative sera (see reverse SNT). 
12. After 5 days harvest supernatant from flasks and stain flasks with crystal violet 
using 2 mL crystal violet (working stock). Stain 1-24 hours, remove stain, rinse 
flasks with tap water and read.  
13. All semen samples are placed in freezer zip lock storage bags and stored at -70°C.  
14. Permanently store negative SSP at -20°C and positive SSP at -70°C. 
 
Second passage  
1. Aspirate media from 2 “high passage” and 2 “low passage” confluent 3-5 day old 
RK-13 cells in T-25 flasks for each negative semen sample. 
2. From 2 flasks of 10-1 passage #1 take up 0.5 mL from each with same pipet (1 mL) 
and add 1 mL to the new flask for each high and low passage. Do the same for 10
-
2
 passage #1, taking up 1 mL from each. Do 10
-1
 to 10
-2
 only. Close caps and 
incubate at 37°C for 1-2 hours (minimum 1 hour) in air incubator.  
3. Add 10 mL of CMC overlay to all flasks, close caps, and incubate at 37°C in air 
incubator (without CO2). 
4. Read after 3-4 days. 
5. After 4 days, harvest media and stain flasks (see passage #1). 
 
Preparation of working virus stock  
Materials 
EAV  
Five confluent monolayers of RK-13 cells in T-150 flasks 
EMEM 
RK-13 medium 
50 mL conical centrifuge tubes 
Freezing vials  
 
Method  
1. Inoculate monolayers with EAV at an m.o.i. of 1. Resuspend the virus in 
approximately 50 mL of serum-free MEM and add 10 mL per T-150 flask. 
2. At the same time mock infect one T-75 flask of RK-13 cells. 
3. Adsorb for 1 hour at 37°C. 
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4. Add 40 mL of complete RK-13 medium / T-150 flask. Incubate at 37°C for 48 
hours or until 95-100% CPE.  
5. Centrifuge at 5,000 g (or 3,000 rpm in the tabletop centrifuge) at 4°C for 15 min. 
6.  Make 1.8 mL and 0.5 mL aliquots of supernatant and store at -70°C. 
7. Use one 0.5 mL frozen vial to titrate the virus. 
 
Preparation of high titer virus stock 
Method 
1. Seed cells into 3, triple-deck flasks and grow until confluent.  
2. Remove the medium and leave approx. 50 mL of complete medium 
contaminating 10% fetal bovine serum. Add 500 μL/mL of virus per flask. If the 
titer of the virus is known use an m.o.i. of 1 (higher m.o.i. will may produce 
deletion mutants).  
3. Adsorb for 1 hour at room temperature on the orbital shaker. 
4. Add 20-40 mL of complete medium containing 10% fetal bovine serum and 
incubate at 37°C for 3-4 days. Check for signs of infection 2 days after the start of 
infection. 
5. Pellet down the cellular debris (3,000 rpm/4°C/15 min) and aliquot into freezing 
vials and store at 4°C (stable for up to 6 months) or -70°C (for long term storage). 
Virus should be stored away from the fluorescent lights since the virus titer 
appears to decrease when exposed to fluorescent light for a prolonged period of 
time.  
6. Determine the virus titer using the plaque assay procedure.  
 
Microtitration assay for estimation of virus titers  
Materials 
96-well microtitration plates (FALCON#3072) 
Sterile snap cap tubes (FISHER or FALCON#2054) 
Multi channel pipette (8 or 12 channels) 
Antiserum or ascetic fluid (monoclonal antibodies) 
Negative control serum or control ascetic fluid 
EMEM (BIOWHITTAKER) 
Complete RK-13 medium 
Confluent RK-13 cells (one T-75 flask is sufficient for five 96-well plates) 
Virus stock to be titrated 
Crystal violet staining (working solution) 
 
Method 
1. Each test virus is done in triplicate. Label the 96 well plates with cell controls. 
2. Dilute the test virus from 10-1 to 10-8 in EMEM (10-fold serial dilution). Use 200 
μL of virus and 1800 μL of EMEM. 
 
  10
-1   
           10
-2 
    ...Continue...
    
10
-8   
 
1800 μL EMEM 1800 μL EMEM 1800 μL EMEM 
  200 μL Virus   200 μL Virus   200 μL Virus 
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3. Add 50 μL of EMEM to all the wells except to control wells (column 10, 11 and 
12) where 100 μL of EMEM should be added. 
4. Trypsinize a confluent T-75 flask or RK-13 cells and resuspend the pellet in 10 
mL of RK-13 cell medium. Take 2 mL of the cell suspension and resuspend in 10 
mL (1:5) of RK-13 medium (or 4 mL in 20 mL would be better. This gives 
enough volume to work). 
5. Add 50 μL of diluted virus to test wells in triplicate. Start with the highest dilution 
(10
-8
) and go to the lowest dilution (10
-1
; therefore, can use the same pipet tip). 
6. Add 100 μL of resuspended RK-13 cells to each well. Incubate at 37°C for four 
days. 
7. Feed the plates with 50 μL of growth media on day 2 and day 3 (if necessary) to 
maintain monolayers. 
8. When CPE occurs (usually 4 days), dump out the media into infectious waste 
container and stain with crystal violet (1X working solution) for 20-30 min and 
then wash gently with tap water to remove excess crystal violet (three times). Air 
dry plates and determine titer by Reed and Munch method.  
9. 50% end point values, by Reed and Munch Method. Underlined numbers indicate 
logarithmic characteristic of end point dilution. In triplicates. 
3 – 2 – 0 – 0 = 0.25   3 – 1 – 2 – 0 = 0.5  
 3 – 2 – 1 – 0 = 0.5   3 – 1 – 3 – 0 = 0.2  
 3 – 2 – 2 – 0 = 0.0   3 – 0 – 0 – 0 = 0.5 
 3 – 2 – 3 – 0 = 0.3   3 – 0 – 1 – 0 = 0.7 
 3 – 1 – 0 – 0 = 0.75   3 – 0 – 2 – 0 = 0.8 
 3 – 1 – 1 – 0 = 0.0   3 – 0 – 3 – 0 = 0.0 
10. Report virus titers as TCID50 per 50 μL.  
 
Plaque assay  
Materials 
6-well plates  
RK-13 cells 
Carboxymethylcellulose (CMC) overlay media (1.3X EMEM 10% FSCS) 
Virus for titration 
Method  
1. Prepare RK-13 cell in 6-well plates 
2. Make virus dilution (10-1 to 10-8) in complete 10% EMEM growth media. 
3. Aspirate the medium and add 200 μL of diluted virus to each well in duplicate 
(start from 10
-8 
and go to 10
-1
). Mix gently by rocking the plate.  
4. Incubate the plate at 37°C for 1 hour to allow virus particles to adsorb into cells.  
5. Following 1 hour incubation period, overlay cells with 4 mL (per well) of CMC 
overlay media adding to the side of the plate. 
6. Allow plates to sit undisturbed on a leveled surface for 4 days until visible 
plaques develop.  
7. After 4 days, discard supernatant and stain with crystal violet staining solution.  
8. Count >10 to <100 plaques per well.  
9. PFU/mL – (number of plaques in each well [duplicate]/2) x (highest dilution that 
gives number of plaques) x (dilution factor). 
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10. E.g. [(25 + 30)/2] x 10-5 x 5 (200 μL) = 137.5 x 10-5 = 1.37 x 10-7 PFU/mL. 
 
Our standard laboratory protocol for commonly used serology technique 
Serum neutralization test (SNT) 
Method 
1. Inactivate sera at 56°C for 30 min. 
2. Label plate, tube after calculate working dilution depends on result of 200 TCID50 
titration. Ex) 50 μL x 96 well plate = 4800 μL = 5 mL / plate needed 
Ex) Virus: 10
5.5
 200 TCID50 / 50 μL 
200/1E5.5 (log10) -3.19 (round up to -3.20) = 1E3.20 = 1584 = 1/1600  
3. Dilute the virus to 1/1600 for total volume: 30 mL (4 plates)  
1/100 (1/10) 1/100 (1/4) 1/400 (1/2) 1/800 (1/2) 1/1600 
200 μL Virus 1 mL 
 
5 mL 
 
10 mL 
 
15 mL 
1800 μL  MEM 9 mL 
 
15 mL 
 
10 mL 
 
15 mL 
4. Prepare back titration (virus working dilution [w]) 
               10
-1   
      10
-2   
   10
-3   
 
100 μL Virus 900 μL  900 μL  
900 μL MEM 100 μL  100 μL  
5. Label 4 plates, depends on number of antibodies. Antibody dilution starts at 1:4. 
Duplicate the antibody and virus. Triplicate may used including toxicity control. 
 
6. Add 50 μL of 1XMEM to plate, except add 100 μL on cell control by using 
multichannel pipet (6 or 12 channels). 
7. Add 50 μL acitis (Ab) by single channel pipet individually. Then, mix 10 times by 
multichannel pipet. 
8. Add 50 μL virus (final working dilution).  
a. Pour working dilution stock into reservoir. 
b. Load with multichannel pipet. 
9. Incubate 30 min at 37°C in CO2 incubator.  
10. During incubation, prepare cells (use 10% EMEM FSCS). 
a. 30 mL for 1 T-75 flask will make 4 plates. 
b. 40 mL for 4 T-25 flask will make 4-5 plates. 
11. Pour cells in reservoir. Use multichannel pipet.  
a. Add 50 μL to plates. 
b. Except, add 100 μL to cell control. 
12. After 24 hour incubation, add 50 μL of EMEM FSCS to all plates. 
13. Stop assay when working dilution (w) is showing 100% CPE.  
A B C D E F G H A B C D E F G H
1 1:16 1 Back titration Cell control
2 1:32 2 w -1 -2 -3
3 1:64 3
4 1:128 4
5 1:256 5
6 1:512 6
7 1:1024 7
8 1:2048 8
9 1:4096 9
10 1:8192 10
11 1:16384 11
12 1:32768 12
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 Virus neutralization test (VNT) 
Method 
1. Inactivate sera at 56°C for 30 min. 
2. Put 25 μL of serum diluent (10% GP complement in EMEM 10% FSCS [keep on 
ice until needs]) in all wells. 
3. Put 25 μL of test serum to the first well of three rows (including row for checking 
toxicity*). Dilute with 25 μL multichannel pipet.  
4.  Add 25 μL of virus (200 TCID50) diluted in EMEM 10% FSCS to all wells 
except control (“see cell controls”). 
5. Incubate plates at 37°C (5% CO2 incubator). Read after 48 hours, and do final 
read at 72 hours.  
“Cell controls”: positive or negative sera and virus titration controls 
Cell controls: add 50 μL serum diluent to 2 wells.  
Serum controls: add 25 μL serum diluent to 1 well/each test serum, add 25 μL test 
serum. Known positive or negative serum: set up in same way as test sera.  
 
Virus titration 
Add 25 μL serum diluent into each of 4 wells for cell controls (Row#1).  
Add 25 μL of working virus dilution to each of 4 wells (Row#2). 
Add 25 μL of 1:10 dilution of working virus in EMEM 10% FSCS to each of 4 wells 
(Row#3). 
Add 25 μL of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 
wells (Row#4). 
Add 25 μL of 1:100 dilution of working virus in EMEM 10% FSCS to each of 4 
wells (Row#5). 
Add 125 μL of trypsinized cells to all 20 wells.  
*If serum is toxic in serum control well (1:4 dilution), then repeat test with a row to 
check for toxicity.  
 
Reverse SNT for EAV verification – confirmation test  
Materials  
Known positive serum, inactivated and diluted 1:4 in PBS (should come from field 
sample(s), not from vaccinated horses) 
Known negative serum inactivated and diluted 1:4 in PBS 
Stock virus (Virulent Bucyrus strain) 
Unknown virus isolate 
 
 
Method 
1. Add 0.3 mL of known negative serum to 4 tubes for each virus sample to be 
tested (including stock virus). 
2. Add 0.3 mL of known positive serum to 3 tubes for each virus sample to be tested 
(including stock virus). 
3. Make up 1:10 dilution of guinea pig complement in EMEM 10% FSCS with 
antibiotics (10 mL for each sample). 
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4. Make up 10-1 to 10-5 dilutions of all virus samples to be tested using 1.8 mL of 
media in #3 and 0.2 mL of virus (It may be necessary to dilute stock virus to 10
-3 
before starting these dilutions).   
5. To positive serum (3 tubes), add 0.3 mL of 10-1, 10-2 and 10-3 virus dilutions. 
6. To negative serum (4 tubes), add 0.3 L of 10-3, 10-4 and 10-5 virus dilutions. 
7. Incubate serum-virus mixture for 1 hour at 37°C.  
8. 14 of T-25 flasks [7 RK-13 (KY) “high passage” and 7 RK-13 (ATCC-CCL37) 
“low passage”] are used for each virus to be tested. Aspirate off media from 3-5 
day RK-13 flasks and add 0.25 mL of above serum-virus mixture to 2 
flasks/dilution. 
9. Incubate for 2 hours at 37°C (closed caps, no CO2), rock flasks after 1 hour.  
10. Add 10 mL of CMC overlay/flask. Incubate for 4-5 days according to 
development of CPE, remove media, and stain with crystal violet plaque stain.  
 
Treatment of serum with toxicity due to (Duvaxyn) antibodies to RK-13 cells 
This procedure has been used successfully to eliminate (or reduce to readable at 1:4) 
toxicity from serum samples demonstrating the vaccine-induced “European” toxicity at 
1:4 and greater in the EAV SNT. These horses have been vaccinated with Duvaxyn EHV 
1 and 4 (the EHV-1 component is made in RK-13 cells).  
Always treat a known negative and a known positive serum whenever this treatment is 
performed on toxic serum specimens. Preferably, use serum that has not been previously 
inactivated. Use sterile technique for the following method below.  
 
Method 
1. Decant growth media from as flask or 7-10 day old RK-13 (KY) cells (P399-409). 
Wash the flask three times by 10 mL of PBS. Add 1 mL trypsin EDTA/flask, rotate 
to spread over cell monolayer, then incubate approx. 6-8 min at 37°C. 
2. When cells have detached, add 2 mL EMEM with 10% FSCS/flask. Mix well with 5 
mL pipet, and then divide between three 1.5 mL microcentrifuge tubes.  
3. Spin tubes at 20,000 rpm for 15 sec in microcentrifuge. Use a Pasteur pipet to 
remove and discard all supernatant.  
4. Add 0.5 mL of toxic serum or control serum per tube; mix with pipet until cells are 
resuspended; label tube appropriately. Incubate for 1 hour at 37°C. Flick tubes after 
30 min to resuspend.  
5. Spin 2,500 rpm for 15 sec. Use a Pasteur pipet to transfer each serum to a new, 
labeled 1.5 mL microcentrifuge tube.  
6. Inactivate at 56°C for 30 min if serum has not been inactivated previously. Proceed 
with EAV SNT test, running sera (toxic, negative, positive) as usual and in pre-
seeded (planted 18-24 hours prior) plates. 
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Our standard laboratory protocol for commonly used molecular 
biology/recombinant DNA techniques 
Primer design 
The approach for designing of specific and efficient primers remains somewhat empirical; 
there are no hard and fast rules. With experience and by using a good primer designing 
program (e.g. MacDNASIS v3.5; Hitachi) the majority of the primers can be made to 
work. Following are some guidelines to design specific and efficient primers. 
 
1. Where possible, select primers with an average G+C content of around 50%. 
2. Where possible, select primers with a random base distribution. Try to avoid 
primers with stretches of polypurines, polypyrimidines, or other unusual 
sequences.  
3. Melting temperature (Tm) should be between 55-57°C. 
Increasing the Tm therefore, the annealing temperature enhances discrimination 
against incorrectly annealed primers and reduces misextension of incorrect 
nucleotides at the 3′-end of the primers. Therefore, increasing the annealing 
temperature will help to increase the specificity. An applicable annealing 
temperature is 5°C below the true Tm of the amplification primer. The best 
annealing temperatures is in the range of 55-72°C. Quick way to calculate 
annealing temperature is:  
Annealing temp (°C) = (# of A and T [A+T] x 2 + # of G and C [G+C] x 4)-5°C.  
4. Try to design both positive and negative primers with same Tm (1-2°C difference 
will not matter).  
5. Make sure the primer ends (3′) with a G or C. 
6. Primer length should be between 19 and 30 bases (19 to 22 bases are preferred). 
7. If possible select a unique area of the genome to design the primer.  
8. Avoid sequences with significant secondary structure (computer programs are 
very useful for this). 
9. Check the primers against each other for complementarily. Avoiding primers with 
3′ overlaps will reduce the incidence of “primer-dimer” artifacts. 
10. If possible do a simple homology matching (compare the primers with the whole 
genome using a computer program) and see whether primer(s) have <50% 
homology in the area closer to be amplified (or to be desired area). This will 
reduce the number of nonspecific products of same size. 
 
Agarose gel electrophoresis  
Materials 
Agarose (SEAKEM
®
 LE agarose; FMC BIO PRODUCTS) 
50X TAE buffer (Tris Acetate EDTA, pH 8.0) 
Gel casting plate 
Gel sealing tape 
Buffer tank 
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Method 
1. Make 1,000 mL of 1X TAE, by measuring 20 mL of 50X stock into a 1,000 mL 
graduated cylinder and q.s. to 1,000 mL mark with deionized water. 
2. Weight 1 g of agarose (for 1% gel) and dissolve it in 100 mL of 1X TAE. Melt 
agarose solution in microwave until completely dissolved. Let stand at room 
temperature (or at 45°C in a water bath) to remove air bubbles but not enough to 
solidify. 
3. Prepare gel-casting plate by taping the ends with gel sealing tape. Place the 
sample comb in the proper position on the plate. 
4. Pour 100 mL of 1% agarsoe on to the gel casting plate slowly and allow it to 
solidify (volume of agarose needed depends on the size of the gel casting plate). 
The gel should be between 0.3 and 0.5 cm thick. After gel has set, final gelling 
carried out at 4°C for 30 min. There should not be any air bubbles in the gel. 
5. Remove the tapes and keep the gel plate in the buffer tank. Add 1X TAE buffer 
into the reservoirs until it covers the surface of gel at a depth of 3-4 mm. 
6. Slowly remove the sample comb and load the samples into the wells (Mix 1-20 
μL of RNA or DNA with 6X gel loading buffer; loading volume depends on the 
sample and make sure gel loading buffer get diluted to 1X with sample).  
7. Voltage 70V for 2-3 hours (95V for 45-60 min) or until the first band has 
migrated at least 2.5 inches away from the wells. The voltage must never exceed 
100V. For low melt Agarose use low voltage (70V). Always run the gel in 
constant voltage. 
8. Stain gel in ethidium bromide, letting it sit for 5-10 min. Destain gel by placing in 
deionized distilled water for 5 min. 
9. Transfer the gel onto a UV light source. Usually, a transilluminator is used to 
facilitate this step. Place a piece of plastic wrap between the gel and surface of the 
illuminator. Use a face shield, gloves and body shield to minimize the UV 
exposure. Take a picture for records.  
10. Locate the DNA or RNA bands and excise by using a sharp scalpel blade (e.g. to 
obtain the desired band).  
11. Range of separation in gels containing different concentrations of agarose.  
% agarose (% [w/v]) Efficient range of separation of linear DNA molecules (Kb) 
 0.3     5-60 
 0.6     1-20 
 0.7     0.8-10 
 0.9     0.5-7 
 1.2     0.4-6 
 1.5     0.2-3 
 2.0     0.1-2 
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Viral RNA extraction 
Followed manufacturer’s recommended protocol 
 
Total viral RNA extraction 
Material 
MagMax-96 viral RNA isolation kit (THERMO FISHER# AM1836) 
Purpose: Purification of viral RNA (and DNA) from clinical specimens (e.g.) to do 
reverse transcription (RT) PCR amplification. 
Materials 
Kit storage condition 
 
Amount Component Storage Temperature (°C) 
1 unit Processing Plate & Lid Room temperature 
16.0 mL Lysis/binding concentration Room temperature 
36.0 mL Wash solution 1 
(Add 12mL of Isopropanol) 
4°C 
40.0 mL Wash solution 2 
(Add 32mL of 100% ethanol) 
4°C 
9.0 mL Elution buffer 4°C 
1.1 mL RNA binding beads 4°C 
125 μL Carrier RNA -20°C 
1.1 mL Lysis/Binding Enhancer -20°C 
 
Required materials that not included with kit 
RNase Zap (RNA remover) 
100% Ethanol, Isopropanol 
96-well plates magnetic stand 
96-well U-bottom plate & lids 
96-well plates shaker  
General use needs (e.g. pipette, tips) 
 
Protocol 
1. Prepare your Lysis/Binding Solution preparation: 
Specimens 
Lysis/Binding 
Soln. Conc.  
Carrier 
RNA 
100% 
Isopropanol 
Total 
Volume 
(μL) 
13 845  13 845 1703 
a. Calculate the total volume of lysis/binding solution per your sample number. 
b. Add 13 μL l of lysis/binding solution in each cell by single channel pipet. 
2. Prepare your Bead Mix preparation: 
Component 
Per Reaction 
(μL) 
Specimens 
Total volume  
(μL) 
RNA Binding Beads 10 13 130 
Lysis/Binding Enhancer 10 13 130 
a. Make 2 extra per your number of samples. 
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b. Add 20 μL of bead mix in each cell by single channel pipet on well A 
3. Add 150 μL of Wash Buffer 1 into row B and C using by 300 multichannel 
pipette. 
4. Add 150 μL of Wash Buffer 2 into row D and E using by 300 multichannel 
pipette. 
5. Add 50 μL of Elution Buffer into row F using by 300 multichannel pipette. 
6. Add 50 μL of your RNA sample into row A in the hood room. 
7. Turn the machine and add Combs above the plate in the machine. 
8. RNA extraction machine takes about 30 min to extract the RNA. 
9. Turn off your machine, and aliquot out your RNA in row F. 
10. Aliquot out your negative control in each cell at the end of plate. If you are 
running negative sample, add your positive sample at the end of plate. 
11. Turn on your RNA extraction machine in Sheila's lab, click "start" button twice. It 
takes about 30 min to extract your RNA. 
 
MagMax-96 viral RNA isolation kit (THERMO FISHER# AM1836) 
Materials 
Add 12 mL of 100% isopropanol to the wash solution 1 
Add 32 mL of 100% ethanol to wash solution 2 
Carrier RNA and Lysis/binding solution are stored at -20°C. 
 
Reagent preparation  
Mix 1 μL of carrier RNA + 65 μL of lysis/binding solution + 65 μL of isopropanol / 1 
sample 
Mix 10 μL of RNA binding beads + 10 μL of lysis/binding enhancer / 1 sample  
 
Method 
1. Add 50 μL sample to 130 μL lysis/binding solution. 
a. Pipet 130 μL of lysis/binding solution (carrier RNA and isopropanol are 
added). 
b. Transfer up to 50 μL of sample. Avoid aerosol cross contamination. 
c. Shake plate for 1 min on orbital shaker. 
2. Add 20 μL beads and mix for 5 min. 
a. Vortex bead mix. 
b. Add 20 μL of beads. Mix to each sample. 
c. Shake the plate for 5 min to lyse viruses and bind RNAs to RNA binding 
beads. 
3. Capture RNA binding beads and carefully discard the supernatant.  
a. Move processing plate to magnetic stand to capture RNA binding beads. 
Leave the plate for 3 min. RNA binding beads will form pallets. 
b. Carefully, discard the supernatant without disturbing beads. 
4. Wash twice with 150 μL of wash solution 1. 
a. Add 150 μL of wash solution 1. Shake the place for 1 min. 
b. Processing plate on magnetic stand for 1 min. 
c. Discard supernatant without disturbing beads carefully. 
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d. Remove processing plate off the magnetic stand. Repeat 4a. to 4c. second 
time with 150 μL of wash solution 1. 
5. Wash twice with 150 μL of wash solution 2. 
a. Repeat 4a. to 4d. with wash solution 2. 
6. Dry the beads by shaking plate for 2 min to allow remaining from wash solution 2. 
If there is residual solution, shake the plate for another 2 min. 
7. Elute the RNA/DNA in 20-50 μL of elution buffer. 
a. Add 20-50 μL elution buffer, shake vigorously for 3 min. 
b. Capture the RNA binding beads. The purified RNA will be in the 
supernatant.  
c. Transfer the supernatant (contains RNAs) to nuclease-free container. Store 
the purified RNA at -80°C.  
 
RNA extraction protocol for Next-generation sequencing prep 
Materials 
Norgen Biotek Total RNA purification Kit (NORGEN BIOTEK# 17200 - 50 prep) 
Buffer RL    40 mL 
Wash Solution A   38 mL 
Elution Solution A     6 mL 
Mini Spin Columns   50 
Collection Tubes   50 
Elution tubes (1.7 mL)   50 
Product Insert    1 
 
Customer-Supplied Reagents and Equipment 
Benchtop microcentrifuge 
96-100% Ethanol 
B-mercaptoethanol (optional) 
 
Protocol 
1. Cell Lysate Preparation from Plasma/Serum. 
a. 1.0 mL of sample vial centrifuged at 9,000 g force at 4°C (in walk-in room) 
for 20 min, discard the pellets. 
b. Transfer the supernatant, and then use 200 μL of the sample for RNA 
extraction. 
c. Add 700 μL of Lysis Solution. Lyse viral-infected cells by vortexing for 15 
sec. Ensure that mixture becomes transparent before proceeding to the next 
step. 
d. Add 400 μL of 100% ethanol and mix by vortex for 10 sec. 
2. Binding RNA to Column. 
a. Assemble a column with one of the provided collection tubes. 
b. Apply up to 600 μL of the lysate with the ethanol (from step 1) onto the 
column and centrifuge for 1 min (3,500 x g).  
Note: If the entire lysate volume has not passed, spin for an additional minute 
at 14,000 x g 
c. Discard the flow through. Reassemble the spin column with its collection tube. 
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d. Depending on your lysate volume, repeat Step 2b and 2c as necessary. 
Optional step: For maximum removal of residual DNA that may affect 
sensitive downstream application, use One-Column DNA Removal Protocol 
(Norgen's RNase-Free DNase I Kit#25710) 
 
3. Column Wash. 
a. Apply 400 μL of 100% ethanol to the column and centrifuge for 1 min. 
b. Discard the flow through and reassemble the spin column with its collection 
tube 
c. Repeat steps 3a and 3b to wash column a second time. 
d. Wash column a third time by adding another 400 μL of 100% ethanol. 
e. Discard the flow through and reassemble the spin column with its collection 
tube. 
f. Spin the column for 2 min in order to thoroughly dry the resin. Discard the 
collection tube. 
4. RNA Elution. 
a. Place the column into a fresh 1.7 mL Elution tube provided with the kit. 
b. Add 50 μL of Elution Solution A to the column. 
c. Centrifuge for 2 min at 200 x g, followed by 1 min at 14,000 x g. 
Note: If the entire 50 μL has not been eluted, spin the column at 14,000 x g 
for 1 additional min. 
5. Storage of RNA. The purified RNA sample may be stored at -80°C for long-term 
storage. 
 
cDNA synthesis 
Followed manufacturer’s recommended protocol 
 
Synthesis of first cDNA strand with oligo dT 
Material 
Kit: SuperScript III First-Strand Synthesis System for RT-PCR (THERMO FISHER# 
18080-051 LIFE TECHNOLOGY) 
Purpose: Use SuperScript III First-Strand synthesis with Oligo (dT) and Gene Specific 
Primers (GSP) 
 
Protocol 
Template RNA (1 pg-500 ng recommended) - Use about 1,000 ng (1 μg) 
 
Template mix 
   
Components Volume per 
reaction (μL) 
Number 
of 
reactions 
Master 
mix 
Olgo dT primer (50 um) 1.0 20 20 
10 mM dNTP 1.0 20 20 
Template RNA 3.0 20 60 
DEPC-treated water  5.0 20 100 
 
10.0 
 
200 
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Aliquot out 10 μL per tube and keep them in ice.   
Run the first thermo cycler program: SuperScript III at 65°C for 5 min. 
 
 
 
RT Master Mix 
   
Components 
Voume per 
reaction (μL) 
Number 
of 
reactions 
Master 
Mix 
10X RT buffer 2.0 20 40 
25 mM MgCl2 4.0 20 80 
0.1 M DTT 2.0 20 40 
RNaseOUT (40 U/μL) 1.0 20 20 
Superscript III RT (200 U/μL) 1.0 20 20 
 
10.0 
 
200 
 
Add 10 μL of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, and collect 
by brief centrifugation. Incubate as follows. 
Oligo dT: 60 min at 50 °C 
 
Terminate the reactions at 85 °C for 5 min. Chill on ice. 
Collect the reactions by brief centrifugation. Add 1 μL of Rnase H to each tube and 
incubate the tubes for 20 min at 37°C. 
cDNA synthesis reaction can be stored at -30 to -10°C or used for PCR immediately. 
 
Roche Pure PCR template prep  
High Pure PCR Template Preparation Kit Version 20 for 100 isolations (ROCHE# 11 
796 828 001) 
 
Preparation of working solution 
Proteinase K: Dissolve Proteinase K in 4.5 ml double distilled water, aliquot solution. 
Store at -15°C to -25°C. Stable for 12 months. Sample Lysis and DNA Binding Protocol 
step 1.    
Inhibitor removal buffer: Add 20 mL absolute ethanol to inhibitor Removal Buffer 
Lable and date bottle accordingly after adding ethanol. Store at +15°C to +25°C. Stable 
through the expiration date printed on label. Washing and Elution protocol step 1. 
Wash Buffer: Add 80 mL my absolute ethanol to Wash Buffer Label and date bottle 
accordingly after adding ethanol. Store at +15°C to 25°C Stable through expiration date 
printed on kit label. Washing and Elution protocol step 2 and 3. 
 
Protocol 
1. Thaw 200 μL of EAV KY84 SS cDNA Template x 2vials.  
2. Add 200 μL or Binding Buffer. Add, 40 μL Proteinase K, mix immediately, 
incubate for 10 min at 70°C in each vial.  
3. Add 100 μL isopropanol. Mix well and apply each vial mixture into one High 
Pure filter tube. 
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4. Centrifuge for 1 min at 8,000 x g. 
5. Discard flow through and collection tube. 
6. Add 500 μL of inhibitor removal buffer. 
7. Centrifuge for 1 min at 8,000 x g. 
8. Discard flow through and collection tube. 
9. Add 500 μL of Wash Buffer. 
10. Centrifuge for 1 min at 8,000 x g. 
11. Discard flow through and collection tube. 
12. Repeat #9-10. 
13. Discard flow through. 
14. Centrifuge for 10 seconds at 13,000 x g. 
15. Discard collection tube. 
16. Add new tube and 200 μL of elution buffer at  70°C E2: 100 μL. 
17. Centrifuge for 1 minute at 8,000 x g. 
18. Purified Template DNA is ready to go. 
 
Reverse transcription 
Followed manufacturer’s recommended protocol 
Expand Long Template PCR System (ROCHE# 11 681 834 001) 
Preparation 
All buffers at + 37°C to +56°C before use. Vortex all other reagents thoroughly. 
If the initial reaction produces too many primer dimers, try using two separate master 
mixes:   
Master Mix 1 contains dNTPs and primers 
Master Mix 2 contains buffer, template cDNA and enzyme 
Add these two to the tube on ice, then just before starting the reaction. 
 
Protocol 
Amplification cDNA. DNA System 3: >12kb 
 
Master Mix 1 (for 10 viruses) 
Components 
Volume 
(μL) per 
reaction 
Number 
of 
reactions 
Master 
mix (μL) 
Final 
concentration  
10mM dNTP Mix 10.0 5 50 500 uM 
Downstream      1.0 5 5 
800 nM  
(400 nm) 
Upstream primer  1.0 5 5 
800 nM  
(400 nm) 
10x PCR Buffer with 
MgCl2 (Buffer 3) 5.0 5 25 
 Expand Long Tem- 
0.75 μL plate Enzyme 
mix 0.75 5 3.75 
 Template DNA after 
High Pure PCR Tem 5.0 5 25 
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Prep Kit  
Sterile DW 27.3 5 136.25   
 
50.0 
 
250 
 DNA quantification (ng/μL) 
 
Qiagen One Step RT-PCR kit (QIGEN# 210210) 
Protocol 
Component 
  
Volume Reaction Master Mix 
Master mix 
     Rnase-Free 
water(provided) 
 
14.0 μL 13 182 
5X Qiagen One Step RT-PCR Buffer 5.0 μL 13 65 
 
(contains MgCl2) 
   dNTP Mix 
  
1.0 μL 13 13 
(containing 10 mM of each dNTP) 
   Qiagen OneStep RT-PCR Enzyme Mix  1.0 μL 13 13 
Rnase Inhibitor (optional, not provided) 0.5 μL 13 6.5 
   
21.0 μL  
 
279.5 
Aliquot out the master mix into tubes (6) 
 
Primer 1  
  
1.0 μL 
Primer 2  
  
1.0 μL 
Template RNA  
  Template RNA, added at step 4 1.5 μL 
  
Total 
volume 25 μL 
Add each forward and reverse primer to master mix tubes (6). 
    
Thermocyclor   Duration  Temperature 
Reverse transcription 30 min 50°C 
Initial PCR activation step 15 min 95°C 
3 step 
cycling: Denaturation 30 sec 94°C 
 
Annealing 30 sec 55°C 
 
Extension 1 min 72°C 
Final extension 10 min 72°C 
 
QIAGEN HotStar Taq DNA Polymerase PCR  
Components 
Volume 
(μL) 
# Reactions 
Volume 
(μL) 
10X PR Buffer (with 15 mM MgCl2) 5.0 12 60 
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25 mM MgCl2 (to get final conc.  
2.5 mM) 2.0 12 24 
dNTP Mix (10 mM of each dNTP) 1.0 12 12 
QIAGEN HotStart DNA Polymerase 0.3 12 3.6 
Nuclease-free water 38.7 12 464.4 
Master mix 47.0 
 
564 
Aliquot out 47 μL into tubes (10). 
Forward primer  (20 μm)  1.0 μL 
Reverse primer (20 μm)  1.0 μL 
Template DNA  1.0 μL 
 
Add each forward and reverse primer to master mix tubes (10). 
Thermal Cycler Conditions  
  Initial activation step  95°C 15 min 
3-step cycling (40 cycles) 
  Denaturation  94°C 30 sec 
Annealing  55°C 30 sec 
Extension 72°C 1 min 
Final extension  72°C 10 min 
 
Roche pure PCR purification 
Purification of DNA Fragments from Agarose Gel 
 
Protocol 
1. Cut desired DNA band from gel using an ethanol-cleaned scalpel or razor blade. 
a.      Minimize gel volume by visualizing DNA and cutting the smallest possible 
gel slice on a UV light box. 
2. Place excised agarose gel slice in a sterile 2.0 mL microcentrifuge tube. 
a.      Determine gel mass by first pre-weighting the tube, and then reweighting 
with the excised gel slice 
3. Add 300 μL Binding Buffer for every 100 mg agarose gel slice to the 
microcentrifuge tube. 
a.      1 g = 1,000 mg/ 100 mg = 0.1 g. 
4. Dissolve agarose gel slice in order to release the DNA. 
a. Vortex the microcentrifuge tube 15-30 sec to resuspend the gel slice in the 
binding buffer. 
b. Incubate the suspension for 10 min at 56°C in water bath. 
c. Vortex the tube briefly every 2-3 min during incubation. 
5. After the agarose gel slice is completely dissolved. 
a.      Add 150 μL isopropanol for every 100 mg agarose gel slice to the tube.     
i.     1g = 1,000 mg/ 100mg = 0.1 g 
b.      Vortex thoroughly. 
6. Insert one high pure filter tube into one collection tube. 
a. Pipette the entire contents of the microcentrifuge tube into the upper 
reservoir of the filter tube. 
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b. Do not exceed 700 μL total volume. If mixture is >700 μL, split the volume 
and use two separate Filter Tubes for each portion. 
7. Centrifuge 30-60 sec at maximum speed in a standard tabletop centrifuge at +15 
to +26°C. 
8. Discard the flow through solution. 
a.      Reconnect filter tube with the same collection tube 
9. Add 500 μL wash buffer to the upper reservoir. 
a.      Centrifuge 1 min at maximum speed (as above) 
10. Discard the flow through solution. 
a. Recombine filter tube with the same collection tube. 
b. Add 200 μL wash buffer. 
c. Centrifuge 1 min at maximum speed. 
i.     This second 200 μL wash step ensures optimal purity and complete 
removal of Wash Buffer from the glass fibers.  
11. Discard the flow through solution and collection tube 
12. Add 50-100 μL of nucleic acid free water to the paper reservoir of the filter tube 
(70 μL E1/ 30 μL E2 at 70°C). 
13. The microcentrifuge tube now contains the purified DNA. 
a. Either use the eluted DNA directly or store the eluted DNA at +2°C to 
+8°C or -15°C to -25°C for later analysis. 
 
5′ RACE System for Rapid Amplification of cDNA ends (THERMO FISHER# 
18374-058 Invitrogen (10rxn) LIFE TECHNOLOGY) 
Materials  
Reagent        Volume        Storage 
10X PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl]  500 μL -20°C 
25 mM MgCl2 
   
500 μL -20°C 
*Note: 10X PCR buffer does not contain MgCl2. Therefore, 
MgCl2 must be added to the first strand reaction mix   
  
       10 mM dNTP mix [10 mM each dATP, dCTP, dGTP, dTTP] 100 μL -20°C 
0.1 M DTT 
    
100 μL -20°C 
SuperScript II Reverse Transcriptage (200 units/ μL) 
 
10 μL -20°C 
Rnase mix 
    
10 μL -20°C 
5X tailing buffer [50mM Tris-HCl (pH 8.4), 125 mM KCl, 7.5 
mM MgCl2] 500 μL -20°C 
2 mM dCTP 
   
50 μL -20°C 
Terminal deoxynucleotidyl transferase (TDT) 
 
15 μL -20°C 
5' RACE abridged anchor primer (AAP, 10 μM) 
 
80 μL -20°C 
Universal amplification primer (UAP, 10 μM) 
 
40 μL -20°C 
Abridged universal amplification primer (AUAP, 10 μM) 40 μL -20°C 
DEPC-treated water 
   
1.25 mL -20°C 
Control gene-specific primer 1 (GSP1, 1 μM) 
 
25 μL -20°C 
Control nested gene-specific primer 2 (GSP2, 10 μM) 
 
80 μL -20°C 
Control PCR primer, gene-specific primer 3 (GSP3, 10 μM) 20 μL -20°C 
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Control DNA (2x104 copies/ μL; ~0.1 pg/ μL) 
 
100 μL -20°C 
Control RNA (50 ng/ μL)       10 μL -20°C 
 
 
 
 
DNA Purification System              Volume        Storage 
S.N.A.P. Columns 
      
10 
columns 4°C 
Collection tubes 
   
10 tubes 4°C 
Binding solution (6M sodium iodide) 
  
30 mL 4°C 
Wash buffer concentrate       1 mL 4°C 
 
Additional materials required 
Sterilized, RNase-free thin-walled 0.2 or 0.5 mL PCR tubes 
Automatic pipettes capable of dispensing 1 to 20 μL and 20 to 200 μL 
Sterilized, RNase-free disposable tips for automatic pipettes 
Sterilized, distilled water 
Absolute ethanol 
GSP   1   (cDNA primer, user-defined)  
GSP 2 (nested primer for PCR amplification of dC-tailed cDNA, user-defined, 
appropriately engineered) 
Taq DNA polymerase *Note: Purchased: AccuPrime Pfx DNA Polymerase Cat# 12344-
024 Invitrogen  
37°C, 42°C, 65°C and 70°C water baths or heat blocks (or use thermal cycler) 
Microcentrifuge capable of generating a relative centrifugal force of 13,000 x g 
Programmable thermal cycler 
Mineral oil (if necessary for your thermal cycler) 
 
Method 1  
1X Wash Buffer for S.N.A.P. Procedure 
*1X wash buffer must be prepared from the wash buffer concentrate. 
1. Pipette 1mL (individually wrap) of the wash buffer, concentrate into a 50 ml 
conical tube. 
2. Add 18 mL of molecular biology grade distilled water and 21 mL of absolute 
ethanol. Mix thoroughly. 
3. Transfer half into a second 50 mL conical and store and store at 4°C. 
 
70% Ethanol Wash for S.N.A.P. Procedure 
1. Add 35 mL of absolute ethanol and 15 mL of molecular biology grade distilled 
water to a 50 mL conical tube. 
2. Transfer half into a second 50 mL conical and store and store at 4°C. 
*Note: Molecular Biology grade distilled water = Nuclease-Free Water 
(Cat#AM9937 AMBION) 
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Method 2  
First Strand cDNA Synthesis 
*Add following to a 0.5 mL microcentrifuge tube (or thin-walled PCR tube if using a 
thermal cycler) 
Components Voume per 
reaction (μL) 
Number 
of 
reactions 
Mol 
GSP1 (20 um) 1 2 2.5pmoles 
Sample RNA (5 μg) 5 2 
 DEPC-treated water 9.5 2   
*** Note: RNA of EAV measurement 
Aliquot out each 0.5 mL microcentrifuge tube #1 and #2 
*Incubate the mixture 10 min at 70°C to denature RNA. Chill 1min on ice. 
Collect the contents of the tube by brief centrifugation and add the following in the order 
given: 
Components 
Voume per 
reaction (μL) 
Number 
of 
reactions 
10X PCR buffer 2.5 2 
25 mM MgCl2 2.5 2 
10 mM dNTP mix 1 2 
0.1 M DTT 2.5 2 
Final volume (8.5)** 8.5 
 ***Total final volume of step 1 and 2: 24 μL 
Mix gently, and collect the reaction by brief centrifugation. Incubate for 1 min at 42°C. 
Add 1 μL of SuperScript II RT immediately. Mix gently and incubate for 50 min at 42°C. 
30 min incubation is usually sufficient for shot (<4 kb) mRNAs. 
Longer transcripts require at least 50 min to synthesize enough cDNA for a 
consistent signal in long PCR.  
Incubate at 70°C for 15 min to terminate the reaction. 
Centrifuge 10 to 20 sec and place the reaction at 37°C (at room temp right away). 
Add 1 μL of RNase mix gently but thoroughly, and incubate for 30 min at 37°C. 
Collect the reaction by brief centrifugation and place on ice or keep the reaction storeed 
at -20°C. 
* Final composition of the reaction: 
20 mM Tris-HCl (PH 8.4) 
50 mM KCl 
2.5 mM MgCl2 
10 mM DTT 
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100 nM cDNA primer (GSP1) 
400 μM each dATP, dCTP, dGTP, 
dTTP 
1-5 ug (~40ng/ μL) RNA 
200 units SuperScript II RT 
 
Thermocyclor cycle  Temp Time 
Denature RNA 70°C 10 min 
Incubation 1 42°C 1 min 
Incubation 2 42°C 50 min 
 
70°C 15 min 
Incubation 3 37°C 30 min 
 
Method 3 
Materials 
Collection tube 
S.N.A.P. Column (spin cartridge) 
40X wash buffer concentration 
Binding buffer 
 
S.N.A.P. Column Purification of cDNA 
1. Equilibrate the binding solution to room temperature. 
2. For each sample to be purified, equilibrate ~100 μL of sterilized, distilled water at 
65°C for use in step 9. 
3. Add 120 μL of binding solution (6 M Nal) to the first strand reaction. 
4. Transfer the cDNA/Nal solution to a S.N.A.P. column. Centrifuge at 13,000 x g for 20 
sec. 
5. Remove the cartridge insert from the tube and transfer the flow through to a 
microcentrifuge tube. Save the solution until recovery of the cDNA is confirmed. Place 
the cartridge insert back into the tube. 
6. Add 400 μL of cold (4°C) 1X wash buffer to the spin cartridge. Centrifuge at 13,000 x 
g for 20 sec. Discard the flowthrough. Repeat this wash step three additional times. 
7. Wash the cartridge two times with 400 μL of COLD (4°C) 70% ethanol as described in 
step 6. 
8. After removing the final 70% ethanol wash from the tube centrifuge at 13,000 x g for 1 
min. 
9. Transfer the spin catridge insert into a fresh sample recovery tube. 
Add 50 μL of sterilized, distilled, water (preheated to 65°C) to the spin cartridge. 
Centrifuge at 13,000 x g for 20 sec to elute the cDNA. 
 
Important Note 
*Failure to remove all the ethanol can result in poor recovery of the DNA. 
** It is very important that the distilled water be at 65°C in order to maximize recovery 
of DNA. 
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Method 4 
TdT Tailing of cDNA 
1) Add the following components to each tube and mix gently: 
Components 
Voume per 
reaction (μL) 
Number of 
reactions 
DEPC-treated water 6.5 2 
5X tailing buffer 5 2 
2 mM dCTP 2.5 2 
S.N.A.P.-purified cDNA sample 10 2 
Final volume 24 
 * Aliquot out to PCR tubes #3 and #4 
 2) Incubate for 2 to 3 min at 94°C. Chill 1 min on ice. 
Collect the contents of the tube by brief centrifugation and place on ice. 
3) Add 1 μL TdT to the each tubes, mix gently, and incubate for 10 min at 37°C. 
4) Heat inactivate the TdT for 10 min at 65°C.  
Collect the contents of the reaction by brief centrifugation and place on ice. 
*Final composition of the 
reaction: 
10 mM Tris-HCl (PH 8.4) 
25 mM KCl 
1.5 mM MgCl2 
200 μM dCTP 
cDNA 
TdT 
Thermocyclor cycle  Temp Time 
Incubation 4 94°C 3 min 
Incubation 5 37°C 10 min 
TdT Inactivation 65°C 10 min 
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Method 5 
PCR of dC-tailed cDNA 
1. Equilibrate the thermal cycler block to 94°C. In most cases, the "good start" 
procedure gives specific amplification products. For some target and primer sets, 
"hot start" has been reported to improve the specificity of the reaction. 
2. Add the following to a 0.2 or 0.5 mL thin-wall PCR tube sitting on ice. 
 
Components 
Voume per 
reaction (μL) 
Number of 
reactions 
Sterilized, distilled water 31.5 2 
10X PCR buffer [200mM Tris-HCl (pH8.4), 500mM 
KCl 5 2 
25 mM MgCl2 3 2 
10 mM dNTP mix 1 2 
Nested GSP2 (prepared as 10 μM solution)* 2 2 
Abridged Anchor Primer (10 μM) 2 2 
dC-tailed  (PCR tubes #3 and #4) 5 2 
Final volume 49.5 
 * Aliquot out to PCR tubes #5 and #6 
3. Add 0.5 μL of Taq DNA polymerase (5 units/μL) immediately before mixing. 
**New enzyme: DNA Taq Polymerase, Native (LIFE TECH#18038-018) 
4. Mix the contents of the tube (Taq DNA polymerase is added immediately before 
going into the thermal cycler).  
 
Overlay with 50 to 100 μL of mineral oil (if necessary). 
*Final composition of the reaction: 
20 mM Tris-HCl (PH8.4) 
500 mM KCl 
1.5 mM MgCl2 
400 nM GSP2 
400 nM Abridged Anchor Primer 
200 μM each dATP, dCTP, dGTP, dTTP 
Tailed cDNA 
2.5 units Taq DNA polymerase 
 
5. Transfer tubes directly from ice to the thermal cycler preequilibrated to the initial 
denaturation temperature (94°C) 
6. Perform 30 to 35 cycles of PCR. A typical cycling protocol for cDNA with < 1 kb 
amplified region is: 
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Thermocycler cycle  Temp Cycle Time 
 
94°C  1 2 min 
Denaturation 94°C  
35 
1 min 
Annealing of primers 55°C  1 min 
Primer extension 72°C  2 min 
Final extension 72°C  1 5 min 
Indefinite hold 
5°C  
  
Until samples are 
removed 
 
7. Analyze 5-20 μL of 5' RACE products by agarose gel electrophoresis according to 
standard protocols, using appropriate size standards. Either TAE or TBE 
electrophoresis buffer may be used for the procedure. The volume of the sample 
used for analysis will depend on the volume and thickness of the sample well. If 
products will be extracted for reamplification, ultraviolet (UV) visualization of 
ethidium bromide-stained products should be performed using either a long 
wavelength (356 nm) UV or 302 nm wavelength source to minimize DNA 
nicking. 
 
Nested GSP2 (10 uM solution) Preparation 
 N1V1 = N2V2         (20 uM to 10 μM Dilution) 
20 uM : 50 μL = 10 μM:V2 
V2= 25μL 
Working stock (1:1) 
25 μL Nucleic Acid-Free water + 25 μL of 20uM Primer  
= Total 50 μL of Nested GSP2 (10 μM solution) of BN 291N 
 
Performing 1% agarose gel electrophoresis 
Materials for small box (10 well combs) Amt. of materials 
TAE (1X) Buffer) [diluted from 10X Tris-Acetate-EDTA] 50 mL  
Agarose (1%) [Seakem GTG Agarose Cat#50074 Cambrex) 0.5 g 
Ethidium Bromide [GIBCO] 2.5 μL 
*When you pour the gel, use pipet and get use to the height of the gel.  
  You can make 100 mL gel stock and can use about 30 mL for small box (10-well 
combs) 
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Method 6 
Nested Amplification 
1. Dilute a 5 μL aliquot of the primary PCR (tube# 5 and #6) into 495 μL Nucleic 
Acid Free Water 
* Aliquote out to PCR tubes #5b and #6b (diluted primary PCR) 
2. Equilibrate the thermal cycler block to 94°C. 
Add the following to a 0.2 or 0.5 mL thin-wall PCR tube sitting on ice. 
Components 
Voume 
per 
reaction 
(μL) 
Number 
of 
reactions 
Sterilized, distilled water  33.5 2 
10X PCR buffer [200 mM Tris-HCl (pH8.4), 500 mM 
KCl] 5 2 
25 mM MgCl2 3 2 
10 mM dNTP mix 1 2 
Nested GSP2 (prepared as 10 uM solution) 1 2 
UAP (10 μM) 1 2 
Dilution of primary PCR product (PCR tubes #5a and 
#6a) 5 2 
Final volume 49.5 
 * Aliquot out to PCR tubes #9 and #10 
  3. Add 0.5 μL of Taq DNA polymerase (5 units/μL) immediately before mixing. 
4. Mix the contents of the tube (Taq DNA polymerase is added immediately before 
going into the thermal cycler) 
Overlay with 50 to 100 μL of mineral oil (if necessary) 
*Final composition of the reaction: 
20 mM Tris-HCl (pH 8.4) 
50 mM KCl 
1.5 mM MgCl2 
200 nM nested GSP 
200 nM UAP or AUAP 
200 μM each dATP, dCTP, dGTP, dTTP 
Diluted primary PCR product 
2.5 units Taq DNA polymerase 
5. Transfer tubes directly from ice to the thermal cycler preequilibrated to the initial 
denaturation temperature. 
6. Perform 30 to 35 cycles of PCR. 
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Thermocycler cycle  Temp Cycle Time 
  94°C  1 2 min 
Denaturation 94°C  
35 
1 min 
Annealing of primers 55°C  1 min 
Primer extension 72°C  2 min 
Final extension 72°C  1 5 min 
Indefinite hold 
5°C 
  
Until samples are 
removed 
 
7. Analyze 5 to 20 μL of the amplified sample, using agarose gel electrophoresis, 
ethidium bromide staining, and the appropriate molecular size standards. 
 
3′ RACE System for Rapid Amplification of cDNA ends (THERMO 
FISHER#18373-019) 
Materials 
 
Contents 
Amount 
(μL) 
10X PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl] 500 
25 mM MgCl2 500 
10 mM dNTP mix (10mM each dATP, dCTP, dGTP, dTTP) 100 
0.1M DTT 100 
SuperScript II Reverse Transcriptase (RT, 200units/ μL) 20 
Adapter primer (AP, 10 μM) 20 
Universal amplification primer (AUAP, 10 μM) 20 
Abridged universal amplification primer (AUAP, 10μM) 20 
E. coli RNASE H (2units/ μL) 20 
DEPC-treated water 1.2 mL 
Control RNA (50ng/ μL) 10 
Control gene-specific primer (GSP, 10 μM) 20 
Additional preparations 
GSP (user-defined, appropriately engineered) 
 
Method 1 
First Strand cDNA Synthesis 
This procedure converts 1 to 5 μg of total RNA into first strand cDNA. Poly (A) RNA 
may be used in this protocol. 
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1. Mix and quickly centrifuge each component before use.  
2. Combine 1-5 μg of total RNA or 50 ng of poly (A) RNA and DEPC-treated water to a 
final volume of 11 μL in a 0.5 mL microcentrifuge tube. 
3. Add 1 μL of the 10 μM AP solution, (adapter primer) mix gently, and collect reaction 
by brief centrifugation. 
4. Heat the mixture to 70°C for 10 min and chill on ice for at least 1min. 
Collect the contents of the tube by brief centrifugation and add the following: 
Components 
Volume 
(μL) Reaction Mastermix 
10X PCR buffer 2 5 8 
25 mM MgCl2 2 5 8 
10 mM dNTP mix 1 5 4 
0.1 M DTT 2 5 8 
Total 7 
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Aliquot out 7 μL into 4tubes (#1-4) 
Final composition of the reaction: 
20 mM Tris-HCl (pH 8.4 at 22℃) 
50 mM KCl 
2.5 mM MgCl2 
10 mM DTT 
500 nM AP 
500 μM each dATP, dCTP, dGTP, 
dTTP 
1-5 μg (<50 ng/μL) of RNA 
 
5. Mix gently and collect the reaction by brief centrifugation. Equilibrate the mixture to 
42°C for 2 to 5 min. 
6. Add 1 μL of SuperScript II RT. Incubate the tube in a 42°C water bath or heat block 
for 50 min. 
7. Terminate the reaction by incubating at 70°C for 15 min. 
8. Chill on ice. Collect the reaction by brief centriugation. Add 1 μL of RNase H to the 
tube. Mix, and incubate for 20 min at 37°C before proceeding to Protocol 2. 
9. The reaction mixture may be stored at -20°C and STOP or continue the Method 2. 
 
Method 2. 
Amplification of the Target cDNA 
1. To a fresh 0.5 mL microcentrifuge tube, add the following: 
Component Volume (μL) Reaction Master Mix 
10X PCR buffer 5 5 25 
25 mM MgCl2 3 5 15 
Autoclaved, distilled water 36.5 5 182.5 
10 mM dNTP mix 1 5 5 
GSP (prepared as 10 uM solution) 1 5 5 
UAP (10 μM) 
 
1 5 5 
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Taq DNA polymerase (2 to 5 units/μL) 0.5 5 2.5 
 
Total 48 
 
240 
 
 
 
Final composition of the reaction: 
20 mM Tris-HCl (pH 8.4) 
50 mM KCl 
1.5 mM MgCl2 
200 nM GSP 
200 nM AUAP or UAP 
200 μM each dATP, dCTP, dGTP, 
dTTP 
0.04 to 0.1 unit/ μL Taq DNA 
polymerase 
 
 
    
2. Add 2 μL from the cDNA synthesis reaction to the tube. Collect the reaction 
briefly by centrifugation. 
3. Perform 20 to 35 cycles of PCR, using the protocol accompanying Taq DNA 
polymerase. 
 
Temp Cycle Time 
94°C  1 3 min 
94°C  
35 
45 sec 
55°C  30 sec 
72°C 1 min 30 sec 
72°C  1  10 min 
4°C    Until samples are removed 
 
4. Analyze 10 to 20 μL of the amplified sample, using agarose gel electrophoresis 
and ethidium bromide staining, and the appropriate molecular size standards. If 
the positive control RNA was used, a single 720 bp band will be visible. 
Method 3. 
Gel purification.  
Follow previous protocol. 
Miniprep 
Followed manufacturer’s recommended protocol 
 
QIAprep Spin Miniprep Kit (QIAGEN# 27104) 
***Note: Optional: Add LyseBluse reagent to Buffer P1 at a ratio of 1 to 1,000. 
Add the provided Rnase A solution to Buffer P1, mix, and store at 2-8°C. 
(*Total 20 mL of Buffer P1 + 20 μL of Lyseblue + 200 μL of RNase solution) 
Add ethanol (100%) to Buffer PE before use. 
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All centrifugation steps are carried out at 13,000 rpm (~17,900) in a conventional 
tabletop microcentrifuge. 
 
Method 
1. Take the bacterial culture tubes out from shaker incubator overnight (37°C, 200 
rpm). 
2. Using 2 mL pipet, aliquot out 1.5 mL of bacterial growth in 2 mL microcentrifuge 
tubes. 
3. Centrifugation the tubes at >800 rpm (6,800 x g) for 3 min at room temperature. 
4. Discard supernatant without disturbing pelleted bacterial cells. 
5. Add 250 μL of Buffer P1 and scratch the tube on the rack to mix thoroughly. 
Solution will turn cloudy. 
6. Add 250 μL of Buffer P2 and mix thoroughly by inverting the tube 4-6 times 
(gently flipping the tube) until the solution becomes clear. Do not allow the lysis 
reaction to proceed for more than 5 min. If using LyseBlue reagent, the solution 
will turn blue. Solution turns blue, then clear 
7. Add 350 μL of N3 Buffer and mix thoroughly by inverting the tube 4-6 times 
(gently flipping the tube). If using LyseBlue reagent, the solution will turn 
colorless. Solution will be cloudy. 
8. Centrifuge for 10 min at 13,000 rpm (~17,900 x g) in a tabletop microcentrifuge. 
9. Aliquot out all the supernatant without disturbing pellet (bacterial DNA, no 
needed) and try to avoid to pipetting white floating stuff. You only want the 
supernatant into Qiaprep spin column by decanting or pipetting. 
10. Add 500 μL of PB buffer to wash the QIAprep spin column. Centrifuge for 30-60 
sec and discard the flow through, or apply vacuum to the manifold to draw. 
Centrifuge for 30-60 sec and discard the flow through, or apply vacuum to the 
manifold to draw the solution through the QIAprep spin column and switch off 
the vacuum source. 
11. Wash the QIAprep spin column by adding 750 μL Buffer PE. Centrifuge for 30-
60 sec and discard the flow through, or apply vacuum to the manifold to draw the 
solution through the QIAprep spin column and switch off the vacuum source. 
Transfer the QIAprep spin column to the collection tube. 
12. Centrifuge hard for 1 min to remove residual wash buffer. 
13. Place the QIAprep column in a clean 1.5 mL microcentrifuge tube. To elute DNA, 
add 50 μL Buffer EB (10mM Tris-HCl, pH 8.5) or nucleic acid-free water to the 
center of the QIAprep spin column, let it stand for 1min, and centrifuge for 1 min. 
14. Do DNA quantification. 
 
Preparation of Restrict Enzyme Reaction 
Reagent 
 
Amount 
Nucleic Acid Free water 7 μL 
10X FD (fast digest) Buffer  2 μL 
Miniprep DNA (Elute 2) 10 μL 
Eco R1 (Restriction Enzyme) 1 μL 
  
20 μL 
Incubate the tubes in 37°C water bath for 15 min. Then, ready to load the gel. 
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Cloning 
Followed manufacturer’s recommended protocol 
 
Generating Blunt Ends  
Materials 
T4 DNA Polymerase THERMO FISHER# 18005-016 
1. To a Sterile 1.5 mL microcentrifuge tube on ice, add: 
Component 
  
Amount 
5X T4 DNA polymerase buffer 20 μL 
0.5 mM dNTP mix 
 
20 μL 
DNA [5' Race Final PCR product 
pooled  6 μL 
 
(Tube#9,10,11,12)] 
 T4 DNA polymerase (5U/μL) 2 μL 
Autoclaved, distilled water 52 μL 
  
Total 
volume: 100 μL 
 
2. Mix gently, and incubate at 11°C for 15 min. 
3. Place reaction on ice. Store at -20°C. 
4. Terminate reaction by phenol extraction, chloroform extraction and ethanol 
precipitation. 
Heat inactivation is not recommended, as heat inactivation may cause ends to 
"breathe" and be more susceptible to 3' to 5' exonuclease activity. 
 
Phenol extraction, chloroform extraction and ethanol precipitation 
1. Extract the sample twice with phenol/chloroform/isoamyl alcohol (25:24:1).  
Increase the volume of the sample to about 300 μL by adding sterile deionized 
water into the sample. For each extraction, mix the DNA sample with an equal 
volume of phenol/chloroform/isoamyl alcohol (25:24:1) until an emulsion is 
formed. 
2. The centrifuge the tube(s) at 12,000 x g for approximately 15 sec at room 
temperature. The upper aqueous phase contains the DNA and should be 
transferred to a fresh sterile microcentrifuge tube after each extraction. 
3. Add sodium chloride (to a final concentration of 0.1M; use 20 μL of 5M NaCl) or 
sodium acetate (final concentration, 0.25 M) to the sample. Then, precipitate the 
DNA by adding a 2.5 volume of cold absolute alcohol (750-800 μL). Incubate for 
30-45 min at -70°C, then centrifuge (12,000 x g) for 10 min at 4°C. 
4. Discard the supernatant, dry DNA pallet under vacuum (or in a 37°C oven) and 
resuspend the pellet in a convenient volume (20-200 μL) of sterile deionized 
water and measure the optical density of the solution. Calculate the concentration 
of the plasmid and the total amount of DNA obtained. DNA is ready for 
restriction enzyme digestion and PCR analysis. 
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Zero Blunt TOPO PCR Cloning  
Materials  
Zero Blunt TOPO PCR Cloning Kit THERMO FISHER# K2800-020SC 
Produce Blunt PCR Product 
1. Set up the following 6 μL TOPO Cloning reaction 
Reagent 
 
Amount* 
 Fresh PCR Product 0.5-4 μL 
 Salt Solution 1 μL 
 
Sterile Water 
Add to a total volume of 5 
μL 
PCR Blunt II TOPO 1 μL 
 
 
Total 6 μL 
 *For transformation of chemically competent E. coli only 
2. Mix gently and incubate for 5 min at room temperature 
3. Place tubes on ice. Proceed to Transformation and 
Analysis. 
 
Transformation 
1. Thaw 1 vial of One Shot E. coli cells on ice for each transformation. 
2. Add 2 μL of the TOPO Cloning reaction to each vial of One Shot cells to be 
transformed, and mix gently. 
3. Incubate the vials on ice for 5-30 min. 
4. Heat-shock the cells for 30 sec at 42°C without shaking. 
5. Add 250 μL of room temperature S.O.C. medium to the cells. 
6. Cap the tubes and shake them at 37°C for 1 hour. 
7. Spread 10-50 μL from each transformation on pre-warmed LB plates containing 
50 μg/mL kanamycin or pre-warmed Low Salt LB plates containing 25 μg/mL 
Zeocin selective antibiotic. 
Refer to the Zero Blunt TOPO PCR Cloning Kit manual for a Low Salt LB 
medium recipe. 
8.  Incubate plates overnight at 37°C. 
An efficient TOPO Cloning reaction should produce several hundred colonies. Pick 
~10 colonies for analysis. Proceed to Analyze Positive Clones. 
 
Analyze Positive Clones 
1. Culture the 10 colonies overnight in LB medium containing 50 μg/mL kanamycin 
or low Salt LB medium containing 25 μg/mL Zeocin selective antibiotic. 
2. Isolate plasmid DNA using your method of choice. For ultrapure plasmid DNA, 
we recommend the PureLink HQ Mini Plasmid Purification Kit (Cat# K2100-01). 
3. Analyze the plasmid by restriction analysis or by sequencing to confirm the 
presence and orientation of the insert. 
 
 
 
NGS data analysis command line coding method 
Protocol from Dr. Ganwu Li’s laboratory at Iowa State University 
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1. In DataAnalysis file, separate each sample file. 
2. Choose individual file to work on.  
3. Turn on Terminal 
4. Type ls : view files 
5. Type cd Desktop: enter to desktop 
6. Type ls : view files on desktop 
7. Type cd DataAnalysis to enter into the folder 
8. Type ls : to view files in DataAnalysis 
9. Choose EAV folder and Type cd  (EAV-folder name) : to enter into the folder  
10. Type ls : to view files in EAV file  
11. Choose a sample folder and Type cd (sample folder name) 
12. Create sample_list file : bash namelist.sh 
13. View sample_list file : less sample_list 
14. Trim the raw NGS data materials : bash batch_trim_Truseq.sh  
a. First batch use the program: Trueseq.sh 
b. Second batch use the program: Nextera.sh 
c. You can check the condition of trimmed data looking at surviving % 
15.  Enter to cd trimmed/ : new folder  
16.  Type ls to view the trimmed folder  
17. Type mkdir other : create other folder to keep unnecessary sample files 
18. Type mv sample name R1 and R2 /others/ : to move two unnecessary sample files 
to other folder 
a. D107_S20_FUP_L001_R1_001.fastq.gz ./others/ 
b. D107_S20_RUP_L001_R2_001.fastq.gz ./other/ 
19. Create sample_list file in trimmed folder : bash namelist.sh  
20. View sample_list file to check the right sample name : less sample_list  
21. Copy EAVKY84.fasta file and paste into Trimmed folder in each sample folder 
22. Do partial De Novo assembly to collect reads : bash general102314.sh 
EAVKY84.fasta  
a. To complete de Novo assembly, you need four different programs 
including Seqman pro (commercial). But in my case, I don’t do complete 
de novo assembly in my data analysis..  
23. Enter into a folder cd (trimmed_sample name)  
24. Type ls to view the folder (trimmed_sample name)  
25. Type cd single_id txt .. : Copy single_id txt file in trimmed sample name folder  
26. Type cd .. : to come out of trimmed sample name folder  
27. Type ls : to view trimmed sample name folder and see if there is folder (single_id 
txt)  
28. Use seqtk subseq to get the reads Type and create two files (sample_R1 and 
R2.fastq) : 
a. seqtk subseq trimmed_S-S-D107_S20_L001_R1_001.fastq.gz  single_id.txt > 
sample_R1.fastq 
b. seqtk subseq trimmed_S-S-D107_S20_L001_R2_001.fastq.gz  single_id.txt > 
sample_R2.fastq 
29. Finally, you will do mapping of sample_R1 & R2.fastq and EAVKY84 with bwa 
program :  
a. EAVKY84 will be your reference EAV sequence  
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b. Otherwise, you can use 33 EAV full length genome sequences for the 
reference sequence 
c. To do mapping, you can change the parameter for reads (how long or short 
you want). But right now, I stick with one parameter to be simple 
d. Create Index : bwa index EAVKY84.fasta 
e. Then Type and create sam file : bwa mem -M EAVKY84.fasta sample_R1.fastq 
sample_R2.fastq > sample.sam 
f. Now it will do mapping 
30.  You need to convert sam file to bam file to visualize in IGV : 
a. Type and convert sam to bam file : samtools view -hbS sample.sam > 
sample.bam 
b. Type and create sorted bam file : samtools sort sample.bam >sample.sorted.bam 
c. Type : samtools index sample.sorted.bam  
i. Samtools index for bam file is different from bwa index 
ii. After sorting you will have (sample.sorted.bam.bai) 
iii. Sample.sorted.bam is your final bam file that visualize via IGV program 
31. Now you can view in IGV 
a. First, you need to convert your EAVKY84.fasta into genome file 
b. Press genome and click create genome file  
i. Load EAVKY84.fasta  
ii. Name and describe the file  
iii. Save EAVKY84.genome in sample folder 
c. Second, click load from file, then you load sample.sorted.bam file  
d. You can see % at the ambiguous sites (ambiguity) 
32. Now, type below to create consensus sequence :  
a. samtools mpileup -uf EAVKY84.fasta sample.sorted.bam |bcftools call -c | 
vcfutils.pl vcf2fq > cns.fq 
b. To view your consensus sequence type : less cns.fq  
c. To convert your consensus sequence from fastq to fasta, type : seqtk seq -a cns.fq 
> cns.fasta 
 
33.  To find the numbers and location of your ambiguous sites, type :  
a. perl ~/Desktop/boracode/ambcount.pl cns.fasta 
 
At ISU, Ying helped me to download these below software programs and set up PATH 
through command line (terminal) to do NGS data analysis: Also I need Ying’s self 
written script to run these programs (boracode folder)  
Trimmomatic.0.36 : for trim, clean the data to run the batch_trim_TruSeq or Nextera 
IGV: visualizing for map 
BWA : mapping  
SAM tools : manipulate the mapping files SAM file will convert to BAM file 
Seqtk: manipulate the fastq files  
BWA (not Abyss and SeqPro): to run the de novo assembly  
Lofreq: Variants calling software find the variant percentages 
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